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Abstract: Privileged structures have been widely used as an effective template for the research and
discovery of high value chemicals. Coumarin is a simple scaffold widespread in Nature and it can be
found in a considerable number of plants as well as in some fungi and bacteria. In the last years, these
natural compounds have been gaining an increasing attention from the scientific community for their
wide range of biological activities, mainly due to their ability to interact with diverse enzymes and
receptors in living organisms. In addition, coumarin nucleus has proved to be easily synthetized and
decorated, giving the possibility of designing new coumarin-based compounds and investigating their
potential in the treatment of various diseases. The versatility of coumarin scaffold finds applications
not only in medicinal chemistry but also in the agrochemical field as well as in the cosmetic and
fragrances industry. This review is intended to be a critical overview on coumarins, comprehensive
of natural sources, metabolites, biological evaluations and synthetic approaches.
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1. Introduction
Coumarins are a wide family of secondary metabolites found in various species of plants (more
than 1300 coumarins have been identified from natural sources, especially green plants) but also fungi
and microorganisms [1,2]. The main pathway of coumarin biosynthesis occurs by shikimic acid route,
via cinnamic acid, through phenylalanine metabolism [3]. The history of these natural products began
200 years ago—the name of the class derived from the plant Coumarouna odorata (Dipteryx odorata)
from which the simplest member of this family, coumarin itself (Figure 1), was isolated by Vogel in
1820 [3,4]. Chemically speaking, coumarins are organic heterocycles and their nucleus is represented
by benzo-α-pyrone (2H-1-benzopiran-2-one), whose systematic nomenclature was established by
International Union of Pure and Applied Chemistry (IUPAC) [5].
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Natural coumarins are subdivided in different classes based on their chemical diversity and 
complexity—simple coumarins, isocoumarins, furanocoumarins and pyranocoumarins (both 
angular and linear), biscoumarins and other coumarins such as phenylcoumarins (Table 1) [6]. 
Coumarins have several attractive features, such as low molecular weight, simple structure, high 
bioavailability, high solubility in most of the organic solvents and low toxicity, which, together with 
their multifaceted biological activities, ensure them a prominent role as lead compounds in drug 
research and development [2,6,7]. Coumarins exhibit several pharmacological effects including 
anticoagulant, antimicrobial, anti-inflammatory, neuroprotective, antidiabetic, anticonvulsant and 
antiproliferative [8]. Their importance is also clear in the food industry where their fungicide and 
antioxidant activities are investigated and exploited [9,10]. Moreover, some natural benzocoumarins 
show anti-algal activity [11]. Despite being recognized for their biological activities, coumarins 
present another important characteristic widely explored by the industry: their luminescent 
properties. The luminescence of some derivatives results from the intrinsic charge transfer properties 
of electron-rich conjugated π-π systems [3]. These compounds present a broad variety of 
applications, for example as photocleavable protecting groups or fluorescent probes [12].  
Table 1. Classification of natural coumarins. 
Class General Structure Examples 
Simple 
coumarins 
 
Osthole (neuroprotective, osteogenic, 
immunomodulatory, anticancer, hepatoprotective, 
cardiovascular protective and antimicrobial) [13] 
Furanocoumarins 
 
Psoralen (antifungal) [14] 
Antoghenol (antibacterial) [15] 
Columbianedin (anti-inflammatory) [15] 
Pyranocoumarins 
 
Grandivittin (antibacterial) [16] 
Inophyllum A, B, C, E, P, G1, andG2 (antiviral) [17] 
Biscoumarins 
 
Dicoumarol (anticoagulant) [18] 
Figure 1. Structure of coumarin nucleus.
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Natural coumarins are subdivided in different classes based on their chemical diversity and
complexity—simple coumarins, isocoumarins, furanocoumarins and pyranocoumarins (both angular
and linear), biscoumarins and other coumarins such as phenylcoumarins (Table 1) [6].
Coumarins have several attractive features, such as low molecular weight, simple structure,
high bioavailability, high solubility in most of the organic solvents and low toxicity, which, together
with their multifaceted biological activities, ensure them a prominent role as lead compounds in
drug research and development [2,6,7]. Coumarins exhibit several pharmacological effects including
anticoagulant, antimicrobial, anti-inflammatory, neuroprotective, antidiabetic, anticonvulsant and
antiproliferative [8]. Their importance is also clear in the food industry where their fungicide and
antioxidant activities are investigated and exploited [9,10]. Moreover, some natural benzocoumarins
show anti-algal activity [11]. Despite being recognized for their biological activities, coumarins present
another important characteristic widely explored by the industry: their luminescent properties. The
luminescence of some derivatives results from the intrinsic charge transfer properties of electron-rich
conjugated pi-pi systems [3]. These compounds present a broad variety of applications, for example as
photocleavable protecting groups or fluorescent probes [12].
Table 1. Classification of natural coumarins.
Class General Structure Examples
Simple
coumarins
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show anti-algal activity [11]. Despite being recognized for their biological activities, coumarins 
present another important characteristic widely explored by the industry: their luminescent 
properties. The luminescence of some derivatives results from the intrinsic charge transfer properties 
of electron-rich conjugated π-π systems [3]. These compounds present a broad variety of 
applications, for example as photocleavable protecting groups or fluorescent probes [12].  
Table 1. Classification of natural coumarins. 
Class General Structure Examples 
Simple 
coumarins 
 
Osthole (neuroprotective, osteogenic, 
immunomodulatory, anticancer, hepatoprotective, 
cardiovascular protective and antimicrobial) [13] 
Furanocoumarins 
 
Psoralen (antifungal) [14] 
Antoghenol (antibacterial) [15] 
Columbianedin (anti-inflammatory) [15] 
Pyranocoumarins 
 
Grandivittin (antibacterial) [16] 
Inophyllum A, B, C, E, P, G1, andG2 (antiviral) [17] 
Biscoumarins 
 
Dicoumarol (anticoagulant) [18] 
Osthole (neuroprotective, osteogenic,
immunomodulatory, anticancer,
hepatoprotective, cardiovascular
protective and antimicrobial) [13]
Furanocoumarins
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properties. The luminescence of some derivatives results from the intrinsic charge transfer properties 
of electron-rich conjugated π-π systems [3]. These compounds present a broad variety of 
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Table 1. Classification of natural coumarins. 
Class General Structure Examples 
Simple 
coumarins 
 
Osthole (neuroprotective, osteogenic, 
immunomodulatory, anticancer, hepatoprotective, 
cardiovascular protective and antimicrobial) [13] 
Furanocoumarins 
 
Psoralen (antifungal) [14] 
Antoghenol (antibacterial) [15] 
Columbianedin (anti-inflammatory) [15] 
Pyranocoumarins 
 
Grandivittin (antibacterial) [16] 
Inophyllum A, B, C, E, P, G1, andG2 (antiviral) [17] 
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Dicoumarol (anticoagulant) [18] 
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Pyranocoumarins
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the search for new drug candidates. Here, we critically review the actual state of the art on natural 
and synthetic coumarins, focusing on the biological activity, structure–activity relationships (SARs), 
pharmacokinetics (PKs) and their potential applications in the pharma and agri-food sectors. 
Furthermore, an overall overview of the most common synthetic routes applied to obtain simple 
coumarins are provided, together with a further discussion on alternative, innovative and green 
synthetic methodologies. 
Metabolism 
Coumarin is metabolized by cytochrome P450-linked mono-oxygenase enzyme (CYP2A6) 
system in liver microsomes, which leads to hydroxylation; subsequently, the hydroxylated 
metabolite follows phase II conjugation reactions. Although coumarin could potentially be 
hydroxylated at all six possible positions (i.e., carbon atoms 3, 4, 5, 6, 7 and 8) (Figure 1), 7-
hydroxycoumarin and 3-hydroxycoumarin are the main metabolites. The former one faces phase II 
conjugation reaction resulting in the glucuronide derivative, whereas 3-hydroxycoumarin can be 
further metabolized by ring splitting to form two products, o-hydroxyphenyllactic acid and o-
hydroxyphenylacetic acid (Figure 2) [4,21]. Since the expression of CYP2A6 varies between 
individuals, due to genetic and environmental factors, an inter-individual variation in the 
metabolism of coumarin drugs is possible [4]. 
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In a recent work, eight coumarin metabolites, which had not been identified previously, were 
detected by means of UPLC/Quadrupole-TOF tandem mass spectrometry in human urine [22]. 
Among them, positional isomers of 7-hydroxycoumarin glucuronide and 7-hydroxycoumarin 
sulphate were found. It was proposed that such isomers should bear the substituent in position 5, 6 
or 8. Metabolites coming from a double hydroxylation and subsequent conjugation with glucuronic 
acid or sulphate group (and their isomers) were detected as well. Another metabolite was the one 
obtained by a double hydroxylation of the coumarin ring, followed by methylation and 
glucuronidation at the two newly generated hydroxyl groups. Finally, the N-acetylcysteine 
conjugated metabolite was identified. In this work, o-hydroxyphenylacetic acid was also detected in 
the samples, whereas free coumarin and o-coumaric acid were not found, indicating that coumarin 
was completely metabolized before excretion, after oral administration. This meant that o-coumaric 
Thunberginols (antidiabetic) [19]
Phenylcoumarins
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 83 
Isocoumarins 
 
Thunberginols (antidiabetic) [19] 
Phenylcoumarins 
 
Isodispar B (anti-inflammatory) [20] 
This privileged scaffold serves as an important platform for the design of compound libraries in 
the search for new drug candidates. Here, we critically review the actual state of the art on natural 
and synthetic coumarins, focusing on the biological activity, structure–activity relationships (SARs), 
pharmacokinetics (PKs) and their potential applications in the pharma and agri-food sectors. 
Furthermore, an overall overview of the most common synthetic routes applied to obtain simple 
coumarins are provided, together with a further discussion on alternative, innovative and green 
synthetic methodologies. 
Metabolism 
Coumarin is metabolized by cytochrome P450-linked mono-oxygenase enzyme (CYP2A6) 
system in liver microsomes, which leads to hydroxylation; subsequently, the hydroxylated 
metabolite follows phase II conjugation reactions. Although coumarin could potentially be 
hydroxylated at all six possible positions (i.e., carbon atoms 3, 4, 5, 6, 7 and 8) (Figure 1), 7-
hydroxycoumarin and 3-hydroxycoumarin are the main metabolites. The former one faces phase II 
conjugation reaction resulting in the glucuronide derivative, whereas 3-hydroxycoumarin can be 
further metabolized by ring splitting to form two products, o-hydroxyphenyllactic acid and o-
hydroxyphenylacetic acid (Figure 2) [4,21]. Since the expression of CYP2A6 varies between 
individuals, due to genetic and environmental factors, an inter-individual variation in the 
metabolism of coumarin drugs is possible [4]. 
O O
O OHO
O O
OH
7-hydroxycoumarin
3-hydroxycoumarin
O
O
O
H
H
3,4-epoxide
OH
COOH
OH
o-hydroxyphenyl-
lactic acid
OH
CHO
o-hydroxyph nyl-
acetaldehyde
OH
COOH
o-hydroxyphenyl-
acetic acid
Phase II metabolism (glucuronide derivative)
 
Figure 2. Coumarin metabolism. 
In a recent work, eight coumarin metabolites, which had not been identified previously, were 
detected by means of UPLC/Quadrupole-TOF tandem mass spectrometry in human urine [22]. 
Among them, positional isomers of 7-hydroxycoumarin glucuronide and 7-hydroxycoumarin 
sulphate were found. It was proposed that such isomers should bear the substituent in position 5, 6 
or 8. Metabolites coming from a double hydroxylation and subsequent conjugation with glucuronic 
acid or sulphate group (and their isomers) were detected as well. Another metabolite was the one 
obtained by a double hydroxylation of the coumarin ring, followed by methylation and 
glucuronidation at the two newly generated hydroxyl groups. Finally, the N-acetylcysteine 
conjugated metabolite was identified. In this work, o-hydroxyphenylacetic acid was also detected in 
the samples, whereas free coumarin and o-coumaric acid were not found, indicating that coumarin 
was completely metabolized before excretion, after oral administration. This meant that o-coumaric 
Isodispar B (anti-inflammatory) [20]
This privileged scaffold serves as an important platform for the design of compound libraries
in the search for new drug candidates. Here, we critically review the actual state of the art on
natural and synthetic coumarins, focusing on the biologi l activ ty, structure–activity relati nships
(SARs), pharmacokinetics (PKs) and their potential application i the pharma and agri-f od sectors.
Furthermore, an overall ov rview of the most common synthetic routes appli d to btain simple
coumari s are provided, together with a further discussion on alternative, innovative and green
synthetic methodologies.
Metabolism
Coumarin is metabolized by cytochrome P450-linked mono-oxygenase enzyme (CYP2A6) system
in liver micr somes, which leads to hydroxylation; subsequently, the hydr xyl ted metabolite follows
phase II conjugation reactions. Although c umarin could pote ti lly be hydroxylated at all six possible
positions (i.e., carbon atoms 3, 4, 5, 6, 7 and 8) (Figure 1), 7-hydroxycoumarin and 3-hydroxycoumarin
are the main metabolites. The former one faces phase II conjugation reaction resulting in the
glucuronide derivative, whereas 3-hydroxycoumarin can be further metabolized by ring splitting
to form two products, o-hydroxyphenyllactic acid and o-hydroxyphenylacetic acid (Figure 2) [4,21].
Since the expression of CYP2A6 varies between individuals, due to genetic and environmental factors,
an inter-individual variation in the metabolism of coumarin drugs is possible [4].
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Figure 2. Cou arin etabolis .
In a recent work, eight coumarin metabolites, which ad not been identified previously, were
detected by means of UPLC/Quadrupole-TOF tandem mass spectrometry in human urine [22]. Among
them, positional isomers of 7-hydr xycoumarin glucuronide nd 7-hydroxycoumarin sulphate were
found. It was proposed that such isomers should bear the sub tituent in position 5, 6 or 8. Metabolites
coming from a double hydroxylation and subsequent conjugation with glucuronic acid or sulphate
group (and their isome s) were etected as well. Anoth r metabolite was the one obtained by a
double hydroxylation of the coumarin ring, foll wed by methylation and g ucuronidation at the two
newly generated hydroxyl groups. Fi ally, the N-acetylcysteine conjugated metaboli e was id ntified.
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In this work, o-hydroxyphenylacetic acid was also detected in the samples, whereas free coumarin and
o-coumaric acid were not found, indicating that coumarin was completely metabolized before excretion,
after oral administration. This meant that o-coumaric acid found in human plasma [23] underwent a
biotransformation process before being eliminated, probably leading to o-hydroxyphenylacetic acid.
2. Biological Activities
2.1. Antioxidant Activity
In a healthy human body, normal metabolic processes produce free radicals and other highly
reactive species such as ions, molecules with unpaired electrons, Reactive Oxygen, Carbon, Nitrogen or
Sulfur Species (ROS, RCS, RNS or RSS). When these species are overproduced, oxidative processes might
cause cellular damage, affecting cellular components and causing ionic imbalance or mitochondrial
disfunction [24]. The role of oxidative stress in different pathologies is well know: inflammation,
cardiovascular diseases, cancer, diabetes and even neurodegenerative disorders often count oxidative
damage among their pathological features [25–27]. Therefore, exogenous antioxidants might be useful
in order to maintain the right concentration of radicals, reducing the amounts of free radicals and
avoiding oxidative stress [28].
The antioxidant potential of natural and synthetic coumarins has been deeply investigated in the
last years and it became clear that poly-hydroxy or phenolic coumarins are efficient antioxidants in
biologicals systems [29]. Here below the most recent updates in this field are reported.
In 2019, Couttolenc and collaborators studied the radical scavenging activity of three
hydroxy-4-methylcoumarins (1–3, Figure 3) by means of experimental and theoretical methods [30].
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Firstly, the scavenging activity of the compounds was evaluated on ABTS (2,2′-azino-bis
(3-ethylbenzothiazoline-6-sulfonic acid) dia monium salt), DPPH (2,2-diphenyl-1-picrylhydrazyl)
and galvinoxyl radicals as Trolox (a Vitamin E analogue) equivalent antioxidant capability (TEAC).
The results showed that, whereas 1 did not exhibit radical scavenging activity, 2 resulted more active
than Trolox against the ABTS•+ radical (EC50 30.83 µM) and 3 displayed better antioxidant activity
than Trolox against ABTS•+, DPPH and galvinoxyl radicals (EC50 values of 39.98, 150.99 and 13.19 µ ,
respectively). It is likely that such differences in antioxidant activity ay rely on the differences in
the relative positions of hydroxy groups [31]. Then, compound 3, which showed the best scavenging
activity, was evaluated for its primary antioxidant capacity. In this step, three reaction mechanisms
were considered: single electron transfer (SET), hydrogen transfer (HT) and radical adduct formation
(RAF), involving •OOH, •OOCH3 and •CH(OH)CH3 as radicals. These experiments were carried out
in lipidic and aqueous media, in order to mimic membrane and intra-cellular environment [32], [33].
The results indicated that different mechanisms are involved depending by the medium and that
positions 4, 7 and 8 of compound 3 are probably involved in HT mechanism, whereas positions 3, 4, 5
and 7 could be involved in RAF mechanism. Finally, the secondary antioxidant activity of compound 3
in aqueous media at physiological pH was evaluated. In the Haber-Weiss reaction (i.e., the reduction
of copper in aqueous media and subsequent copper-catalyzed hydroxy radical formation), 3 was able
to inhibit copper (II) reduction avoiding oxidative stress. It was found that hydroxy groups in position
7 and 8 are fundamental for the primary and secondary antioxidant activity in both lipid and aqueous
media. Recently, Wang and co-workers investigated the antioxidant activity and the mechanism of the
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antiradical action of six coumarin-fused coumarins (4–9, Figure 4) previously synthesized by Xi and
Liu [34,35].
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Density functional theory (DFT) calculations were performed, foll wed by the examination of the
primary mechanisms, including HT, electron transfer-prot n transfer (SET-PT) and sequential prot n
loss transfer (SPLET). The most able conformation of all the compounds was a no -plan r structure,
due to he steric repulsion of the groups in positions 5 and 5′. Such conformation was retained by the
correspondent anions and cation radicals (ArO−, ArOH+•). HT process resulted the most ignificant in
gas or no -polar phase, where compound 9 showed the highest activity. The HT path was possible for
compounds 7, 8 and 9, having two or three OH groups, whereas 4 resulted inactive due to he absence
of OH groups; compound 5, with only the 6-OH group, was less active than other compounds and 6
could merely trap DPPH radical with a small rate constant. A second HAT process was possible only
for compound 9 and this finding could explain the higher activity of this molecule. In polar media,
SPLET mechanism was favored—in this case the studied compounds wer more efficient than Trolox
in the deprot nation step and, a ound 7 resulted to be the most promising, being
more prone than the other compounds to deprotonate in a polar enviro ment.
The antioxidant potential of coumarin nucleus can be exploited in the production of new hybrid
compound with enhanced antioxidant activity. A rec nt example of this strategy is the synthesis of a
new seri s of chitosan derivatives (10a–d, Figure 5) containi g the coumarin nucleus, achiev d by Li
and collaborators [36].
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Figure 5. Chitosan derivatives 10a–d.
The antioxidant potential of compounds 10a–d was investigated by evaluating the inhibition of
lipid peroxidation, metal ion chelation and free-radical scavenging activity. Since both chitosan and
coumarins have antioxidant properties themselves, the synthesized compounds were expected to
show a stronger activity. Lipid peroxidation inhibition was determined by quantifying thiobarbituric
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acid-reactive substance (TBARS), using linoleic acid as a reference compound [37]. The results
displayed the ability of the synthesized molecules to inhibit TABRS in a concentration-dependent
manner; compound 10d emerged as the most active (IC50 = 0.11 mg/mL), showing a more efficient
scavenging activity than chitosan alone (IC50 = 0.38 mg/mL). Then, the radical-scavenging activity
was evaluated. For this purpose, free radicals •OH, DPPH and O2•− were used. Compounds 10a–d
showed a stronger •OH scavenging activity (IC50 = 0.09–0.12 mg/mL) compared to that of chitosan.
These results suggested that the coumarin moiety strongly enhances chitosan antioxidant properties.
Since the chelating ability of antioxidants prevents oxidative stress by avoiding •OH production,
iron-chelating properties of the new compounds were also evaluated through measurements of
inhibition of ferrozine-Fe2+ complex formation. Again, the obtained results (IC50 = 0.02–0.04 mg/mL)
were better than those of chitosan alone. Finally, cytotoxicity of the synthesized compounds was
tested: no toxic effects were detected on 3T3-L1 and HHL-5 cells. Interestingly, 3T3-L1 cells showed an
increase in their viability, probably because of the antioxidant activity of the tested compounds.
A similar approach was followed by Popova and co-workers, who designed and synthesized
a series of 4-methylcoumarins with tert-butyl, isobornyl and isocamphyl substituents (11, 12, 13–17,
Figure 6) [38].
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Figure 6. Chemical structures of tert-butylcoumarins 11 and 12 and terpenylcoumarins 13–17.
The synthesized compounds were evaluated in terms of antioxidant, membrane-protective (MPA)
and radical-scavenging (RSA) activities in vitro. All the tested compounds, at a concentration of 100
µM, exhibited good inhibitory activity against lipid peroxidation products (LPO) formation (IC50 =
3.33–7.12 nM), whereas 7-hydroxy-4-methylcoumarin, used as reference compound, showed no activity.
The scavenging activity, evaluated using DPPH, strictly depended on the structure: only isobornyl
derivatives showed moderate activity in the DPPH assay (compound 15 showed RSA% = 57.48 ± 0.60
at 100 µM; RSA% = 87.95 ± 0.22 at 500 µM). Moreover, the protective activity towards cell membrane
was assessed, measuring the inhibitory activity against H2O2-induced hemolysis of red blood cells
(RBCs). In all the experiments, the most promising compound was 15, having two isobornyl moieties.
From these studies, it appears clear that coumarin derivatives show a great potential as antioxidant,
membrane-protective and radical-scavenging compounds and that their activity depends mainly on
the number and the position of the hydroxy groups.
2.2. Anticancer Activity
The t rm “cancer” defines a wide range of diseases caused by the accumulation of mutations and
characterized by a multi-step process, involving many different factors which may not directly cause
cancer themselves but can increase the chances of genetic mutations [39,40].
Recently, Maleki et al. have synthesized eighteen O-prenylated coumarin derivatives and tested
them on HeLa cervical cancer and HDF normal cells by MTT assay [41]. The most promising compounds
are reported in Figure 7.
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The results represent a good starting point for the design of novel derivatives, because most of the
examined compounds exhibited selective toxicity on HeLa cells (IC50 values between 136.4 ± 1.90 µM
and 172.2 ± 1.80 µM after 24 h), whereas no negative effects on HDF normal cell’s gro th as
detected. S R studies proved that the substitution on 6 position of cou arin nucleus provided the
best anticancer activity, follo ed by substitution on 8. In addition, it as found that the cytotoxic
properties of -prenylated cou arins depends on the length of the prenyl chain, hich increases the
lipophilicity of the olecule, thus facilitating its penetration into the cells.
The cytotoxic activity of prenylated-coumarin derivatives had been evaluated also by other groups.
Recent studies have shown a functional role of lipoxygenases (LOXs) in carcinogenesis, precisely in
prostatic cancer and the capability of 5- farnesyloxycoumarin (18, Figure 8) to inhibit 15-LOX-1 [42–44].
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Starting from these observations, Orafaie and collaborators investigated the inhibitory activity
of compound 18 on 15-LOX-1 [45]. The cytotoxic effects of 18 were evaluated by means of MTT
assay on two carcinoma cell lines (PC-3 and DU145) and a normal cell line (HFF3), using 4-MMPB
(4-methyl-2-(4-methylpiperazinyl) pyrimido [4,5-b] benzothiazine) as reference compound. When
PC3 and DU145 human PCa cells were treated with different concentrations of both 4-MMPB and
18 for 24, 48 and 72 h, a dose-dependent and time-dependent decrease in the survival of the cells
was exhibited. PC3 cells resulted to be more sensitive than DU145 cells to both inhibitors (IC50 in
µg/mL for compound 18 on PC3 cells: 24 h, 40.1 ± 7.9, 48 h, 27.05 ± 3.9, 72 h, 26.43 ± 2.1; DU145 cells:
24 h, 98.14 ± 48.3, 48 h, 62.5 ± 17.3, 72 h, 41.85 ± 7.8; IC50 in µg/mL for 4-MMPB: PC3 cells: 24 h,
32.01 ± 3.2, 48 h, 25.47 ± 1.9, 72 h, 18.97 ± 2.8; DU145 cells: 24 h, 35.22 ± 1.9, 48 h, 27.84 ± 2.22, 72 h,
19.52 ± 4.92). Moreover, compound 18 had no significant anti-proliferative activity on normal cells.
Concerning the mechanism of action, it was found that 5- farnesyloxycoumarin acts as a cytotoxic agent
causing chromatin condensation and DNA damage and induces the arrest of the cell cycle in G0/G1
phase. A similar study was carried out on 8-farnesyloxycoumarin (19, Figure 8) by Hosseinymehr and
collaborators [46]. Again, the coumarin derivative showed inhibitory activity on 15-LOX-1 in PC3 and
DU145 cell lines, thus inducing apoptosis of the cancer cell, with the same mechanism of compound 18.
PC3 cells resulted to be more sensitive to 19 inhibition than DU145 cells; IC50 values of 19 on PC3 cells
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were similar to those of cisplatinum (PC3 IC50 in µg/mL 24 h, 34.98 ± 95.57, 48 h, 14.92 ± 40.76, 72 h,
14.12 ± 38.58).
Halawa et al. synthesized and characterized a new series of 4-arylamino-3-nitrocoumarin
analogues from 4-hydroxycoumarin and tested them on the human cervix carcinoma cell line KB-3-1 [47].
These compounds were found to target the DNA-Topo I (human Topoisomerase I) complex, thus
blocking cell replication and leading to cell death. Among this series, thiazolidinylidene derivative 20
(Figure 9) containing a malononitrile fragment exhibited the best cytotoxic activity with an IC50 value
of 21 µM. The cytotoxicity of 20 was explained also by docking studies which highlighted that it forms
important H-bonds with Arg364, Asp533, Gln633 and 5′-thio-2′ deoxyguanosine phosphonic acid of
the DNA backbone.
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Figure 9. 4-arylamino-3-nitrocoumarin derivative 20.
Herrera et al. synthesized a series of 3- and 7-styrylcoumarins, s me of w ich showed
anti-prolif r tive activity on SW480 hum n c lon adeno arcinoma cells [48]. Among them,
7-(4-hydr -3,5-dimethoxystyryl)-2H-chromen-2-one (21, Figur 10) showed the highest activity
(IC50 = 1.01 µM) as it was capable of inducing apoptosis in SW480 cells, probably by mod lating the
tumor-suppressor protein p53. The new compou d was also te ted i vivo, demonstrating to b able
to inhibit the early progression of colon adenocarcinoma [49].
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As coumarin nucleus can be widely decorated, it can be u ed in the synthesis of hybrid compounds,
targeting different proteins involved not only in tumor growth but also in metastatic and angiogenetic
processes. In this co text, Diao and collaborators synthesized series of iethyl ne glycol tethered
isatin-1,2,3-triazole-coumarin derivatives (22a-l, Figure 11) [50]. Several isatin-based or 1,2,3- triazole
or coumarin-based compound (semaxanib, carboxyamidotri z le and STX64) ar involv d in clinica
trials or have al ady been used the treatment of various cancers ( s colon- ctal, prostatic, endometrial
and breast cancer) [51,52], whereas i atin-1,2,3-triazole-coumar n de ivatives sh wed activity against
different cancer types. In addition, SAR studi s demonstrated that the linker between isatin and
1,2,3-triazole influences the activity [52,53] and that hydrogen bonds are fundamental for the biological
activity [54]. These evidences guided Diao and collaborat rs in the choice of diethylene glycol as a
linker [47]. Ten compounds were tested o H pG2 (liv r carcinoma), HeLa (cervic l cancer), A549 (lung
adenocarcinoma), DU145 (prostatic ancer), SKOV3 (ovar an carcinoma), MCF-7 (breast cancer) and
drug-resistant MCF-7/DOX (doxorubicin-resistant MCF-7) human canc r cell li es. All the synthes zed
compounds showed weak to moderate in vitro activity against all the cell lines, ther fore further SAR
studies are necessary for th obtai ment of new, more active compounds.
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Cai et al. developed a series of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates [55].
These compounds act on STAT3, which is involved in the regulation of mitochondrial apoptotic
pathway [56]. In particular, they hypothesized that the inhibition of phosphorylation of Tyr705 and
Ser727 might prevent STAT3 activation. Four STAT3 over-activated human cancer cell lines (i.e.,
human breast carcinoma MDA-MB-231 and MCF-7 cells, human colonic carcinoma HCT-116 cells
and human hepatocellular carcinoma HepG2 cells) were selected to assess the biological activity of
the newly-synthesized compounds. Compound 23 (Figure 12) showed high potency in inducing
cancer cell apoptosis and ROS generation, inhibiting STAT3 phosphorylation on Tyr705, affecting
mitochondrial membrane potential and preventing STAT3 DNA-binding activity. In addition, 23
inhibited implanted 4T1 breast cancer growth in vivo. The antiproliferative effects of compound 23
on normal cells were investigated by MTT assays comparing it to the STAT3 inhibitor Stattic, which
showed growth inhibition activity in both tumor and normal cells, whereas compound 23 exhibited
selective inhibitory activity against cancer cells (IC50 14.62 µM for MCF-10A cells and IC50 35.60 µM
for L02 cells), indicating a higher selectivity than Stattic.
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2.3. Carbonic Anhydrase Inhibition
ic a rases (CAs) are ubiquitous metalloenzymes that catalyze the reversible hydration
of carbon d oxide to bicarbonate and protons, which is an essential physiological r action [57]. Thus,
this enzyme is involved in a wide ange of physiological and pathological proces es (pH regulatio ,
CO2 homeostasis, respiration, bone resorption and tumorigenesis) [58] and its deregulati n by means
of carb ic anhydrases inhibito s (CAIs) may be useful in the treatment f many disorders [59–61].
Th ideal CA inhibitor would sele tivel act agai st th se isoforms (hCA IX, XII, for ins ance) related
to a certain disease [62,63]. In this context, coumarins em rged as potent al a ypical hCA ligands that,
unlike classical hCAIs, o not need to chelate the prosthetic zinc ion but, after binding the catalytic site,
are hydrolyzed to the corresponding 2-hydroxy cinnamic acid derivatives, the actual inhibitors [64,65].
Some studies highlighted that coumarins are capable of binding at the entrance of hCA catalytic site,
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blocking the enzyme activity. Furthermore, 7-hydroxycoumarins derivatives showed good selectivity
toward IX and XII isoforms over hCA I and II and, in some cases, they exhibited cytotoxic activity
on cancer cells [66–69]. Many efforts have been made in this direction and the most recent results
are here reported. Fois and collaborators have recently investigated the selective inhibitory activity
towards CA IX and CA XII of extracts of Magydaris pastiacea seeds, from which they isolated ten linear
furocoumarins, four simple coumarins and a new angular dihydrofurocoumarin [70] All the mentioned
compounds were tested against four isoforms of hCA: both extracts showed selective activity towards
CA IX and XII whereas no effect was seen on isoforms I and II at a concentration of 100 ng/mL. The
most promising compound was umbelliprenin (24, Figure 13), highly active (Ki = 5.8 nM) against CA
XII and highly selective over isoforms I and II.
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Figure 13. Chemical structure of umbelliprenin (24).
Umbelliprenin (24) was then tested on HeLa cancer cells in order to evaluate its cytotoxic activity
and resulted to possess a moderate cytotoxicity (IC50 = 75 µM) proving to be able to inhibit tumor
growth, angiogenesis and metastasis formation in mice (after i.p. administration). It is noteworthy
that CA IX and XII are overexpressed in tumor cells under hypoxic conditions, whereas the mentioned
tests were carried out under normoxic conditions, which could explain the moderate cytotoxic activity
of the isolated compound.
In 2019, starting from 4-methylumbelliferone (25, Figure 14), Buran and co-workers synthesized
a series of 8-substituted coumarin-based compounds bearing alkylpiperazine and arylpiperazine
chains (26–37, Figure 14), and evaluated their inhibitory activity against hCA I, II, IX and XII [71].
All the tested compounds were able to inhibit hCA isoforms IX and XII, without showing any
inhibitory activity towards the cytosolic isoforms I and II up to a 10 µM concentration. The test
pointed out that these compounds had higher affinity for hCA XII over IX and, except for compound 36
(Ki (hCA XII) = 26.4 nM), they all had Ki values comparable to those of the reference drug acetazolamide
(Ki (hCA XII) = 5.7 nM).
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It is remarkable that the substitution of C8 position of 4-methylumbelliferone (25) did not
have any influence on in ibition of hCA XII, suggesting that no significant interaction may b
achieved between the side chains of compounds 26–37 and the catalytic site of isoform XII. On the
other hand, alkylpiperazine derivatives showed better activity on hCA IX when compared with the
other synthesized compounds, being compound 30 the one with the highest activity among them
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(IC50 = 27.1 nM). Similar results were obtained by many other groups that have recently synthesized
coumarin-based compounds and evaluated them as hCA IX and XII inhibitors. Sulphocumarins,
bis-coumarins and coumarins 1,3,4-oxadiazole derivatives are some examples [72–74].
2.4. Antibacterial Activity
The battle against infections and multidrug resistant bacteria is almost certainly one of the
most challenging issue that the scientific community and the whole mankind will face in the near
future. Multidrug resistant (MDR) bacteria are defined as non-susceptible strains to one or more
antimicrobials on three or more antimicrobial classes, whereas strains that are non-susceptible to all
antimicrobials are classified as extremely drug-resistant strains [75,76]. The plant kingdom provides a
virtually endless source of novel chemicals and scaffolds, such as polyphenols and coumarins [77].
In 2005, the antibacterial potency of nearly 50 coumarin derivatives, natural and synthetic, was
evaluated and then correlated by a SAR study. Bacterial susceptibility to coumarins was evaluated
by determining the minimal inhibitory concentration (MIC) and minimum bactericidal concentration
(MBC), considering active compounds exhibiting MIC values ranging from 62.5 to 2000 µg/mL. Among
the active compounds, osthenole (a natural coumarin having also the anti-inflammatory activity)
showed the most potent activity with a MIC of 62.5 µg/mL against S. aureus and B. cereus [78].
In 2015, Nagamallu and co-workers exploited the Vilsmeier-Haack reaction to obtain a series
of novel pyrazole-containing coumarins and then evaluated their antioxidant and antibacterial
activities [79]. Among the series, two compounds (38 and 39, Figure 15) showed a good antibacterial
and antifungal activity, with MIC values comparable with the ones of ciprofloxacin (positive control
against bacteria species) and fluconazole (positive control against fungi strains).
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Figure 15. Chemical structure and minimal inhibitory concentration (MIC) values of antibacterial
coumarins proposed by Nagamallu and colleagues [79].
Following the idea that the introduction of an additional coumarin nucleus on a parent coumarin
molecule could improve the pharmacological activity (i.e., dicumarol as anticoagulant), in 2017,
Chougala and colleagues designed and synthesized a series of bis-coumarin derivatives [80].
Figure 16 shows the common scaffolds of the bis-coumarins synthesized using l-proline as catalyst
in a multi-component reaction approach.
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In 2018, Chavan and Hosamani proposed a facile method for the microwave assisted synthesis
of a series of pyrazole-containing coumarins and tested eir antibacterial and anti-inflammatory
activities [83]. The res archers evaluated the in vitro antibacterial activity of the newly synthesized
compounds through ag -w ll diffusion method against two Gram-pos tive (Bacillus subtilis (ATCC no.
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23857) and Staphylococcus aureus (ATCC-29213)) and two Gram-negative (Escherichia coli (ATCC-25922)
and Pseudomonas aeruginosa (ATCC No.25619)) bacterial strains [84]. The MIC values were compared
to those of ciprofloxacin and all the compounds showed significant antibacterial activity. In particular,
compounds 50 and 51 (Figure 18), showed an excellent activity against S. aureus (MIC 0.78 µg/mL and
MIC 1.562 µg/mL, respectively). Docking studies were in good agreement with the biological results.
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In , adeiro and co-workers focalized their interest towards the antibiotic activity of oumarins
isolated from Rutacea species (Figure 19) [85]. Bergapten, xantoxin, isopimpinellin and i peratorin did
not exhibit any a tibacterial ctivity, even at the highest concentration, against S. aureus strains resistant
to tetracycline, rythromycin and norfloxacin. However, their role as modulator of other antibiotics
seemed quite promising, becau isopimpin llin and imperatorin reduced th MIC of erythromycin,
tetracycline and norfloxacin. Nevertheless, more detailed research is nec ary in order to enable t e
us of these atural products as adjuvants to antimicrobial agents.
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Liu and colleagues made a huge effort to synthesize and identify coumarin-pyrazole 
carboxamide derivatives as potential topoisomerase-II inhibitors: 70 novel compounds were obtained 
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Three of them (52–54, Figure 21) were endowed with promising antimicrobial activities. In 
particular, compound 52 showed a considerable inhibitory activity compared with ciprofloxacin 
against Escherichia coli and compound 53 exhibited excellent antibacterial activity against Salmonella 
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2.5. Antifungal Activity 
Fungal diseases are a well-known plague for animal and plant worlds but a more hidden menace 
for human health. More than 90% of all reported fungal-related deaths results from species that belong 
to one of four genera: Cryptococcus, Candida, Aspergillus and Pneumocystis [88–90]. Coumarin derivatives 
are endowed with antifungal activity, potentially useful in both pharma and agri-food sectors. In this 
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inhibition (mm) and minimum inhibitory concentration (MIC) values.
Liu and colleagues made a huge effort to synthesize and identify coumarin-pyrazole carboxamide
derivatives as potential topoisomerase-II inhibitors: 70 novel compounds were obtained and
evaluated [87].
Three of them (52–54, Figure 21) were endowed with promising antimicrobial activities. In
particular, compound 52 showed a considerable inhibitory activity compared with ciprofloxacin against
Escherichia coli and compound 53 exhibited excellent antibacterial activity against Salmonella typhi. The
selected compounds exhibited also potent inhibition against Topo II and Topo IV with IC50 values in
the range 9.4–25 mg/L.
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2.5. Antifungal Activity
Fungal diseases are a well-known plague for animal and plant worlds but a more hidden menace
for human health. More than 90% of all reported fungal-related deaths results from species that belong
to one of four genera: Cryptococcus, Candida, Aspergillus and Pneumocystis [88–90]. Coumarin derivatives
are endowed with antifungal activity, potentially useful in both pharma and agri-food sectors. In this
paragraph, we will focus on the recent progresses in the development of novel antifungal drugs for
human use whereas agri-food applications can be found in Section 3.2, Food systems.
Diseases by Candida species, a family of fungi that normally live on the host epithelial species but
can initiate a fatal infection in particular cases like immunodeficiency, are the fourth most common
cause of nosocomial blood-stream infections. Despite several species of Candida can cause disease,
Candida albicans prevails in term of incidence [88,91,92]. Therefore, in 2016, Shaik and colleagues
Int. J. Mol. Sci. 2020, 21, 4618 15 of 81
designed a novel series of coumarin derivatives conjugated with 1,2,3-triazole moieties, on the basis of
a previous work by Shi and Zhou and of the common use of azoles as antifungal drugs [93,94]. The
antifungal potency of the novel compounds was tested against Candida albicans and other four fungal
pathogens (i.e., Fusarium oxysporum, Aspergillus flavus, Aspergillus niger and Cryptococcus neoformans);
MIC values were evaluated and compared to MIC of the reference compounds miconazole and
fluconazole. Compounds 55–57 and 59 (Figure 22) were found to be equipotent to miconazole against
C. albicans and compound 58 was found to be two-fold more active compared with miconazole and
equipotent to fluconazole.
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Furthermore, molecular docking studies showed that these compounds have a high affinity
toward the active site of enzyme P450 cytochrome lanosterol 14α-demethylase and analysis of ADME
parameters confirmed their drug-like properties [94].
In 2017, fifteen novel coumarin derivatives were synthesized by Tiwari et al., under solvent free
conditions and exploiting the ionic liquid [Et3N ][HSO4] as a catalyst [95]. The compounds were
tested both for their antifungal and antibacterial activities and, among the series, compounds 60 and
61 resulted to be the most potent as fungicides (Figure 23). The MIC values observed for compound 60
and 61 were comparable to the standard drug iconazole.
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Figure 23. Antifungal coumarins synthesized under solvent-free conditions and exploiting ionic liquid
as catalyst.
Further studies demonstrated that compound 60 acts by inhibiting ergosterol biosynthesis in C.
albicans. Molecular docking studies revealed, as for previous study on compounds 55–59, a highly
spontaneous binding ability of the tested compounds to the active site of lanosterol 14α-demethylase,
Int. J. Mol. Sci. 2020, 21, 4618 16 of 81
which suggests that the tested compounds inhibit the synthesis of this enzyme. Moreover, in silico
ADMET properties were evaluated and demonstrated that all the compounds exhibited a good percent
absorption (% ABS) ranging from 84.9% to 100%. Moreover, these compounds had proven to be safe
after in vitro toxicity, in vivo acute oral toxicity and behavioral studies.
Coumarin-based antifungal azoles had been further investigated by Elias and co-workers, who,
in 2019, developed a series of 11 coumarins conjugated with 1,2,4-triazole and imidazole motifs [96].
The analysis of the biological effects of these novel chemical entities highlighted that imidazole-based
derivatives (Figure 24) were more efficient against several Candida strains compared to 1,2,4-triazole
derivatives. Moreover, the mode of action of the two classes of compounds were different. Whereas
the antifungal activity of the triazole-based azoles was dependent on expression of CYP51, the target
of the azole antifungals, imidazole-based compounds displayed antifungal activity against a mutant
lacking CYP51, indicating that imidazole-based azole antifungals have additional modes of action.
This peculiarity could be favorable in the struggle against drugs-resistant fungal strains.
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colleagues conducted the first antimicrobial activity guided isolation of the molecular constituent of 
this particular species of Ferulago [97]. Four coumarin compounds (Figure 25) were isolated and 
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marmesin senesioate, suberosin and crenulatin showed antifungal activity with 625 mg/L MIC 
against Candida albicans.  
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The antifungal potency of coumarin itself against Candida albicans had been previously 
evaluated, in particular its antibiofilm activity [98,99]. Recently, Xu and co-workers focused their 
attention on the possible way to prevent the adhesion and formation of biofilm by Candida albicans 
on implanted medical devices. The research group observed that coumarin not only suppresses 
biofilm formation but also affects the structure of the mature biofilm; moreover the adhesion, the cell 
surface hydrophobicity (CSH) and the filamentous growth of C. albicans significantly decreased after 
coumarin treatment, indicating that coumarin inhibits biofilm formation by suppressing adhesion 
[100].  
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Furthermore, it should not be forgotten the contribution of natural coumarins to the fight against
Candida infections. Ferulago trachycarpa Boiss. is one of the species of Ferulago W. Koch., common in
Anatolian region, exploited in traditional medicine but also in culinary field. Previous studies showed
that coumarins are the main compounds found in Ferulago but only in 2018, Dikpinar and colleagues
conducted the first antimicrobial activity guided isolation of the molecular constituent of this particular
species of Ferulago [97]. Four coumarin compounds (Figure 25) were isolated and purified and then
three of them were tested against bacterial and fungal strains; in particular, marmesin senesioate,
suberosin and crenulatin showed antifungal activity with 625 mg/L MIC against Candida albicans.
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The antifungal potency of coumarin itself against Candida albicans had been previously evaluated,
in particular its antibiofilm activity [98,99]. Recently, Xu and co-workers focused their attention on
the possible way to prevent the adhesion and formation of biofilm by Candida albicans on implanted
medical devices. The research group observed that coumarin not only suppresses biofilm formation but
also affects the structure of the mature biofilm; moreover the adhesion, the cell surface hydrophobicity
(CSH) and the filamentous growth of C. albicans significantly decreased after coumarin treatment,
indicating that coumarin inhibits biofilm formation by suppressing adhesion [100].
The antifungal potency of coumarin-based triazoles against other fungal strains in addition
to Candida species had been evaluated by Dharavath and colleagues in 2020. Coumarin-based
1,4-disubstituted 1,2,3-triazole derivatives were synthesized using a highly efficient, eco-friendly
protocol via a copper(I)-catalyzed click reaction between various substituted arylazides and terminal
alkynes. The in vitro antifungal activity was tested against Aspergillus niger, Aspergillus flavus and
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Fusarium oxysporum by using the disc diffusion method and the results were compared with those of
clotrimazole, the reference drug. Compounds 63–68 (Figure 26), characterized by the presence of a
para-substituted phenyl moiety, directly linked to the triazole ring, showed comparable activity in
respect to the reference compound clotrimazol [101,102].
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2020 has been a crucial year for the timeless war between human and viruses: World Health 
Organization (WHO) declared the outbreak of Sars-COVID-19 a Public Health Emergency of 
International Concern on 30 January 2020 and on 11 March WHO characterized COVID-19 as a 
pandemic [103]. Whole developed countries have been quarantined and generations that never faced 
medical crisis are now struggling with the consequences of the viral diffusion. Human history is 
afflicted by the cyclic succession of pandemic events and the research of new antivirals is still 
ongoing, due to the ability of viruses to mutate and the continuous appearance of new viruses on the 
medical scenario [104]. 
The natural world is a priceless source of valuable medical compounds and also in the fight 
against viral diseases there are several natural molecules which exhibit antiviral activity [105–109]. 
Coumarins, likewise other polyphenolic compounds, exert a remarkable antiviral activity [110,111]. 
The antiviral activity of coumarins explicates through different mechanisms which affect the life cycle 
of viruses and their biological activities could be changed depending upon the combination of 
various substituents and conjugates [104,112]. Coumarins appears to be active against several viruses, 
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Liu and co-workers after a phytochemical study on the stem of Clausena lenis isolated three new 
and nine known prenylated coumarins [113]. All the prenylated coumarins were evaluated both for 
their anti-inflammatory and anti-HIV reverse transcriptase (RT) activities. In this last case, the 
inhibition assay for the cytopathic activities of HIV-1 (EC50) as well as cytotoxic activity assay against 
C8166 cell line (CC50) according to MTT methods were applied [114,115]. 
The three new isolated compounds (69–71, Figure 27) showed the best inhibitory activity with 
an EC50 of 0.29, 0.68 and 0.17 μM, respectively. Furthermore, no cytotoxicity was observed against 
C8166 cell line (CC50 > 200.00 μM). 
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2020 has been a crucial year for the timeless war between human and viruses: World Health
Organization (WHO) declared the outbreak of Sars-COVID-19 a Public Health Emergency of
International Concern on 30 January 2020 and on 11 March WHO characterized COVID-19 as a
pandemic [103]. Whole developed countries have been quarantined and generations that never faced
medical crisis are now struggling with the consequences of the viral diffusion. Human history is
afflicted by the cyclic succession of pandemic events and the research of new antivirals is still ongoing,
due to the ability of viruses to mutate and the continuous appearance of new viruses on the medical
scenario [104].
The natural world is a priceless source of valuable medical compounds and also in the fight
against viral diseases there are several natural molecules which exhibit antiviral activity [105–109].
Coumarins, likewise other polyphenolic compounds, exert a remarkable antiviral activity [110,111].
The antiviral activity of coumarins explicates through different mechanisms which affect the life cycle
of viruses and their biological activities could be changed depending upon the combination of various
substituents and conjugates [104,112]. Coumarins appears to be active against several viruses, like
HIV, influenza, hepatitis, Dengue and Chikunguya [104].
Liu and co-workers after a phytochemical study on the stem of Clausena lenis isolated three new
and nine known prenylated coumarins [113]. All the prenylated coumarins were evaluated both
for their anti-inflammatory and anti-HIV reverse transcriptase (RT) activities. In this last case, the
inhibition assay for the cytopathic activities of HIV-1 (EC50) as well as cytotoxic activity assay against
C8166 cell line (CC50) according to MTT methods were applied [114,115].
The three new isolated compounds (69–71, Figure 27) showed the best inhibitory activity with an
EC50 of 0.29, 0.68 and 0.17 µM, respectively. Furthermore, no cytotoxicity was observed against C8166
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Figure 27. New prenylated coumarins from Clausena lenis.
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Prenylated coumarins came to the fore in 2019 thanks to a work by Liu et al., who revealed for
the first time the presence of these type of derivatives in the fruits of Manilkara zapota, an ever-green
tropical tree. Also in this case, three new derivatives were identified (72–74, Figure 28) together with
seven known compounds and the team evaluated their anti-inflammatory and anti-HIV activities,
exploiting the methods described above [116].
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Figure 28. Prenylated cou arins fro anilkara zapota.
The new prenylated coumarins showed the highest anti-HIV RT effect among the prenylated
coumarins derived from the fruit of Manilkara zapota; in particular, compound 72 displayed the most
powerful effect with an EC50 value of 0.12 µM. Comparative studies between compounds 72–74 and
the other coumarin derivatives isolated from the fruits highlighted the importance of the isopentenyl
group as a substituent at C6 and 2-methylbut-3-en-2-yl group as a substituent at C3 for the anti-HIV
RT effect.
In the same year, Jesumoroti and co-workers approached the problem from another point of view,
both regarding the target and the origin of the coumarin derivatives [117]. First of all, a different
viral target was chosen, HIV-1 IN, which is essential for a stable infection. Moreover, there are no
homologous enzymes in the host cell [118]. Secondarily, the coumarin derivatives were obtained
decorating the coumarin nucleus with an hydrazide group, in order to achieve a synergistic effect
against-HIV-1-IN and reducing the toxicity correlated to the salicylhydrazide, which was however
essential for the activity [119–121]. The synthesized compounds were evaluated for their in vitro HIV-1
IN inhibitory activity using chicoric acid (CA) as a reference compound, according to the method
described by McColl et al. [122].
Compounds 75–78 (Figure 29) appeared to be the most active among the whole series
showing an inhibition of extracellular IN (evaluated in vitro according to the method described
by McColl et al. [122]) in a range from 95% to 86 % and IC50 between 13 nM (compound 76) and 31
nM (CA IC50 = 10 nM). Furthermore, the cytotoxicity of all the obtained compounds was tested and
derivatives 75–78 showed low or negligible cytotoxicity.
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Seasonal influenza claims around 0.29–0.65 million victims annually, even if several drugs are
commercially available [123]. The flu is a contagious respiratory disease caused by influenza viruses,
manifesting major epidemics with no predictable periodicity or pattern and all different from one to
another [124]. For these reasons, a constant effort in the development of new drugs for the treatment of
this disease is of greatest importance. In 2019 Osman and co-workers combined two bioactive moieties
into a single molecule in order to obtain new bioactive compounds with antibacterial and antiviral
effects [125]. In particular, based on a previous study of the same research team, in which coumarin
scaffolds and thiazole moiety were combined leading to compounds endowed with both antibacterial
Int. J. Mol. Sci. 2020, 21, 4618 19 of 81
and antiviral activities, the potentiality of this combination was further explored [126], [127]. Four new
molecules of the series showed a remarkable antiviral activity against H1N1 virus. Compounds 79–82
(Figure 30) seemed to be promising agents, having IC50 values of 4.84, 19.72, 6.12 and 9.13 µg/mL,
respectively, against the H1N1 virus.
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Bizzarri et al. exploited the regioselective oxidation of coumarin derivatives with 2-
iodoxybenzoic acid (IBX) in order to obtain catechol and pyrogallol moieties [129]. After cytotoxicity 
studies that confirmed the safety of the series of derivatives, the antiviral activity against influenza 
viruses A/PR8/H1N1 was evaluated and compounds 84–89 (Figure 32) resulted able to inhibit the 
viral replication. Interestingly, pyrogallol derivatives 88 (IC50 = 69.9 μg/mL) and 89 (IC50 = 47.9 μg/mL) 
turned out to be more active than catechol derivatives 84 (IC50 = 106.5 μg/mL) and 85 (IC50 = 91.5 
μg/mL). Moreover, pyrogallol and catechol derivatives were more active than the 
monohydroxycoumarins 6-hydroxycoumarin and 7-hydroxycoumarin (IC50 110 μg/mL for both the 
parent compounds).  
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Figure 30. Hybrid pharmacophores proposed by Osman and co-workers [125].
A similar approach was followed by Pavurala et al., in 2019, who exploited the versatility of the
coumarin scaffold by combining it with another bioactive moiety, in this case a triazolothiadiazine [128].
The result was the synthesis of a series of bis-coumarinyl-bis-triazolothiadiazinyl ethane derivatives
that were evaluated for their antiviral activities against different DNA and RNA viruses. Among the
tested compound 83 (Figure 31) exhibited a good antiviral activity against influenza A virus. More
specifically, in cytopathic effect (CPE) reduction assay against influenza virus infected Madin–Darby
canine kidney (MDCK) cells, it displayed antiviral EC50 values of 20–72 µM.
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i rri et al. exploited he regioselectiv oxidation of coumarin derivatives with 2-iodoxybenzoic
acid (IBX) in order to obtain catechol and pyrogallol moieties [129]. After cytotoxici y studies that
confirmed he safety of the s ries of derivatives, the antiviral cti ity aga nst influenza viruses
A/PR8/H1N1 was evaluated and compounds 84–89 (Figure 32) sulted abl to inhibit t e viral
replication. Interes ingly, pyrogallol derivati es 88 (IC50 = 69.9 µg/mL) and 89 (IC50 = µ
out o be more active than c te hol derivatives 84 (IC50 = 106.5µg/mL) and 85 (IC50 = 91.5µg/mL).
Moreover, pyrogallol and catechol derivatives were more active than the onohydroxycoumarins
6-hydroxycoumarin nd 7-hydroxycoumarin (IC50 110 µg/mL f r both the parent compounds).
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by esculetin (or 6,7-dihydroxycoumarin) against hepatitis B virus (HBV) [131]. The results suggested 
that esculetin efficiently inhibits HBV replication both in vitro and in vivo, which provides an 
opportunity for further development of the compound as antiviral agent. 
2.7. Anti-Inflammatory Activity 
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many inflammatory effectors and mediators are produced and involved, often with a common effect 
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One of the possible advantages of oxidized coumarins could be their mode of action against viruses.
Indeed, due to their antioxidant activity, coumarins derivatives could affect intracellular redox-sensitive
pathways useful for viral replication, independently fro the variability of the strains [129].
As already mentioned, coumarins have been studied also for their potential application as
anti-hepatitis agents. Tsay and co-workers studied the activity against hepatitis C virus (HCV) of
some unnatural imidazole-coumarin conjugates [130]. Above all, three compounds (90–92, Figure 33)
showed a noteworthy antiviral activity against HCV with EC50 values ranging from 5.1 to 8.4 µM and
selective indices (SI = CC50/EC50, which is a measure for the therapeutic window of the compound in
an assay system) higher than 20.
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Huang and co-workers focused their atte on on the investigation of the potentiality expressed by
esculetin (or 6,7-dihydroxycoumarin) against hepatitis B virus (HBV) [131]. The results suggested that
esculetin efficiently inhibits HBV replication both in vitro and in vivo, which provides an oppo tunity
for further development of the co pound as antiviral agent.
2.7. Anti-Inflammatory Activity
Inflammation is a general physiological response that aims, firstly, to the circumscription of the
harmful factors, which could be both endogenous (e.g., cancer, ischemia, autoimmune diseases) and
exogenous (e.g., viral or bacterial infections, trauma), secondarily, to the removal of the causes f t
da age nd finally to the reparation of th tissues and restoration of the functions. Nevertheless,
the inflammation and the consequent restorative process could become harmful for the organism
itself when there is a persistent stimulation and the pha es of inflammation and reconstruction ar
contemporary activated, causing tis ue injuries and fibrosis [132]. During an inflammatory process,
many inflammatory effectors and mediators are produc d and involved, ften with a common effect
on vascular system an on the recruitment of leukocytes [133]. Freq e tly, inflam atory mediators
are the target of anti-inflamm tory drugs [134–137].
Among the numerous biological activities shown by coumarin derivatives, the anti-inflamm y
effect could n t cer ai ly iss. Dawood et al., in 2015, developed a new series of coumarin derivatives
hybridizing two pharmacophoric moieties—the coumarin scaffold itself and thiazoline or thiazolidinone
groups, both showing cyclooxygenase 2 (COX-2) inhibitor effect [127], [138–143]. The compounds were
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evaluated in vivo for their systemic effect, in vitro for their ability to inhibit human COX-1 and COX-2
and also to evaluate the ulcerogenic potential compared to the reference drug, indomethacin, always
following standard methods reported in literature. Most of the new compounds showed significant
in vivo anti-inflammatory activity with a superior gastro-intestinal safety profiles (0–7% ulceration) as
compared to indomethacin. The IC50 values of all the bioactive compounds ranged between 0.31 and
0.78 mM, showing an in vitro high affinity and selectivity toward the COX-2 isoenzyme, compared to
the reference celecoxib. Ethyl thiosemicarbazone 93, thiazoline derivatives 94–98 and the thiazolidinone
compounds 99–100 exhibited the highest in vivo and in vitro anti-inflammatory activities with good
COX-2 selectivity (Figure 34) [143].
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Nevertheless, cyclooxygenases are not the only enzymes involved in the inflammatory process.
Actually, 5-lipoxygenase (5-LOX) catalyzes two different steps in the arachidonic acid metabolism
that brings to the production of leukotriene A4, which is successively metabolized into leukotriene
B4 [144]. Molecular inhibitors of leukotrienes competitively bind the active site of 5-LOX and are
divided in three category: redox-active compounds (i.e., coumarins), iron-ligand inhibitors with weak
redox-active properties a d non-redox-type inhibitors [145].
In 2016, Srivastava nd colleagues valu ted the anti-inflammatory and analgesic effect of a series
of synthesized 7- ubstituted co marins and, consequently, the mos active compounds were assess d
in vitro for 5-LOX inhibition [146]. Compounds 101 an 102 (Figure 35) resulted th most promising
derivatives, also in the u cerogenic risk evaluation when compared to acetylsali ylic cid. In vitro
ki etic study of compound 102 (IC50 = .09 nM) showed mixed or non-competitive type of inhibition
of 5-LOX. The presence of a substituent on C6 position of benzothiaz le ri g was f und very important
for increasing the activity.
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The nuclear factor-kB (NF-kB) family of transcription factors is composed by a set of related, 
evolutionarily conserved DNA-binding proteins. In response to multiple stimuli such as 
inflammatory cytokines, bacterial lipopolysaccharide (LPS), viral infection or stress, a series of 
cascade reactions bring towards the entry on NF-kB into the nucleus and to the activation of several 
genes participating in immune and inflammatory responses, cell adhesion, growth control and 
regulation of apoptosis [148,149]. In 2019, Fan and co-workers evaluated in vivo and in vitro the anti-
inflammatory activity of osthole (Figure 37) [150], a natural prenylated coumarin from Cnidium 
Monnieri (L.) Cuss. but also found in other medicinal plants, which has already shown different 
biological and pharmacological properties such as neuroprotective, osteogenic, immunomodulatory, 
anticancer, hepatoprotective, cardiovascular protective and antimicrobial activities [13]. The team 
established that osthole inhibited the production of NO, PGE2, TNF-a and IL-6 in LPS-induced 
macrophages and suppressed the activity of iNOS and COX-2, probably by blocking the activation 
of NF-kB and p38/MAPK signaling pathways.  
  
Figure 35. Anti-inflammatory 7-substituted coumarins proposed by Srivastava [146].
In 2018, Liu et al. identified ten new coumarin derivatives (3 monomers and 7 dimers) isolated in
a phytochemical study on Murraya exotica, a dwarf tree that is native of the tropical and subtropical
areas of Asia and traditionally used in the treatment of inflammatory-related diseases [147]. Previous
studies had shown that the main active components in M. exotica were coumarins; also bis-coumarins
were isolated from the plant. A further investigation on the 95% aqueous EtOH extract of the roots
allowed the obtainment of new coumarins, together with other bioactive molecules. The compounds
were tested for their inhibitory effect on NO production and compound 103 (Figure 36) stood out
among the coumarins in the inhibition against LPS-induced NO production in BV-2 microglial cells
with IC50 value of 8.6 µM.
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Figure 36. One of the coumarin derivatives isolated from M. exotica.
The nuclear factor-kB (NF-kB) family of transcription factors is composed by a set of related,
evolutionarily conserved DNA-binding proteins. In response to multiple stimuli such as inflammatory
cytokines, bacterial lipopolysaccharide (LPS), viral infection or stress, a series of cascade reactions
bring towards the entry on NF-kB into the nucleus and to the activation of several genes
participating in immune and inflammatory responses, cell adhesion, growth control and regulation of
apoptosis [148,149]. In 2019, Fan and co-workers evaluated in vivo and in vitro the anti-inflammatory
activity of osthole (Figure 37) [150], a natural prenylated coumarin from Cnidium Monnieri (L.) Cuss. but
also found in other medicinal plants, which has already shown different biological and pharmacological
properties such as neuroprotective, osteogenic, immunomodulatory, anticancer, hepatoprotective,
cardiovascular protective and antimicrobial activities [13]. The team established that osthole inhibited
the production of NO, PGE2, TNF-a and IL-6 in LPS-induced macrophages and suppressed the activity
of iNOS and COX-2, probably by blocking the activation of NF-kB and p38/MAPK signaling pathways.
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Figure 37. Structure of the natural coumarin osthole.
In the same year, Mu and colleagues synthesized a series of eleven 7-substituted coumarins and
evaluated their anti-inflammatory activities and their ability to exploit the NF-kB pathway [151]. All
the screened compounds showed a relevant anti-inflammatory activity. In the series, compound 104
(Figure 38) was identified as a hit and further studies of molecular docking were conducted confirming
that 104 could bind to the active site (NLS Polypeptide) of NF-κB p65. Its binding affinity was further
confirmed by surface plasmon resonance (SPR) analysis. Moreover, Western blot assay showed that
104 remarkably blocked the NF-κB signaling pathway in vitro.
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2.8. Neuroprotection: Effect on Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia (60–70% of cases of dementia are
cause by AD) and consists in a neurodegenerative disorder characterized by a slow, progressive and
irreversible loss of cognitive function and memory [152–157]. The current therapeutic approach, mainly
based on the use of acetylcholinesterase (AChE) inhibitors (rivastigmine, donepezil, galantamine)
or N-methy-D-aspartic acid (NMDA) receptor inhibitors (memantine), is merely symptomatic and
does not counteract degeneration progression. New innovative approaches, such as multi-targeted
strategies, are urgently required in order to cure cognition and motor dysfunctions, neurodegeneration
and depression. Among their biological activities, coumarins showed the ability to inhibit some
biological targets involved in AD. With this in mind, some recent works aimed at investigating
coumarins potential in the treatment of AD are discussed below.
In 2019, Karakaya and collaborators investigated the antioxidant and AChE/BuChE inhibitory
activity of aerial parts, fruits, flowers and root extracts from Ferulago cassia Boiss [158]. Root’s and
fruit’s dichloromethane extracts showed the highest antioxidant potential in TBA assay. The evaluation
of anticholinesterase activity was carried out by means of the Ellman’s method [159]: dichloromethane
extracts showed significant inhibition against BuChE (96.56% ± 2.98 and 82.33% ± 2.69, respectively) at
20 µg/mL and appreciable inhibition against AChE (53.24 ± 1.22 and 31.38 ± 5.41%, respectively) at 20
µg/mL. Four coumarins were isolated from Ferulago cassia—peucedanol, suberosin, grandivitinol and
umbelliferone (Figure 39). Therefore, F. cassia can be considered a starting point for the development of
new compounds with antioxidant and anticholinesterase activity.
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Figure 39. Coumarins extracted from Ferulago cassia.
Thanks to their simple structural architecture and chemical stability, coumarins can be easily
synt esized and modified in order to produce more active and selective co pounds. Najafi and
co-workers synthesized a series of tacrine-cou arin deriv tives linked to a 1,2,3-triazole moiety and
evaluated t eir activity in terms of AChE and butyrylcholinesterase (BuChE) inhibition, keeping
donepezil and tacrine as reference drugs [160]. In addition, their beta-secretase 1 (BACE1) inhibitory
activity and neuroprotective potential were evaluated. Since tacrine is a well-known inhibitor of the
catal tic site of AChE, whereas coumarins showed affinity for the peripheral anio ic site (PAS) [161],
this new compounds may be p tential dual—and therefore more powerful - inhibitors of ChEs. The
in vitro AChE a BuChE inhibitory activity was evaluated using the Ellman’s method [159]; among
all the tested molec les, compound 105 resulted the best in AChE inhibitio (IC50 = 0.027 ± 0.009 µM;
tacrine IC50 = 0.048 ± 0.011 µM, onepezil IC50 = 0.039 ± 0.097 µM) and compound 106 was the most
promising BuChE inhibitor (IC50 = 0.006 ± 0.002 µM; tacrine IC50 = 0.010 ± 0.004 µM, donepezil IC50 =
8.416 ± 0.628 µM) (Figure 40).
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Concerning the anti-BuChE activity, structure-activity relationship studies showed that Cl and
Me substituents, as well as the methylene linker, play a complex and not completely understood
role in the enzyme inhibition. From the evaluation of inhibitory activity of the synthesized
compounds on BACE1, a moderate inhibitory activity of compound 105 was observed (inhibition
of 28.69% and 13.97% at 50 and 10 µM, respectively). Nevertheless, compound 105 did not show
neuroprotective action on PC12 cells exposed to Aβ25-35. Then, in vivo evaluation of compound
105 using the Morrison Water Maze method [162] was made and valuable results based on
memory improvement in scopolamine-induced impairment were observed. Similarly, Rastegari
and collaborators synthesized a series of 1,2,3-triazole-chromenone carboxamide derivatives and
investigated their potential as anti-Alzheimer’s agents, in terms of inhibitory activity against AChE,
BuChE and BACE1, besides their neuroprotective and metal-chelating properties [163]. The anti-AChE
activity of coumarin-3-carboxamide was already known [164], as well as the ability of the 1,2,3-triazole
moiety to enhance AChEI activity, if linked with tacrine or phenanthridinium derivatives and its
BACE1 inhibitory potential [165]. In vitro AChEI and BuChEI activities of the new compounds
were evaluated, keeping donepezil as reference. Higher activities were shown by compound
107, bearing 3,4-dimethylbenzyl connected to 1,2,3-triazole moiety and by compound 108, having
3-morpholinopropyl and 2-bromobenzyl moieties (Figure 41), even if they are much less active than
donepezil (IC50 = 0.027 µM). Anti-BChE activity was also modest and resulted to be affected by the
type of amine connected to the amide moiety, that is, morpholine or piperidine and by the position
and electronic properties of substituents on the benzyl group connected to 1,2,3-triazole ring.
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intervention), quercetin+H2O2-treated (positive control) and H2O2-treated (negative control) cells. The 
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methanol by means of UV-vis spectrophotometry. Interaction between 107 and Cu2+ and Zn2+ was 
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Figure 41. Chemical structure and IC50 values of compounds 107 and 108.
Compound 107 was chosen for BACE1 inhibitory activity evaluation, showing only modest
results (IC50 = 21.13 µM compared to the reference OM99-2 having IC50 = 0.014 µM). Also,
neuroprotective potential of 107 was investigated by comparing 107-treated cells with intact (no
intervention), quercetin+H2O2-treated (positive control) and H2O2-treated (negative control) cells. The
mentioned compound showed moderate to good neuroprotective activity, not stronger than quercetin.
Finally, since ROS, which are potentially involved in the neurodegenerative process of AD, may be
generated from unregulated reaction of molecular oxygen with the redox active metals such as Fe, Cu
and Zn, the metal-chelating properties of 107 toward Cu2+, Fe2+ and Zn2+ were tested in methanol
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by means of UV-vis spectrophotometry. Interaction between 107 and Cu2+ and Zn2+ was detected,
whereas no interaction was observed between 107 and Fe2+.
De Souza and co-workers designed and synthesized a series of 3-substituted-7-aminoalcoxy-
coumarin derivatives (109a–d, 110a–c, 111a–c, Figure 42) whose AChEI/BuChEI activities and
antioxidant properties were evaluated [166]. All the compounds showed good inhibitory activity
on AChE, with potencies in the nanomolar range, whereas their activity against BuChE was lower
(IC50 between 0.90 to 15.85 µM); 3-(4-(dimethylamino)phenyl)-7-aminoethoxycoumarin (111a) was
considered a hit, showing an excellent inhibitory activity (IC50 = 20 nM) and selectivity towards AChE
(IC50 BuChE/AChE = 354) compared to the reference drug donepezil (IC50 = 6 nM, IC50 BuChE/AChE =
365). Investigation of antioxidant properties showed that only compounds 111a–c presented activity in
Ferric Ion Reduction Method (FRAP), whereas series 109a–d and 110a–c did not show significant results,
suggesting that the dimethylaminophenyl moiety may be responsible for the antioxidant activity.
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Docking simulations showed that all the compounds were able to bind simultaneously the PAS
and cationic active site (CAS) of the electric eel AChE (eeAChE): the interaction with the CAS took
place by means of cation-pi interaction between piperidinyl group and Trp86. Compounds 111a and
111c showed the ability to give a pi-stacking interaction in the PAS, with Trp286. The smaller spacer of
111a allowed the coumarin moiety to be located properly in the gorge, achieving H-bonds with Tyr337
and Phe295. This is probably the reason for the most efficient binding mode (and consequently the
best activity) to eeAChE of compounds with a short spacer.
Yang and his group synthesized a series of twenty-four 3-aryl coumarin derivatives and tested
their cholinesterase inhibitory activity, monoamine oxidase (MAO) inhibitory activity and antioxidant
activity in vitro [167]. As far as cholinesterase inhibition is concerned, most of the mentioned
compounds showed moderate activity. Compound 117 (Figure 43) exhibited a strong activity (IC50
= 3.04 ± 0.32 µM), whereas compound 116 showed selectivity towards AChE. Compound 114 was
more active against BuChE (IC50 = 2.76 ± 0.57 µM) than donepezil, whereas compounds 112, 113 and
115 showed selectivity towards BuChE. 3-Arylcoumarins bearing hydroxy group both at R5 and R6
positions displayed higher activity respect to the mono-substituted counterparts, especially towards
AChE, whereas no significant impact on BuChE inhibition was observed.
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As mentioned, MAO-inhibitory activity was evaluated as well. In fact, MAO is one of the
enzymes responsible for oxidative stress, which is another factor involved in the neurodegenerative
process characterizing AD and different studies identified various ChE/MAO inhibitors as tools for AD
treatment, showing positive results in clinical trials [168]. In Yang’s work, 3-arylcoumarins anti-MAO
activity was compared to that of rasagiline (a selective MAO-B inhibitor): almost half of the compounds
showed relevant activity [167]. Among them, compound 117 was the most promising, with an IC50
= 27.03 ± 0.50 µM, though weaker than rasagiline (IC50 = 0.125 ± 0.005 µM). Again, the presence of
R5, R6 hydroxy groups provided better MAO inhibitory activity. Finally, the antioxidant power of
3-arylcoumarins was studied by means of Ferric Ion Reduction Method (FRAP), using vitamin C as a
reference. Compound 117 resulted again the most active (FRAP value = 41.42 ± 0.35), also showing a
certain activity in vivo, when tested on zebrafish, leading to an increase of total distance of zebrafish
movement proportional to the concentration of compound used.
In 2017, Joubert and collaborators designed and synthesized a series of 7-substituted coumarins
(118–146, Figure 44), consisting in a coumarin motif (MAO inhibitor) condensed with a benzyl-,
piperidinyl-, N-benzylpiperidinyl- or p-bromo-N-benzylpiperizinyl moiety, which resemble the
N-benzylpiperidine function present in donepezil (AChE inhibitor), connected via an alkyl ether
linkage at position 7 [169]. Their biological activities were evaluated in terms of MAO and ChE
inhibitory potential. Inhibition of hMAO was achieved from all the designed compounds, which
also showed selectivity towards MAO-B. The benzyloxy series showed higher activity, in some cases
even better than the reference selegiline (IC50 = 0.008 µM), with IC50 values in the nanomolar range
(0.5–73 nM).
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perhaps indicating that larger substitutions at position 7 are not well tolerated. Again, no activity 
against MAO-A was shown, whereas IC50 values between 0.29 and 5.64 μM were detected on MAO-
B. Compounds that lacked the N-benzylpiperidine, responsible for anti-cholinesterase activity in 
donepezil, showed little or no activity against eeAChE and equine BuChE (eqBuChE). Compounds 
bearing the N -benzylpiperidin moiety showed moderate inhibitory activity against both ChEs (IC50 
values between 1.42 and 10.22 μM) with some slight selectivity towards BuChE. Compounds 120 and 
136 (Figure 44b) resulted the most promising. In fact, molecular modelling revealed that compound 
120 can realize favorable interactions with the active sites of both BuChE and MAO-B. This double 
activity may be advantageous in AD treatment, because both enzymes are becoming relevant 
biological targets for the treatment of this dementia. Also compound 136 resulted to be a potential 
MTDL because it showed inhibitory activity against hMAO-B (IC50 = 0.30 μM), eeAChE (IC50 = 9.10 
μM) and eqBuChE (IC50 = 5.90 μM). Docking studies showed that 136 binds the substrate cavity 
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The presence of piperidine or piperazine ring caused a decrease in MAO inhibitory activity,
perhaps indicating that larger substitutions at position 7 are not well tolerated. Again, no activity
against MAO-A was shown, whereas IC50 values between 0.29 and 5.64 µM were detected on
MAO-B. Compounds that lacked the N-benzylpiperidine, responsible for anti-cholinesterase activity
in donepezil, showed little or no activity against eeAChE and equine BuChE (eqBuChE). Compounds
bearing the N -benzylpiperidin moiety showed moderate inhibitory activity against both ChEs (IC50
values between 1.42 and 10.22 µM) with some slight selectivity towards BuChE. Compounds 120 and
136 (Figure 44b) resulted the most promising. In fact, molecular modelling revealed that compound
120 can realize favorable interactions with the active sites of both BuChE and MAO-B. This double
activity may be advantageous in AD treatment, because both enzymes are becoming relevant biological
targets for the treatment of this dementia. Also compound 136 resulted to be a potential MTDL
because it showed inhibitory activity against hMAO-B (IC50 = 0.30 µM), eeAChE (IC50 = 9.10 µM)
and eqBuChE (IC50 = 5.90 µM). Docking studies showed that 136 binds the substrate cavity through
the coumarin ring, whereas the benzyl moiety occupies the entrance cavity. In addition, 136 was
able to bind both the CAS and PAS of cholinesterase, which suggested that it could interfere with
PAS-induced β-amyloid aggregation. A different approach was followed by Shi and collaborators,
who designed four derivatives obtained by coupling two pharmacophores (carbazole and coumarin)
to obtain potential multitarget agents for the treatment of AD [170]. The aim was to exploit the
biological activities of both the mentioned moieties: on one hand coumarins are known to have
inhibitory activity on AChE, BuChE and MAO, besides antioxidant properties; on the other hand,
carbazole exhibits antioxidant activity [171] and the ability to inhibit Aβ aggregation [172]. In addition,
carbazole derivatives are reported to have inhibitory effect on ChEs, thus providing neuroprotection
from β-amyloid toxicity [173]. Thus, compounds 147a–d (Figure 45) were synthesized, characterized
and their biological activities were evaluated: anticholinesterase activity was tested on eeAChE and
on hAChE, using Ellman’s method [159], keeping tacrine as reference drug. Whereas all derivatives
showed dose-dependent inhibitory activity on eeAChE (compound 147d resulted the best with an IC50
of 3.75 µM), on hAChE they exhibited weak effects (147b IC50 = 76.63 µM, 147d IC50 = 70.51 µM). None
of the tested compounds inhibited eqBuChE or hBuChE more than 30%, which means that compounds
147b and 147d showed selectivity for AChE over BuChE.
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As the alkyl linker length increased, the anti-cholinesterase activity improved, probably because 
a 5-methylene chain allowed the carbazole and coumarin moieties to bind both the CAS and the PAS, 
respectively. Antioxidant properties were evaluated through the ORAC-FL method (oxygen radical 
absorbance capacity by fluorescein) [174], using Trolox (vitamin E analogue) as a standard; none of 
the tested compounds showed significant activity. Among the tested derivatives, compound 147d 
resulted a promising lead candidate for the treatment of AD.  
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Epilepsy is a widespread neurological disorder, characterized by periodic and unpredictable 
attacks, involving seizures and/or transient behavioral changes. Its pathogenesis has not been 
completely clarified yet; it is known, however, that an impairment between excitatory and inhibitory 
neurotransmission is involved [175–179] Here, we report some recent advances in the use of 
coumarins as anticonvulsant compounds. Abd-Allah and collaborators recently studied the 
anticonvulsant activity of a series of coumarin derivatives, achieved by merging two or more 
pharmacophoric scaffolds in order to create new chemical entities with an improved biological 
activity [180]. The compounds here described possess all the necessary elements to exert anti-
convulsant activity: a lipophilic aryl ring, a hydrogen-bonding domain and an electron-donor moiety 
[178,179,181,182]. All the compounds were initially screened (phase I) using two standard animal 
seizure models, subcutaneous pentylenetetrazole (scPTZ) and maximal electric shock (MES) seizure 
tests using ethosuximide as reference drug. An assessment of the potential neurotoxicity was also 
done by means of rotarod test. Phase II consisted in the determination of ED50 value for compounds 
that conferred 100% protection in one or both tests. In the end, GABA level measurements were 
carried out in whole mouse brain for the most active compounds, using gabapentin as a reference 
drug. The results of phase I tests showed that all the tested compounds had protective activity against 
scPTZ-induced absence epilepsy (variable results in the range of 17-100% protection). Among them, 
148, 149 and 150 (Figure 46) were the most active (100% protection) at 0.238, 0.239 and 0.283 mmol/kg, 
meaning that the compounds are 1.49, 1.48, 1.25 folds more potent than ethosuximide, respectively. 
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As the alkyl linker length increased, the anti-cholinesterase activity improved, probably because a
5-methylene chain allowed the carbazole and coumarin moieties to bind both the CAS and the PAS,
respectively. Antioxidant properties were evaluated through the ORAC-FL method (oxygen radical
absorbance capacity by fluorescein) [174], using Trolox (vitamin E analogue) as a standard; none of the
tested compounds showed significant activity. Among the tested derivatives, compound 147d resulted
a promising lead candidate for the treatment of AD.
2.9. Anticonvulsant Activity
Epilepsy is a widespread neurological disorder, characterized by periodic and unpredictable
attacks, involving seizures and/or transient behavioral changes. Its pathogenesis has not been
completely clarified yet; it is known, however, that an impairment between excitatory and inhibitory
neurotransmission is involved [175–179] Here, we report some recent advances in the use of coumarins
as anticonvulsant compounds. Abd-Allah and collaborators recently studied the anticonvulsant activity
of a series of coumarin derivatives, achieved by merging two or more pharmacophoric scaffolds in
order to create new chemical entities with an improved biological activity [180]. The compounds here
described possess all the necessary elements to exert anti-convulsant activity: a lipophilic aryl ring, a
hydrogen-bonding domain and an electron-donor moiety [178,179,181,182]. All the compounds were
initially screened (phase I) using two standard animal seizure models, subcutaneous pentylenetetrazole
(scPTZ) and maximal electric shock (MES) seizure tests using ethosuximide as reference drug. An
assessment of the potential neurotoxicity was also done by means of rotarod test. Phase II consisted
in the determination of ED50 value for compounds that conferred 100% protection in one or both
tests. In the end, GABA level measurements were carried out in whole mouse brain for the most
active compounds, using gabapentin as a reference drug. The results of phase I tests showed that
all the tested compounds had protective activity against scPTZ-induced absence epilepsy (variable
results in the range of 17–100% protection). Among them, 148, 149 and 150 (Figure 46) were the most
active (100% protection) at 0.238, 0.239 and 0.283 mmol/kg, meaning that the compounds are 1.49, 1.48,
1.25 folds more potent than ethosuximide, respectively. In the MES-induced seizures though, all the
compounds failed in completely protecting the animals. The best profile was exhibited by compound
151 (Figure 46) which was capable of a 50% protection at 2.1 mmol/kg. A quantitative determination
of ED50 values was carried out for compounds 148, 149 and 150, which were able to fully protect
animals in the scPTZ test. Compound 148 was found to be the most active with an ED50 of 54.86 mg/kg
(0.131 mmol/kg). Consequently, it was chosen for further investigation to elucidate the mechanism
of action, which was assessed through an evaluation of GABA levels in mice brain. As a result, the
proposed mechanism for compound 148 is a GABA-mediated one, perhaps non-vesicular release of
GABA, GABAA receptor activation or GABAB receptor inhibition; probably an enhanced synthesis or
reduced metabolism of GABA are also involved.
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A similar bivalent drug approach was followed by Mohammadi-Khanaposhtani and 
collaborators, who synthesized a series of coumarin-1,2,4-oxadiazole derivatives in order to create a 
new chemical entity with better anticonvulsant profile than coumarin and oxadiazole alone [183]. In 
fact, different 5-member heterocyclic rings-containing compounds such as oxadiazoles, triazoles and 
thiadiazoles were reported to have good anticonvulsant activity [184–186] through benzodiazepine 
(BDZ) receptor [187]. The activity of the new derivatives was tested using PTZ- and MES- induced 
seizures in mice, keeping diazepam as a reference drug. Most of the new compounds did not show 
activity against PTZ-induced seizures, except for three of them, 152a, 152b and 152c (Figure 47), being 
152b the most active (25% of protection using 10 mg/kg). Compounds 152d, 152e and 152f (Figure 
47) showed a 100% protection against MES-induced seizures at the doses of 7, 40 and 20 mg/kg, 
respectively (it should be considered that diazepam shows 100% protection at 2 mg/mL) [188]. 
Compound 152d, which showed the best activity, was characterized by the absence of substituents 
on position 4 of the coumarin ring and by a 4-chloroaryl group connected to the 1, 2, 4-oxadiazole 
ring. The most active compounds 152d and 152e were used to investigate the mechanism of action; 
to do so, the effect of flumazenil (a BDZ receptor antagonist) on their activity was evaluated. 
Flumazenil antagonized both 152d and 152e, confirming that these compounds act as BZS receptor 
agonists. Finally, in vivo neurotoxicity of compounds 152d and 152e was assessed and the tested 
compounds gave less neurological deficits that the reference drug diazepam.  
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A similar bivalent drug approach was followed by Mohammadi-Khanaposhtani and collaborators,
who synthesized a series of coumarin-1,2,4-oxadiazole derivatives in order to create a new chemical
entity with better anticonvulsant profile than coumarin and oxadiazole alone [183]. In fact, different
5-member heterocyclic rings-containing compounds such as oxadiazoles, triazoles and thiadiazoles were
reported to have good anticonvulsant activity [184–186] through benzodiazepine (BDZ) receptor [187].
The activity of the new derivatives was tested using PTZ- and MES- induced seizures in mice, keeping
diazepam as a reference drug. Most of the new compounds did not show activity against PTZ-induced
seizures, except for three of them, 152a, 152b and 152c (Figure 47), being 152b the most active (25% of
protection using 10 mg/kg). Compounds 152d, 152e and 152f (Figure 47) showed a 100% protection
against MES-induced seizures at the doses of 7, 40 and 20 mg/kg, respectively (it should be considered
that diazepam shows 100% protection at 2 mg/mL) [188]. Compound 152d, which showed the best
activity, was characterized by the absence of substituents on position 4 of the coumarin ring and by a
4-chloroaryl group connected to the 1, 2, 4-oxadiazole ring. The most active compounds 152d and 152e
were used to investigate the mechanism of action; to do so, the effect of flumazenil (a BDZ receptor
antagonist) on their activity was evaluated. Flumazenil antagonized both 152d and 152e, confirming
that these compounds act as BZS receptor agonists. Finally, in vivo neurotoxicity of compounds 152d
and 152e was assessed and the tested compounds gave less neurological deficits that the reference
drug diazepam.
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MES mice model (grand mal seizures) and the corazole-antagonism test (modelling the so-called petit 
mal seizure). The only statistically significant result was given by compound 153a at doses in the 
range of 60-80 mg/kg, as it could increase the animal survival in MES test up to 60% (in the control 
group survival was 10%). Corazole-induced seizures and animals’ death were not prevented by 
compounds 153a, 153c and 153d. Compound 153e exhibited good protection potential at 10-40 mg/kg 
and was able to prevent death in 50-63% of animals. The most active compound in the MES test was 
153a, containing a coumarin ring with a 3-nitro group and a γ-aminobutirric acid fragment. The 
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nitro groups on the coumarin ring, showed the best profile in corazole-antagonism test. The 
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2.10. Anticoagulant Activity
The recent medical history of anticoagulant drugs has been largely dominated by a simple class of
molecules that has been discovered thanks to a mysterious livestock mortality and, later, employed as a
powerful rodenticide: coumarins. The anticoagulant activity of coumarins was identified when in 1920′s
seemingly healthy cattle of Canada and North America died inexplicably for internal hemorrhages. The
main cause of this decimation was attributed to a mold infestation of the damp hay, later known as the
“sweet clover disease.” However, it was not before 1940 that the responsible molecule was identified
by Karl Link and his student Harold Campbell: it was 3,3’-methylenebis(4-hydroxycoumarin), later
known as dicoumarol. Further studies by Link’s team brought to the discovery of warfarin in 1948
Int. J. Mol. Sci. 2020, 21, 4618 32 of 81
(so named from WARF, Wisconsin Alumni Research Foundation, that financed the project), approved
as a rodenticide in the USA in 1952 and for anticoagulation therapy in human in 1954, under the name
of Coumadin. Currently, warfarin is one of the most widely used anticoagulation drug (in the UK it has
been estimated that at least 1% of the population and 8% of people over 80 years are taking warfarin),
together with other coumarin derivatives like dicumarol and acenocoumarol (Figure 49) [18,190–192].
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coagulation, involving several factors (II, VII, IX and X). Despite the efficacy and the advantages of 
an oral therapy, warfarin is not devoid of side effects, mainly associated with bleeding and 
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pharmacokinetics, which requires a continuous monitoring of the patient [193,194].  
For this reason, the research of new safer and efficient compounds lead to the discovery of a 
novel VKA, tecarfarin (ATI-5923, Figure 50), currently under development [195]. Tecarfarin is active 
after oral administration and acts as a vitamin-K epoxide reductase (VKOR) inhibitor; unlike 
warfarin, is not metabolized by the cytochrome P450 system but by human carboxylesterase-2 (hCE-
2) in hepatic microsomes. Consequently, drug-drug or food-drug interactions are avoided, as well as 
genetic variability of CYP-450 system, providing a more stable anticoagulation effect compared to 
warfarin [196]. A detailed study on pharmacokinetics and pharmacodynamics of tecarfarin had been 
conducted on healthy patients by Albrecht et al., together with the recent phase I study on its 
tolerability among patients with severe kidney disease [197,198]. Tecarfarin has the potentiality to be 
a valid substitute of warfarin in the oral therapy of thromboembolic disease.  
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Warfarin and other anticoagulant coumarins are vitamin-K antagonists (VKAs). Indeed, due to
the structural similarity with vitamin-K, the compounds block the vitamin-K dependent pathways of
coagulation, involving several factors (II, VII, IX and X). Despite the efficacy and the advantages of an
oral therapy, warfari is not devoid of side effects, mainly associated with bleedi g and complications,
like the narrow therapeutic range and interindivi ual genetic difference in pharmacokinetics, which
requires a continuous monitoring of the patient [193,194].
For this reason, the research of new safer and efficient com ounds lead to the discovery of
a novel VKA, tecarfarin (ATI-5923, Figure 50), currently under development [195]. Tecarfarin is
active after oral administration and acts as a vitamin-K epoxi e reductase (VKOR) inhibitor; unlike
warfarin, is not metabolized by the cytochrome P450 system but by human carboxylesterase-2 (hCE-2)
in hepatic microsomes. Consequently, drug-drug or food-drug interactio s are avoided, as well as
genetic variability of CYP-450 system, providing a more stable anticoagulation effect compared to
warfarin [196]. A detailed study on pharmacokinetics and pharmacodynamics of tecarfarin had been
conducted on healthy patients by Albrecht et al., together with the recent phase I study on its tolerability
among patients with severe kidney disease [197,198]. Tecarfarin has the potentiality to be a valid
substitute of warfarin in the oral therapy of thromboembolic disease.
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Another approach reported in literature is the chemical modification of the coumarin scaffold
by conjugation of 7-hydroxylcoumarin and 7-hydroxy-4-methylcoumarin with some derivatives of
salicylic acid. Among the compounds evaluated by Bang and co-workers in 2019, derivatives 154
and 155 (Figure 51) showed high anticoagulant activity, with an increased prothrombin time (PT) of
Int. J. Mol. Sci. 2020, 21, 4618 33 of 81
10.88 ± 0.56 s and 13.10 ± 3.56 s, respectively. Both compounds resulted 1.5 times more active than
warfarin (PT 7.97 ± 1.93) [199].
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Structural modifications of the 4-hydroxycoumarin core was also the rational of Montagut-
Romans et al., who in 2017 explored the potentiality given by modifications performed on C3 position 
by introducing a side chain (with at most one unsaturation) structurally related to vitamin-K cofactor 
[200]. The underlying premise was the SAR study performed by Gebaur in 2007, which pointed out 
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by isoprenyl motifs [201]. In this contest, 14 functionalized 4-hydroxycoumarins with alkyl chains of 
different length, both linear and branched, were synthesized and their activity was evaluated in vitro 
and ex vivo (phenprocoumon was included in the test as internal standard). The ability to inhibit 
VKORC1 in rat liver microsomes was evaluated in vitro and, except for two compounds, the C3-alkyl 
derivatives showed a sub-micromolar activity (from 20 nM to 200 nM) overcoming the benchmark 
compound phenprocoumon. Further ex vivo studies assessed the ability to increase in vivo the 
prothrombin time (PT) and compounds 156a and 156b (Figure 52) showed a promising anticoagulant 
activity after 24 h. It is possible that the presence of the halogen atom protects the drug from liver 
metabolism. Despite the interesting anticoagulant activity, follow-up studies on the liver metabolism 
are necessary to determine if these molecules are substrate of CYP2C9, to which is to attribute the 
variability in the dosage of oral vitamin-K antagonists, due to its polymorphism [202]. 
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Concerning nature-derived coumarins, endowed with promising anticoagulant activity, in 2015 
Lei et al. performed a phytochemical investigation on the Chinese herbal medicine Ainsliaea fragrans 
earning five new derivatives. The team evaluated the anticoagulant activity of all isolates via 
activated partial thromboplastin time (APTT), thrombin time (TT) and prothrombin time (PT) assays 
in vitro and in vivo. These studies concluded that one of the new compounds (157, Figure 53) 
presented a remarkable anticoagulant activity (PT = 41.2s and TT 128.5s) and no significant hepatic 
or renal toxicity when compared to warfarin (PT = 55.7s and TT 80.6s) [203]. Although further studies 
are necessary to understand the mode of action of compound 157, it could be a promising 
anticoagulant agent for preclinical studies.  
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Figure 51. Chemical structure of coumarins conjugated with salicylic acid.
Structural modifications of the 4-hydroxycoumarin core was also the rational of Montagut-Romans
et al., who in 2017 explored the potentiality given by modifications performed on C3 position by
introducing a side chain (with at most one unsaturation) structurally related to vitamin-K cofactor [200].
The underlying premise was the SAR study performed by Gebaur in 2007, which pointed out that
the activity of 4-hydroxycoumarin was enhanced only by structural modification for C3 position by
isoprenyl motifs [201]. In this contest, 14 functionalized 4-hydroxycoumarins with alkyl chains of
different length, both linear and branched, were synthesized and their activity was evaluated in vitro
and ex vivo (phenprocoumon was included in the test as internal standard). The ability to inhibit
VKORC1 in rat liver microsomes was evaluated in vitro and, except for two compounds, the C3-alkyl
derivatives showed a sub-micromolar activity (from 20 nM to 200 nM) overcoming the benchmark
compound phenprocoumon. Further ex vivo studies assessed the ability to increase in vivo the
prothrombin time (PT) and compounds 156a and 156b (Figure 52) showed a promising anticoagulant
activity after 24 h. It is possible that the presence of the halogen atom protects the drug from liver
metabolism. Despite the interesting anticoagulant activity, follow-up studies on the liver metabolism
are necessary to determine if these molecules are substrate of CYP2C9, to which is to attribute the
variability in the dosage of oral vitamin-K antagonists, due to its polymorphism [202].
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Figure 52. C-3 alkyl coumarin derivatives.
Concerning nature-derived coumarins, endowed with p omising anticoagulant activity, in 2015
Lei et al. performed a phytochemical investigation on the Chinese herbal medicine Ainsliaea fragrans
earning five ew derivativ s. The tea evaluate the anticoagulant activity of ll isolates via activated
partial thromboplastin time (APTT), thrombin time (TT) and prothrombin time (PT) assays in vitro
and i vivo. These studies concluded that one of the new compounds (157, Figure 53) presented
remarkable nticoagulant activity (PT = 41.2s and TT 128.5s) and no significant hepatic or renal toxicity
when c mpared to warfarin (PT = 55.7s and TT 80.6s) [203]. Although further studies are necessary
to understand the mod of action of compound 157, it could be a promising anticoa ulant agent for
preclinical studies.
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2.11. Antidiabetic Activity 
Diabetes is a chronic metabolic disease characterized by high blood sugar levels and is generally 
caused by an insufficient production of insulin by β-pancreatic cells or by the inability of human body 
to use this hormone. The consequences of diabetes might be very serious: blindness, kidney failure, 
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Menteşe et al. synthesized a novel series of N’-(2-(3,5-disubstituted-4H-1,2,4-triazol-4-yl)acetyl)-
6/7/8 substituted-2-oxo-2H-chromen-3-carbohydrazides (158a–e, 159a–e, Figure 54) [207], merging 
the 1,2,4-triazole and the coumarin moieties, both characterized by a wide range of biological 
activities (including inhibition of α-glucosidases) and low toxicity profiles [208–213]. Then, their 
activity on α-glucosidases was studied, evaluating the enzyme inhibition in the presence of pNPG 
(p-nitrophenyl-α- D-glucopyranoside) as a substrate in the buffer (pH 6.8). Among the new 
compounds, four molecules showed high inhibition activity, compared to acarbose (IC50 = 8.85 ± 0.23 
μg/ml): 158d (IC50 = 4.28 ± 0.10 μg/ml), 158e (IC50 = 0.96 ± 0.02 μg/ml), 159d (IC50 = 6.75 ± 0.10 μg/ml) 
and 159e (IC50 = 1.44 ± 0.06 μg/ml). 
 
 
 
 
 
 
 
Figure 54. General structures of compounds 158a–e and 159a–e. 
Compounds 158e and 159e resulted the most active, probably because of the metoxy- group at 
position 8 of the coumarin ring. Derivatives without substituents on positions 3 and 5 of the phenyl 
ring linked to the triazole nucleus resulted more active than compounds bearing a chlorine atom or 
a phenyl moiety on such positions. According to kinetic studies, the tested compounds inhibit α-
glucosidases in a competitive way. Other studies focused on coumarins-mediated inhibition of α-
glucosidases were carried out by different groups. Hu and collaborators synthesized through 
microwave radiation heating a new series of more than forty 3-arylcoumarins which were screened 
for antioxidant activity, α-glucosidases inhibition and advanced glycation end-products (AGEs) 
formation inhibition [214]. Only eight of the synthesized compounds (160–167, Figure 55) exhibited 
moderate to high inhibitory activity on α-glucosidase.  
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2.11. Antidiabetic Activity
Diabetes is a chronic metabolic disease characterized by high blood sugar levels and is generally
caused by an insufficient production of insulin by β-pancreatic cells or by the inability of human body
to use this hormone. The consequences of diabetes might be very serious: blindness, kidney failure,
stroke, heart attacks, lower limb amputation [204–206]
Mentes¸e et al. synthesized a novel series of N′-(2-(3,5-disubstituted-4H-1,2,4-triazol-4-yl)acetyl)-
6/7/8 substituted-2-oxo-2H-chromen-3-carbohydrazides (158a–e, 159a–e, Figure 54) [207], merging the
1,2,4-triazole and the coumarin moieties, both characterized by a wide range of biological activities
(including inhibition of α-glucosidases) and low toxicity profiles [208–213]. Then, their activity on
α-glucosidases was studied, evaluating the enzyme inhibition in the presence of pNPG (p-nitrophenyl-α-
D-glucopyranoside) as a substrate in the buffer (pH 6.8). Among the new compounds, four molecules
showed high inhibition activity, compared to acarbose (IC50 = 8.85 ± 0.23 µg/mL): 158d (IC50 = 4.28 ±
0.10 µg/mL), 158e (IC50 = 0.96 ± 0.02 µg/mL), 159d (IC50 = 6.75 ± 0.10 µg/mL) and 159e (IC50 = 1.44 ±
0.06 µg/mL).
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Figure 54. General structures of compounds 158a–e and 159a–e.
Compounds 158e and 159e resulted the most active, probably because of the metoxy- group at
position 8 of the coumarin ring. Derivatives without substituents on positions 3 and 5 of the phenyl ring
linked to the triazole nucleus resulted more active than compounds bearing a chlorine atom or a phenyl
moiety on such positions. According to kinetic studies, the tested compounds inhibit α-glucosidases
in a competitive way. Other studies focused on coumarins-mediated inhibition of α-glucosidases
were carried out by different groups. Hu and collaborators synthesized through microwave radiation
heating a new series of more than forty 3-arylcoumarins which were screened for antioxidant activity,
α-glucosidases inhibition and advanced glycation end-products (AGEs) formation inhibition [214].
Only eight of the synthesized compounds (160–167, Figure 55) exhibited moderate to high inhibitory
activity on α-glucosidase.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 34 of 83 
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Compound 165 was the most promising (IC50 = 1.37 ± 0.67 μM), with a α-glucosidase inhibitory 
activity slightly weaker than acarbose (IC50 = 0.050 ± 0.003 μM). From an extensive SAR study, it 
emerged that the 7-hydroxy group is important for the inhibition of α-glucosidase. Compounds 160, 
163,164, 165 and 166 were then tested in vivo: none of them showed toxicity on mice (LD50 > 5000 
mg/kg). The mentioned compounds were also tested on streptozocin-induced diabetic mice. 
Compound 166 showed the best profile, exhibiting a strong reduction of glucose blood levels. Oral 
daily administration of 166 (30 mg/kg/day) restored glucose blood levels near normal values, 
showing an effect similar to that of the oral antidiabetic glibenclamide.  
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are reported. 
Here, again, two active moieties, both characterized by a wide range of biological activities, were 
merged together: the bis-coumarin and the 1,2,3-triazole moieties [216]. All the synthesized 
compounds showed excellent activities (IC50 between 13.0 ± 1.5 and 75.5 ± 7.0 μM) compared to 
acarbose (IC50 750.0 ± 12.0). Compound 168c, bearing 2-chloro phenyl moiety, resulted the most 
active. The substitution of the chlorine atom with a methyl group or its shift on the C4 position caused 
a decrease in activity. Moreover, the inhibitory activity seemed to depend importantly on the electron 
properties of the substituents. From further kinetic studies it emerged that compound 168c inhibits 
α-glucosidases in a competitive mode (Ki = 11 μM). 
A different therapeutic approach may be the stimulation of insulin secretion. In this perspective, 
Ahmed and collaborators extracted from the aerial parts of Clutia lanceolata (a medicinal plant native 
to sub-Saharan Africa and the Arabian Peninsula) twenty-one coumarins, including methyltio- and 
methylsulfinil-coumarins, thirteen of which were reported for the first time [217]. The structures of 
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Compound 165 was the most promising (IC50 = 1.37 ± 0.67 µM), with a α-glucosidase inhibitory
activity slightly weaker than acarbose (IC50 = 0.050± 0.003µM). From an extensive SAR study, it emerged
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that the 7-hydroxy group is important for the inhibition of α-glucosidase. Compounds 160, 163, 164,
165 and 166 were then tested in vivo: none of them showed toxicity on mice (LD50 > 5000 mg/kg).
The mentioned compounds were also tested on streptozocin-induced diabetic mice. Compound 166
showed the best profile, exhibiting a strong reduction of glucose blood levels. Oral daily administration
of 166 (30 mg/kg/day) restored glucose blood levels near normal values, showing an effect similar to
that of the oral antidiabetic glibenclamide.
Asgari and co-workers synthesized a new series of biscoumarin-1,2,3-triazole derivatives
(Figure 56) and evaluated their α-glucosidase inhibitory potential, using acarbose as a reference
drug [215].
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Figure 56. Chemical structure of biscoumarin-1,2,3-triazole hybrids. Substituents for compound 168c
are reported.
Here, again, two active moieties, both characterized by a wide range of biological activities,
were merged together: the bis-coumarin and the 1,2,3-triazole moieties [216]. All the synthesized
compounds showed excellent activities (IC50 between 13.0 ± 1.5 and 75.5 ± 7.0 µM) compared to
acarbose (IC50 750.0 ± 12.0). Compound 168c, bearing 2-chloro phenyl moiety, resulted the ost active.
The substitution of the chlorine atom with a methyl group or its shift on the C4 position caused a
decrease in activity. Moreover, the inhibitory activity seemed to depend importantly on the electron
properties of the substituents. From further kinetic studies it emerged that compound 168c inhibits
α-glucosidases in a competitive mode (Ki = 11 µM).
A different therapeutic approach may be the stimulation of insulin secretion. In this perspective,
Ahmed and collaborators extracted from the aerial parts of Clutia lanceolata (a medicinal plant native
to sub-Saharan Africa and the Arabian Peninsula) twenty-one coumarins, including methyltio- and
methylsulfinil-coumarins, thirteen of which were reported for the first time [217]. The structures of
these natural compounds were elucidated from 2D-NMR and MS spectra, whereas their anti-diabetic
activity was tested measuring the glucose-triggered insulin secretion of freshly isolated murine islets.
Compounds 169, 170 and 171 (Figure 57) resulted the most active in stimulating glucose-triggered
insulin release, compared to glimepiride. Further studies are needed to understand structure-activity
relationships in order to develop new active compounds.
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3. Other Applications of Coumarin Scaffold
3.1. Coumarins Photoproperties
The applications and properties of coumarin scaffold have remarkably wide boundaries.
Coumarin-based compounds have been exploited in numerous research and industrial sectors,
as active pharmaceutical ingredients, pesticides, fragrances, dyes for several purposes from laser
technology to organic photoredox catalysis, cell imaging, photocleavable protecting groups and
fluorescent biological probes [6,218–225]. In the following paragraphs, the most recent applications
associated with the photophysical properties of coumarins have been reviewed.
3.1.1. Coumarins as Photocleavable Protecting Groups (PPGs)
The development of a suitable formulation is a crucial step in order to achieve new functional
therapeutics. The design of novel strategies aimed at selectively release the bioactive in a specific
district at a determinate time to maximize efficacy and reduce off-target adverse effects represents an
extremely active research frontline. So far, various stimuli-responsive systems have been considered
in therapeutic approaches to regulate the release of the therapeutic cargo, including endogenous
stimuli (e.g., pH, enzymes, redox reactions, etc.) and exogenous stimuli (e.g., light, magnetic field,
ionizing radiations, etc.) [226,227]. Light-mediated therapies have shown excellent results in achieving
on-demand therapeutics and optical tools for studying and controlling complex chemical and biological
processes in localized areas, owing to their superior non-invasiveness and spatiotemporal precision
upon applying a specific light-irradiation wavelength [227–229]. One method for the regulation of
molecular processes with light is the use of photolabile “protecting” groups in key locations. Ideally,
this modification completely blocks the activity of any molecule and restores it only with light [230].
Coumarins, particularly 4-hydroxymethyl derivatives, are known to undergo photolysis. Keeping
this concept in mind, several biomolecules of interest have been linked to the coumarin nucleus, mostly
as acyl derivatives. Then, under UV irradiation, the biomolecules can be released in biological systems.
The photophysical parameters of the formed derivatives are determined by different factors as the
mode of fusion, the chemical nature of additional rings and the presence of electron-donating and
electron-withdrawing substituents [12].
Fournier and co-workers in 2013 proposed a series of methyl-coumarins with redshifted absorption.
In particular, three compounds (172–174, Figure 58), were synthetically easily accessible and exhibited
a significant action cross section for uncaging with blue-cyan light, whereas their uncaging ability in
the UV spectral domain remained low in order to avoid their photoactivation when a properly tuned
UV illumination is applied [231].
In the same year, Fournier and co-workers further proved that compound 172 was a good
blue-absorbing caging group, owing to its strongly donating substituent conjugated to the thiocarbonyl
group. Moreover, the research team demonstrated that this particular caging group could be
used in zebrafish embryos in the context of development biology to perform chromatic orthogonal
photoactivation of two biologically active species [232].
In 2017, Gandioso and colleagues reported the development of green/red-absorbing chromophores
based on coumarin scaffolds that could be useful as photocleavable protecting groups [224].
A series of coumarin derivatives in which the carbonyl of the lactone was replaced by a
cyano(4-nitrophenyl)methylene moiety, by condensation of a thiocoumarin precursor with the
corresponding arylacetonitrile derivatives, was synthesized and subsequently refined with the insertion
of electro-withdrawing groups at the phenyl ring, leading to absorption in the green to red region (175,
Figure 58) [224]. The insertion of more than one electro-withdrawing group (such as -NO2 and -CN)
decreased the fluorescence emission, whereas the mononitro-containing coumarin derivatives had a
strong emission in the red region upon excitation with green light, as denoted by their significantly large
Stokes shifts. In order to demonstrate the utility of these new compounds as PPGs, a small collection
of coumarin-based photocages of benzoic acid was prepared. Thanks to photolysis studies with green
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light, it was demonstrated that the structure of the coumarin chromophore influenced the rate of the
uncaging process. This observation gave the opportunity to exploit these new coumarin scaffolds as
caging groups removable with visible light. On the other hand, Bojtar and colleagues proposed water
soluble red-shifted coumarin caging groups (176–178, Figure 58), activated with green-light [233].
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Iturmendi and co-workers proposed that, through functionalization of polyphosphazenes with a 
coumarin-caged amino acid as a pendant group along the backbone, the sensitivity of the polymers 
to hydrolysis would be accelerated upon irradiation and effectively catalyze its own degradation 
[234]. 
3.1.2. Coumarins as Fluorescent Probes 
Coumarins possess a large electron-rich π-π conjugated system with charge transfer properties, 
reason why coumarin-based fluorophores are widely used for monitoring a variety of biologically 
important species and biochemical process in living cells, for example as diagnostic agent for 
detection of biothiols, enzymes, mitochondrial pH values, glucose and ions [3,222,235]. In particular, 
several coumarin scaffolds have been proposed and evaluated for the detection of ions in different 
fields, from cellular imaging to environmental waters. Gong and co-workers based their work on an 
easily synthesized coumarin-based fluorescent probe (179, Figure 59) that already was effective in the 
detection of glutathione (GHS) in the presence of Cu2+ ions, expanding its potentiality to the detection 
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The optical properties of coumarins as photo-responsive unites could be also applied to polymers
that after a photochemical activation rapidly degrade into small molecules. In 2018, Iturmendi and
co-workers proposed that, through functionalization of polyphosphazenes with a coumarin-caged
amino acid as a pendant group along the backbone, the sensitivity of the polymers to hydrolysis would
be accelerated upon irradiation and effectively catalyze its own degradation [234].
3.1.2. Coumarins as Fluorescent Probes
Coumarins possess a large electron-rich pi-pi conjugated system with charge transfer properties,
reason why coumarin-based fluorophores are widely used for monitoring a variety of biologically
important species and biochemical process in living cells, for example as diagnostic agent for detection
of biothiols, enzymes, mitochondrial pH values, glucose and ions [3,222,235]. In particular, several
coumarin scaffolds have been proposed and evaluated for the detection of ions in different fields,
from cellular imaging to environ ental waters. Gong and co-workers based their work on an easily
synthesized coumarin-based fluorescent probe (179, Figure 59) that already was effective in the
detection of glutathione (GHS) in the presence of Cu2+ ions, expanding its potentiality to the detection
of hypochlorite ions with high selectivity and sensitivity. The probe showed a remarkable fluorescent
intensity change in response to hypochlorite ions; moreover, this probe could be applied to detect ClO−
in cells via intracellular fluorescent imaging [236,237]. Given the importance of hypochlorite ions both
in living systems (being one of the biologically most important reactive oxygens species) and in the
environment (owing to its use as disinfectant), in 2019, Shangguan and colleagues proposed another
probe for this particular ion based on coumarin dye and malononitrile (180, Figure 59). The fluorescence
response of probe 180 at 459 nm towards hypochlorite ions gradually enhanced with the increase of
ClO− concentrations, resulting in 45-fold fluorescence enhancement. Furthermore, probe 180 exhibited
high accuracy for quantitative measurement of hypochlorite ions in real water samples and it can be
used as a potential chemosensor for the detection of ClO− in chemical environmental and biological
systems [238]. In the same year, Tang and co-workers worked on a coumarin based fluorescent probe
(181, Figure 59) able of rapidly discern hypochlorite and copper(II) ions in water sample and biological
systems. Upon the reaction with ClO−, the fluorescence wavelength of 181 displayed a strong blue shift
along with the naked-eye visible changes from yellow to colorless. Moreover, it exhibited an obvious
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fluorescence quenching behavior to copper(II) with colorimetric analysis from yellow to luminous
yellow [239].
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the highest fluorescence intensity in presence of Cu2+ compared to a variety of other common heavy 
and toxic metal ions (for example Pb(II), Co(II), Hg(II)) and in aqueous solution at 320 nm [241]. 
Another approach was attempted for the selective detection of copper (II) ions by He et al. in 2018, 
which based the fluorescent probe on a coumarin-Schiff base derivative (186, Figure 60). This probe 
resulted to be particularly selective for Cu2+ even in the presence of several other ions [242]. Saravana 
Figure 59. Coumarin florescent probes for hypochlorite ion detection.
A noteworthy research on the mechanism of interaction between coumarin based ionic probes
and hypochlorite ions had been conducted by Starzak and collaborators [240]. First, the research
team confirmed the linear decrease in the fluorescence emissions together with the increase in ClO−
concentration of three different coumarin derivatives, 182–184 (Figure 59), which were selected because
of the presence of the 7-diethylamino group and the 3-substituted lactone ring that are well-known
structural pattern accountable for the fluorescence properties. It was observed a different reactivity
profile depending on the pH levels, probably due to the different reactivity of hypochlorite ions
ascribable to the variation of the dissociation of the salt at different pH values. Afterwards, a deeply
investigation on the possible formation of chlorinated derivatives was conducted: HPLC-PDA-ESI-MS
analyses highlighted the presence of chlorinated derivatives and proved that the chlorination reaction
was responsible for the linear fluorescence decays. The results suggest the possibility to exploit these
coumarin ionic probes for the detection and quantitative determination of hypochlorite species in vivo.
A coumarin fluorescent probe based on a nitro-3-carboxamide derivative for selective copper (II)
ions detection was reported by Bekhradnia and colleagues. Compound 185 (Figure 60) showed the
highest fluorescence intensity in presence of Cu2+ compared to a variety of other common heavy and
toxic metal ions (for example Pb(II), Co(II), Hg(II)) and in aqueous solution at 320 nm [241]. Another
approach was attempted for the selective detection of copper (II) ions by He et al. in 2018, which
based the fluorescent probe on a coumarin-Schiff base derivative (186, Figure 60). This probe resulted
to be particularly selective for Cu2+ even in the presence of several other ions [242]. Saravana Mani
and colleagues designed in 2019 a coumarin hydrazine-based fluorescent probe for the detection
of copper(II), called BENZEPYR (187, Figure 60), exploiting a reaction of condensation between
2-hydrazino benzothiazole and N,N′-diethylamino-3-acetyl coumarin [243]. This particular fluorescent
chemosensor could selectively detect Cu2+ among other disturbing metal ions, resulting particularly
specific and highly responsive, with a visible colorimetric change of the solution, which turned from
yellow to wine red. Moreover, the limit of detection (LOD) had been estimated to be 40 nM. BENZEPYR
187 was also tested for the fluorescence bioimaging of Cu2+ ions in HeLa cells using fluorescence
microscopic analysis, resulting suitable for the exploitation as an ion marker in living cells.
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Despite the key role of chemical species like copper and hypochlorite, they are not the only ions 
valuable for detection. For this reason, a dual coumarin probe, fluorescent and colorimetric, was 
designed by Chen and colleagues for the detection of palladium (II) ions that can be used in living 
cells. This oxime-ether coumarin probe (189, Figure 61) exhibited a strong green fluorescence with an 
emission peak at 500 nm. When palladium(II) was added to the solution with compound 189, the 
fluorescence intensity at 500 nm decreased consequently, until 2 equivalents of Pd2+ were reached; at 
that point the fluorescence was almost completely quenched, which could clearly be observed with 
the naked eye. A linear fit between fluorescence and palladium (II) concentration was observed in 
the range 0.0-8.0 μM, while the detection limit was measured to be 40 nM, which is far lower than the 
threshold for palladium content in drugs (5.0 ppm to 10.0 ppm - 47.0 mM to 94.0 mM) specified by 
the World Health Organization [245].  
It is also noteworthy the development of thioacetalised coumarin based fluorescent probes for 
the detection of mercury (II), a hazardous ion both for human health and reproduction. Cheng and 
co-workers exploited the known Hg2+ promoted deprotection reaction of dithioacetals to design two 
novel reactive fluorescent probes (190,191, Figure 61) that showed a different behavior due to the 
different chemical structures: 190 displayed remarkable fluorescence quenching with the addition of 
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Another remarkable case of coumarin-bas d chem s ns r had been pr sented by Li and co-workers,
who synthesized a multifunctional probe able to selectively detect not only copper (II) ions but also
Al3+ ions and amino acids Lys and Arg [244]. In particular, the detection of Lys and Arg took place
with a colorimetric (from yellow to colorless) and a fluorescent response (from a maximum absorption
at 335 nm to 429 nm). At the same time the probe detected either way the presence of Cu2+ ions but
could be used only for the fluorescent sensing of Al3+. A further interesting exploitation of probe
188 (Figure 60) was the fluorescent and colorimetric identification of Cys, Hcy and GSH when it was
complexed with copper ions.
Despite the key role of chemical species like copper and hypochlorite, they are not the only ions
valuable for detection. For this reason, a dual coumarin probe, fluorescent and colorimetric, was
designed by Chen and colleagues for the detection of palladium (II) ions that can be used in living
cells. This oxime-ether coumarin probe (189, Figure 61) exhibited a strong green fluorescence with
an emission peak at 500 nm. When palladium(II) was added to the solution with compound 189, the
fluorescence intensity at 500 nm decreased consequently, until 2 equivalents of Pd2+ were reached; at
that point the fluorescence was almost completely quenched, which could clearly be observed with the
naked eye. A linear fit between fluorescence and palladium (II) concentration was observed in the
range 0.0–8.0 µM, while the detection limit was measured to be 40 nM, which is far lower than the
threshold for palladium content in drugs (5.0 ppm to 10.0 ppm - 47.0 mM to 94.0 mM) specified by the
World Health Organization [245].
It is also noteworthy the development of thioacetalised coumarin based fluorescent probes for
the detection of mercury (II), a hazardous ion both for human health and reproduction. Cheng and
co-workers exploited the known Hg2+ promoted deprotection reaction of dithioacetals to design two
novel reactive fluorescent probes (190, 191, Figure 61) that showed a different behavior due to the
different chemical structures: 190 displayed remarkable fluorescence quenching with the addition
of Hg2+ ions while, in the presence of mercury ions, 191 displayed ratiometric fluorogenic and
chromogenic response [246].
It should not be forgotten an on-off fluorescent probe for the tracking of iron (III) ions based on
7-hydroxy-2-oxo-N-(pyridin-2-ylmethyl)chromene-3-carboxamide. In their work, Warrier and Kharkar
demonstrated that compound 192 (Figure 61) was selective towards Fe3+ ions and exhibited high
fluorescence emission profile at 447 nm. The presence of other ions did not interfere with the detection
of iron (III) ions and the limit of detection was found to be 0.76 µM. Moreover, cell imaging and MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay proved the potential utility of
probe 192 as cell-permeable chemosensor of Fe3+ in living cells [247].
The approach of Jiao and colleagues for the detection of fluoride ions was based on the linkage
between the coumarin scaffold and fluorescein in order to obtain a highly selective and sensitive
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fluorescent probe. The mechanism of F− ions detection by compound 193 (Figure 61) was explained
and involved a desilylation reaction in the presence of fluoride ions. Moreover, a linear relationship
between the ratio of emission intensities at 532 and 465 nm and F− concentration over the range of 0–20
µM with a limit of detection of 0.025 µM was found [248]. Differently, Yao and co-workers exploited
the capability of fluoride ions to form stable complex with Ca2+ to design a novel fluorescent sensor
(194, Figure 61), synthesized from the combination of mandelic acid with 7-hydroxy-8-formylcoumarin
through a hydrazine hydrate bridge, in order to selectively identify these two ionic species over other
metal ions [249]. The fluorescence spectrum of compound 194 clearly increased when calcium ions
were added to the solution with a limit of detection of 5.81 × 10−7 M, while, once the complex between
the probe and Ca2+ ions was obtained, the addition of fluoride ions to the solution lead to the turn-off of
the fluorescence response with a limit of detection 4.28 × 10−7 M. Moreover, bio-imaging studies were
performed in order to assure the possibility to exploit this novel chemosensor for the identification of
Ca2+ and F− ions in vivo, with positive outcome.
Finally, Reddy and Choi designed and synthesized three dicyanovinylcoumarin probes as turn-on
fluorescent sensor for the detection of CN− ions among other anions [250]. Within the different
synthesized probes only compound 195 (Figure 61) showed a remarkable increase of the fluorescence
in presence of fluoride and cyanide ions with an interesting sensibility towards CN− ions: the limit
of detection was up to 11.4 nM, lower than the maximum level in drinkable water according to
WHO guidelines.
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3.2. Food Systems
Coumarins have found important applications also in the agri-food sector. In fact, the antimicrobial
activity characterizing these natural compounds could be exploited for food preservation or for the
treatment of plant pathogens, infections in aquaculture or biofouling caused by eukaryotic organisms.
In addition, because coumarin scaffold has been used in fluorescent probing, natural coumarins might
be used in the detection of some substances in food samples. For instance, Zhang and collaborators
developed a new near-infrared probe constituted by a conjugated coumarin-indolium system, for
rapid, colorimetric and ratiometric fluorescent detection of bisulfite and sulfite anions [251]. (Bi)sulfite
anions (HSO3−/SO32−) are widely used as preservative for foods and beverages in order to prevent
oxidation, browning and microbial reaction during products’ life cycle [252,253]. Unfortunately, high
doses of (bi)sulfites can cause asthma or other allergic reactions. Some individuals are very sensitive
even to low levels of these anions [254]. In addition, sulfur dioxide (SO2) is one of the most distributed
pollutants and it has a relevant impact on human health [252], [253,255]. An efficient tool to detect
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such molecules is provided by fluorescent probes; to date, different probes for HSO3−/SO32− have
been designed but many of them are intensity-based, which means that the signal output can be
conditioned by different factors such as instrumental efficiency, probe concentration, environmental
conditions. In addition, many of these probes show emissions only in the visible region and some
of them need ultraviolet excitation, having limited biological applications. Thus, new, more efficient
probes are required. In Zhang’s work, a conjugated coumarin-indolium system with intramolecular
charge transfer (ICT) effect was developed, merging an electron-donating 7-diethylamino coumarin
moiety and an electron-withdrawing positively charged indolium derivative, connected through an
ethylene linker (Figure 62). The whole system resulted in a typical ‘push-pull’ large conjugation dye
system with ICT properties. The so-designed probe showed NIR fluorescence (667 nm) and a rapid,
highly selective and sensitive detection process for HSO3−/SO32− in aqueous solution under mild
conditions; in addition, this probe exhibited significant colorimetric, NIR fluorescent and ratiometric
signal responses upon one excitation wave and a detection lower limit of ∼27 nM. This probe can be
applied to detect HSO3−/SO32− in real food samples, serum samples and living cells. When tested on
real food samples (sugar, soft sugar, crystal sugar and wine in aqueous solution) this probe proved to
be able to determine HSO3− with good recovery. In addition, a paper test strip was developed, simply
by wetting a strip of neutral filter paper with a solution of the probe in methanol (200 µM). The result
was a deep blue test paper ready for use: when a HSO3− solution is spotted on the test paper, rapid
color changes can be observed, even if many other ions are present in the sample. Different colors
correspond to different concentrations of HSO3−. Thus, probe 196 (Figure 62) can be used to develop a
cheap, easy-to-prepare and easy-to-use paper test strip system for the detection of (bi)sulfites.
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A more recent example is a probe developed by Nair and collaborators, able to selectively detect 
the amphiphilic bisulfate ion (HSO4−) in edible plant foods, dog urine and drugs [256]. Bisulfate 
consumption normally takes place through the ingestion of different edible plants, such as cabbage, 
broccoli, Brussels sprouts, horseradish or seeds (black and white mustard, for instance). These plants 
contain glucosinolates [257,258] that are hydrolyzed in our organism by the enzyme myrosinase, thus 
producing bisulfate ion [259]. In addition, bisulfate salts of many APIs are currently on market, 
constituting another source of bisulfate ions [260]. When trying to evaluate the actual concentration 
of HSO4−, it is important to take account of the deprotonation equilibrium between HSO4− and SO42-, 
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A more recent example is a probe developed by Nair and collaborators, able to selectively detect
the amphiphilic bisulfate ion (HSO4−) in edible plant foods, dog urine and drugs [256]. Bisulfate
consumption normally takes place through the ingestion of different edible plants, such as cabbage,
broccoli, Brussels sprouts, horseradish or seeds (black and white mustard, for instance). These plants
contain glucosinolates [257,258] that are hydrolyzed in our organism by the enzyme myrosinase,
thus producing bisulfate ion [259]. In addition, bisulfate salts of many APIs are currently on market,
constituting another source of bisulfate ions [260]. When trying to evaluate the actual concentration of
HSO4−, it is important to take account of the deprotonation equilibrium between HSO4− and SO42−,
using a highly selective probe able to discriminate between these two ions. Nair and co-workers
developed two fully water-soluble probes, coumarin-integrated glycine (CG) and coumarin-integrated
alanine (CA) zwitterions, for the selective detection of HSO4− at picomolar level (from 50 to 325 pM)
(Figure 63).
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Glycine and alanine can interact selectively with the target through H-bond, due to their 
zwitterionic nature at physiological pH, whereas the 7-hydroxycoumarin moiety constitutes a good 
fluorophore probe, thanks to its biocompatibility, non-toxicity and water solubility. The CG/CA 
probes proved to be able to penetrate and stain living cell. When different unknown concentrations 
of clopidogrel bisulfate were added to a water solution of CG/CA, it was possible to precisely 
measure such concentration by measuring the emission intensity of each sample. Confirmation of the 
experimentally observed values with the theoretically calculated ones supported the accuracy of the 
presented method. CG/CA probes were also tested on food samples: water extracts of cruciferous 
plant foods (cabbage, broccoli, mustard seeds, carrots) were added to aqueous solutions of the probes. 
Again, titration of bisulfate ions was performed by emission measurements—addition of increasing 
volumes of aqueous food saps caused a growing reduction of probe’s emission. Cucumber and 
fenugreek were used as controls, as they do not contain bisulfates. Eventually, bisulfate content was 
measured in pet urine samples (bisulfate is one of the common components of pet foods): urine 
samples were collected from two adult dogs and were treated with aqueous solution of CG/CA; a 
reduction of probe emission was noticed, revealing the presence of HSO4− (quenching was 
proportional to bisulfate quantity). In conclusion, CG and CA probes demonstrated the ability to 
detect bisulfate ions in aqueous solution at pH = 7.4, wherein HSO4− concentration was 105.4 lower 
than that of SO42-, at concentration as low as 50 pM, even in presence of other ions. 
With regards to the antimicrobial activity of coumarin scaffold, some studies have been recently 
carried out, showing the potential of natural coumarins as food preservatives. Yang and co-workers 
have studied the antimicrobial activity of eighteen natural compounds against R. Solanacearum [261], 
a bacterium responsible for the wilting of different plants such as tobacco, tomato, potato in 
(sub)tropical regions, causing significant economic losses [262,263].  
Among them, four coumarins (Figure 64) showed an antibacterial activity stronger than that of 
thiodiazole copper treatment (antibacterial rate (MBC/MIC) of 63.3%). Daphnetin showed the highest 
activity, followed by xanthotol and esculetin (antibacterial rate 97.43%, 80.12% and 71.44%, 
respectively). Antibacterial activity seemed to be enhanced by C6, C7 or C8 substitution, so 
hydroxycoumarins umbelliferone, esculetin and daphnetin were selected for further investigation of 
the mechanism of action. Hydroxycoumarins were tested from 10 to 100 mg/L concentrations and from 
results it was clear that the good activity of umbelliferone can be enhanced by the additional 
hydroxylation of C6 position (esculetin), whereas even better results can be achieved by the 
dihydroxylation of C7 and C8 positions (daphnetin). TEM images of R. solanacearum showed that 
daphnetin and esculetin caused irreversible damages to the cell membrane, whereas umbelliferone 
must follow a different path in inducing cell damage. It is worth noting that hydroxycoumarins showed 
very low cytotoxicity on human cells and have no effects on tobacco seeds’ germination. Furthermore, 
because R. solanacearum forms biofilm-like aggregations on host’s roots, facilitating bacterial infection 
[264], Yang and his group speculated that hydroxycoumarins may interfere with biofilm formation. In 
fact, daphnetin, umbelliferone and esculetin (100 mg/L) reduced biofilm formation by 99.22%, 85.20% 
and 93.90%, respectively, probably influencing the swimming motility of the bacterium. Thus, the 
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zwitterionic nature at physiological pH, whereas the 7-hydroxycou arin oiety constitutes a good
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probes proved to be able to penetrate and stain living cell. When different unknown concentrations of
clopidogrel bisulfate were added to a water solution of CG/CA, it was possible to precisely measure such
concentration by measuring the emission intensity of each sample. Confirmation of the experimentally
observed values with the theoretically calculated ones supported the accuracy of the presented method.
CG/CA probes were also tested on food samples: water extracts of cruciferous plant foods (cabbage,
broccoli, mustard seeds, carrots) were added to aqueous solutions of the probes. Again, titration of
bisulfate ions was performed by emission measurements—addition of increasing volumes of aqueous
food saps caused a growing reduction of probe’s emission. Cucumber and fenugreek were used as
controls, as they do not contain bisulfates. Eventually, bisulfate content was measured in pet urine
samples (bisulfate is one of the common components of pet foods): urine samples were collected from
two adult dogs and were treated with aqueous solution of CG/CA; a reduction of probe emission
was noticed, revealing the presence of HSO4− (quenching was proportional to bisulfate quantity). In
conclusion, CG and CA probes demonstrated the ability to detect bisulfate ions in aqueous solution at
pH = 7.4, wherein HSO4− concentration was 105.4 lower than that of SO42−, at concentration as low as
50 pM, even in presence of other ions.
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carried out, sho ing the potential of natural cou arins as food preservatives. Yang and co- orkers
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a bacterium responsible for the wilting of different plants such as tobacco, tomato, potato in (sub)tropical
regions, causing significant economic losses [262,263].
ong the , four cou arins (Figure 64) sho ed an antibacterial activity stronger than that of
thiodiazole copper treat ent (antibacterial rate ( BC/ IC) of 63.3 ). aphnetin sho ed the highest
activity, followed by xanthotol and esculetin (antibacterial rate 97.43%, 80.12% and 71.44 , respectively).
Antibacterial activity seemed to be enhanced by C6, C7 or C8 substitution, so hydroxycoumarins
umbelliferone, esculetin and daphnetin were selected for further investigation of the mechanism of
action. Hydroxycoumarins were tested from 10 to 100 mg/L concentrations and from results it was
clear that the good activity of umbelliferone can be enhanced by the additional hydroxylation of C6
position (esculetin), whereas even better results can be achieved by the dihydroxylation of C7 and C8
positions (daphnetin). TEM images of R. solanacearum showed that daphnetin and esculetin caused
irreversible damages to the cell membrane, whereas umbelliferone ust follow a different path in
inducing cell damage. It is worth noting that hydroxycoumarins showed very low cytotoxicity on
human cells and have no effects on tobacco seeds’ germination. Furthermore, because R. solanacearum
forms biofilm-like aggregations on host’s roots, facilitating bacterial infection [264], Yang and his
group speculated that hydroxycoumarins may interfere with biofilm formation. In fact, daphnetin,
umbelliferone and esculetin (100 mg/L) reduced biofilm formation by 99.22%, 85.20% and 93.90 ,
respectively, probably influencing the swimming motility of the bacterium. Thus, the expression of the
regulating and structural flagellar genes fliA, flhC and flhD in presence of daphnetin, umbelliferone
and esculetin was evaluated and it turned out that the expression of fliA and flhC was significantly
repressed by the mentioned compounds.
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fungi still cause massive death of crops, limiting production and causing significant financial losses. To 
date, farmers deal with this problem by using chemical fungicides but such solution comes with some 
drawbacks: the long and extensive use of these chemicals may cause environmental pollution, 
accumulation of pesticides residues in the plants and drug resistance by fungi. Thus, there is an urgent 
need for alternative (and green) solutions. In 2019, Ramìrez-Pelayo and his collaborators studied the 
coumarin-based compounds contained in the peel of citrus grown in Colombia [265]. Six coumarins 
were isolated (197–202, Figure 65) and their antifungal activity, in terms of mycelial growth and spore 
germination inhibition, was evaluated against the fungus causing anthracnose (Colletotrichum sp.). The 
production of oranges, mandarins, grapefruit, lemons, limes is limited by the action of microorganisms 
able to proliferate in such fruits because of peculiar condition such as high nutrient content, humidity 
and low pH values. Nevertheless, these plants can defend themselves from pathogens thanks to the 
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Another interesting biological activity ascribed to the coumarin nucleus is its antifungal activity,
which can be useful not only in the medicinal field but also in the agricultural one. As far as the latter is
concerned, there has been an increasing interest in the exploitation of coumarin scaffold for the design
and synthesis of novel fungicides useful in the treatment of many plant diseases. Many pathogenic
fungi still cause massive death of crops, limiting production and causing significant financial losses.
To date, farmers deal with this problem by using chemical fungicides but such solution comes with
some drawbacks: the long and extensive use of these chemicals may cause environmental pollution,
accumulation of pesticides residues in the plants and drug resistance by fungi. Thus, there is an urgent
need for alternative (and green) solutions. In 2019, Ramìrez-Pelayo and his collaborators studied the
coumarin-based compounds contained in the peel of citrus grown in Colombia [265]. Six coumarins
were isolated (197–202, Figure 65) and their antifungal activity, in terms of mycelial growth and spore
germination inhibition, was evaluated against the fungus causing anthracnose (Colletotrichum sp.). The
production of oranges, mandarins, grapefruit, lemons, limes is limited by the action of microorganisms
able to proliferate in such fruits because of peculiar condition such as high nutrient content, humidity
and low pH values. Nevertheless, these plants can defend themselves from pathogens thanks to
the production of antimicrobial compounds which can be constitutive (phytoanticipins) or induced
(phytoalexins) [266,267].
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As already mentioned, from the methanol extracts of C. latifolia and C. aurantifolia peels six
compounds were isolated—5-geranyloxy-7-methoxycoumarin (197), bergamottin (198), bergapten
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(199), isopimpinellin (200), limettin (201) and oxypeucedanin hydrate (202) and their activity was
compared to that of umbelliferone, scoparone and scopoletin. Compounds 197–201 were tested at 0.25,
0.50 and 1.00 mM, whereas 202 was tested at 1.00 mM concentration. Carbendazin and thymol were
used as reference compounds (0.5 mM). The results showed that compounds 197–202 significantly
inhibited mycelial growth of Colletotrichum sp., the activity being proportional to the dose used. The
highest inhibition was exhibited by compounds 199 and 201 (32% and 25%, respectively); therefore, the
fungistatic effect of different mixtures of 199 and 201 (0.25 mM (192):0.75 mM (201), 0.50 mM (199):0.50
mM (201) and 0.75 mM (199):0.25 mM (201)) was investigated, each of them showing enhanced activity
respect to both the individual compounds. Furthermore, the activity of 199, 201 and their mixtures
was compared to that of the phytolaxins scoparone, scopoletin and umbelliferone; the results showed
that phytolaxins were just slightly more active than the isolated compounds, although the highest
fungistatic activity was shown by the mixture of 201 (0.75 mM) and 199 (0.25 mM). This mixture,
along with compounds 197, 199 and 201, was selected for the evaluation of the inhibitory effect on
spore germination in comparison with scopoletin, scoparone and umbelliferone. Compounds 201 and
199 exhibited very good activity, with 96.7% and 95.3% inhibition, respectively but these percentages
rapidly decrease, being less than 5% after 24 h. Again, the 199/201 mixture showed the highest activity
causing a complete, long-lasting inhibition of spore germination, thus suggesting that there may be an
additive or synergistic effect between these compounds. Therefore, coumarins and furanocoumarins
may be useful scaffolds in the design of new antifungal agents. In 2018, Yu and co-workers designed a
series of coumarin-3-carboxamide derivatives and evaluated their antifungal activity against Botrytis
cinerea, Alternaria solani, Gibberella zeae, Rhizoctonia solani, Cucumber anthrax and Alternaria leaf spot [268].
These phytopathogenic fungi are all relevant in agriculture, because they can cause significant losses in
crops and investments. In this work, two different scaffolds were merged in order to design a new
category of more effective fungicides. In fact, the use of carboxylic acid amides (CAA) in this context is
well-established, because amide fungicides have been used for over 50 years [269]. More recently, new
amide fungicides with high activity and broad spectrum of action were developed (e.g., Fluopyram,
Bixafen, Sedaxane, Isopyrazam, Penthiopirad and Boscalid) [1,270]. In addition, hydrazide scaffolds
have been found to have interesting biological and pharmacological activities [271,272]. Similarly, the
antifungal activity of coumarin nucleus is well known (paragraph 0). Considering these elements,
the authors decided to combine the coumarin and the carboxamide/hydrazide scaffolds with the aim
of synthesizing high-performance fungicides. All the synthesized compounds were tested and their
antifungal activities against the mentioned phytopathogenic fungi were evaluated. At 100 µg/mL
concentration, most of the tested compounds showed poor antifungal activity. Only compounds 203
and 204 (Figure 66) showed EC50 values of 1.57 µg/mL and 1.65 µg/mL, respectively, against Botrytis
cinerea, proving to be equivalent to the reference Boscalid (0.51 µg/mL), whereas 203 (EC50 = 1.80
µg/mL) resulted more active than Boscalid (EC50 = 2.98 µg/mL) against Rhizoctonia solani.
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Figure 66. Chemical structure of compounds 203 and 204.
Starting from these data it was possible to suggest some structure-activity relationships: the
replacement of amide bond with a hydrazide bond led to an improvement in antifungal activity
spectrum. Furthermore, coumarins bearing amide group resulted to be remarkably more active
against Botrytis cinerea and Rhizoctonia solani, whereas against Alternaria solani, Gibberella zeae, Cucumber
anthrax and Alternaria leaf spot they showed less potency. It is noteworthy that compounds bearing an
electron-withdrawing group did not show any activity, whereas compounds with an electro-donating
group were active against Alternaria leaf spot. The addition to the coumarin nucleus of Cl/F- substituted
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phenylidrazine gave compounds active on Cucumber anthrax. A similar approach is the one followed by
Yang and collaborators, who decided to exploit coumarin nucleus for the functionalization of chitosan,
in order to create more effective chitosan-based fungicides [273]. In fact, chitosan is becoming more and
more appreciated due to its antimicrobial activity, low toxicity, biodegradability, biocompatibility and
film forming activity. However, its application as fungicide is limited by its low solubility and weaker
activity respect to the on-market fungicides. In this work, four coumarin-functionalized chitosan
derivatives (205a–d, Figure 67), were synthesized and tested against the phytopathogens Alternaria
solani sorauer, Fusarium oxysporum f.sp. vasinfectum and Fusarium moniliforme by evaluating the mycelial
growth rate in vitro. At 1.0 mg/mL, compounds 205a–d showed inhibitory activity against A. solani,
following the sequence 205d > 205b > 205c > 205a (38.25%, 51.23%, 44.01% and 52, 78%, respectively).
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Th se results that the introduction f halogens caused an increase in activity, depending
on the number a d the type of halog ns. For instance, the 3,5-dic loro derivatives were more active
against A. sola i han the correspondent 5-Cl or 5-Br derivatives, probably because of an increase of
hydrophobicity. The four coumarin-chitosan derivatives showed higher activity than ch tosan alone
also ag inst F. oxysporum and F. m niliforme. Compound 205d sh we an inhibitory index of 57.09%
against A. solani, 77.24% agai st F. oxysporum and 66.12% ag i st F. moniliforme.
3.3. Coumarin-Metal Complexes
The great biological potential of coumarins might be even increased by considering the possibility
to complex coumarin scaffold with other substances as, for example, some metals. In fact, it has
been proved that it is possible to enhance the activity of a certain drug simply binding it to a
metallic-element [274]; moreover, by combining known active moieties with metals, it would be
possible to improve the parent compound with a certain selectivity or even with a new mechanism
of action. Therefore, many groups have already started to explore this strategy, aiming to produce
more active compounds, exploiting metals as copper, platinum, zinc or silver. In some cases, due
to its intrinsic potential, coumarin scaffold was exploited in this approach. Some examples are
discussed below.
The nature of coumarin-copper complexes had already been evaluated in 2001 by Karaliota and
co-workers, who synthesized and characterized a binuclear coumarin-3-carboxilate-copper (II) complex
(206) [275]. In this work, thanks to multiple instrumental characterization by means of IR, Raman
and NMR spectroscopy, the authors were able to identify the structure of the complex (Figure 68): a
binuclear molecule [Cu2(Cca)4(H2O)2], where copper is coordinated by four carboxylic oxygens, one
from each Cca molecule and two water molecules.
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on their speciation; for example, 207, monomeric at neutral pH, showed valuable activity, whereas 
212 - a dinuclear specie- resulted inactive. Moreover, their cytotoxicity was not related to their ability 
to induce ROS generation. Such activity was showed only by complex 207, whereas 210 and 212 
exhibited limited ROS induction. 211 and 212 proved to be able to bind DNA but none of the tested 
compounds showed significant nuclease activity. This means that imine-copper(II) complexes 
showing cytotoxicity towards MCF-7 cells do not act by means of ROS generation or nuclease activity, 
being these two the mechanisms of action previously ascribed to copper (II) complexes [280]. In fact, 
complexes 208–210 acted as superoxide dismutase (SOD) and catalase mimics. This is noteworthy, if 
we consider that in some cancer cells hypoxia induces an adaptive mechanism providing protection 
against damage and oxidative stress. In this context, copper (II)-imine complexes acting as SOD 
mimics may constitute a valid tool for the treatment of hypoxic tumors.  
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In the same year, Qin and collaborators investigated the potential of platinum (II) complexes 
against cisplatin resistant human lung adenocarcinoma (A549/DDP) and HeLa cells [281]. Cisplatin 
was used as reference. In this work, eleven complexes between platinum (II) and quinoline-coumarin 
derivatives (214–224, Figure 70) were designed, synthesized and tested. All the new complexes 
showed an improved antineoplastic activity on A549/DDP and HeLa cells when compared to cis-
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A more recent work by MacLean et al. reports a series of copper (II) complexes with seven
imine-derived ligands (207–213, Figure 69) which were tested on MCF-7 human breast cancer cells
to evaluate their cytotoxicity [276]. In fact, the increase of ROS levels might promote oxidative
stress-induced cancer cell death, thus representing an alternative strategy for the treatment of some
forms of tumors [277–279]. Interestingly, it was found that the activity of such compounds depended
also on their speciation; for example, 207, monomeric at neutral pH, showed valuable activity, whereas
212 - a dinuclear specie- resulted inactive. Moreover, their cytotoxicity was not related to their ability to
induce ROS generation. Such activity was showed only by complex 207, whereas 210 and 212 exhibited
limited ROS induction. 211 and 212 proved to be able to bind DNA but none of the tested compounds
showed significant nuclease activity. This means that imine-copper(II) complexes showing cytotoxicity
towards MCF-7 cells do not act by means of ROS generation or nuclease activity, being these two the
mechanisms of action previously ascribed to copper (II) complexes [280]. In fact, complexes 208–210
acted as superoxide dismutase (SOD) and catalase mimics. This is noteworthy, if we consider that in
some cancer cells hypoxia induces an adaptive mechanism providing protection against damage and
oxidative stress. In this context, copper (II)-imine complexes acting as SOD mimics may constitute a
valid tool for the treatment of hypoxic tumors.
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In the same year, Qin and collaborators investigated the potential of platinum (II) complexes
against cisplatin resistant human lung adenocarcinoma (A549/DDP) and HeLa cells [281]. Cisplatin
was used as ref rence. In this work, eleven complexes between platinum (II) and quinoline-coumarin
derivatives (214–224, Figure 70) were signed, synthesized and tested. All the new complexes showed
an improved a tineoplastic activity on A549/DDP and H La cells when compared t cis-Pt(DMSO)2Cl2
and the parent quinolin -coumarin rivatives, wit IC50 v lues ranging be w e 100 n and 10.33
µM (75.02 ± 1.18 µM for A549/DDP or 12.09 ± 0.24 µM for HeLa). In additio , ounds 214–224
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displayed selectivity towards the mentioned cancer cells over other tumoral cell lines and HL-7002
non-tumoral cell line.
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However, metal-coumarin complexes constitute an interesting tool not only in the 
pharmacological field but also in the chemical one. As an example of such application, we report here 
a work from Aslkhademi and collaborators, who designed, synthesized ad characterized a new Zn(II) 
complex with a coumarin-hydrazone ligand (225, Figure 71) [282]. In this case, the complex was 
evaluated as a catalyst for the synthesis of tetrazoles by means of 3 + 2 cycloaddition between a nitrile 
and an azide. To this purpose, many experiments were carried out using different nitriles and 
reaction conditions. In the end, the Zn(II)-coumarin-hydrazone complex resulted to be a suitable 
catalyst for the synthesis of tetrazoles; the most effective amount of catalyst to employ was 0.05 mmol 
and substrates bearing electron-donating groups reacted better than the ones with electron-
withdrawing substituents.  
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Figure 70. Chemical structure of derivatives 214–224.
However, metal-coumarin complexes constitute an interesting tool not only in the pharmacological
field but also in the chemical one. As an example of such application, we report here a work from
Aslkhademi and collaborators, who designed, synthesized ad characterized a new Zn(II) complex
with a coumarin-hydrazone ligand (225, Figure 71) [282]. In this case, the complex was evaluated as a
catalyst for the synthesis of tetrazoles by means of 3 + 2 cycloaddition between a nitrile and an azide.
To this purpose, many experiments were carried out using different nitriles and reaction conditions. In
the end, the Zn(II)-coumarin-hydrazone complex resulted to be a suitable catalyst for the synthesis
of tetrazoles; the most effective amount of catalyst to employ was 0.05 mmol and substrates bearing
electron-donating groups reacted better than the ones with electron-withdrawing substituents.
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Finally, it is worth mentioning the application of metal-coumarin complexes as constituents of
sol-gel coatings. Lately, sol-gels are gaining attention due to their chemical stability, homogeneity and
technological applications (e.g., reservoir for the prolonged release of antimicrobial substances). In 2013,
Jaiswal and co-workers proposed the synthesis of silver-coumarin complexes useful as antibacterial
agents in sol-gel coatings [283]. The e complexes were based on coumarin-3-carboxylatosilver and its
hydroxylated derivatives in 6, 7 and 8. Antimicrobial activity was displayed even at concentration
of 0.3% (w/w). The most active compound showed significative antibiofilm activity at 0.5% and
0.7% (w/w). These results are encouraging in the perspective of using Ag-coumarin co plexes as
biomedical coatings.
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Table 2 reports some of the coumarins mentioned above, summarizing the biological activity, the
molecular target and the origin.
Table 2. Summary table.
Structure Biological Activity MolecularTarget Name/Number Ref. Origin
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4. Synthesis of Coumarin Scaffold
Knoevenagel condensation, Wittig reaction, Claisen rearrangement, Heck reaction, Pechmann
condensation and Perkin reaction are widely used methods for the obtainment of cou arin derivatives
and have been widely reviewed over the years [284,285]. The increasing interest in coumarins
as potential biologically active compounds led to the development of innovative procedures and
approaches aimed at the production of coumarins in high yield and in a sustainable manner. In the
next paragraphs, we will focus on the most recent advances in coumarin synthesis.
4.1. New Approaches in Coumarins Synthesis
4.1.1. Flow Chemistry and Immobilized Reagents
In the past two decades, flow chemistry emerged has a promising synthetic technology, due to
the many advantages it offers compared to the traditional batch method. In fact, by using continuous
flow reactors it is possible to control reaction parameters, such as temperature, stoichiometry, reaction
time and others, very precisely, thus having the possibility to achieve better and more reproducible
reactions. Furthermore, the great surface area/volume ratio in continuous flow reactors often leads
to better reaction yields. This new technology gives also the possibility to work with hazardous
reagents and to perform superheated or pressurized reactions in safer conditions [286–288]. The
applications of this technology are numerous and the improvement of chemical synthesis of natural
compounds is one of them. In 2015, Li and collaborators developed a two-stage synthesis of coumarins
via O-acetylation of salicylaldehyde [289]. The reaction occurred via O-acetylation and intramolecular
aldol-type condensation, followed by dehydration and it was performed using two heated coiled
reactors (Scheme 1). Using this system, it was possible to reach a 120 g scale production.
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too. In 2018, Mhiri and co-workers proposed a synthetic pathway for coumarin derivatives involving
polymer supported reagents [290]. In the mentioned study, coumarin derivative A was prepared from
3-metoxy salicylaldheyde using reagents supported in a macroporous ion exchange resin, through the
hydrolysis of the two intermediates iminocoumarin B and unsaturated nitrile C (Scheme 2).
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The first step provided the prep ration of polymer supported henate ions that then reacted with
phenylacetonitrile, leading to the formation of iminocoumarin and unsaturated nitrile, which were
finally deblocked from the resin with chloroform. The acid hydrolysis of the obtained mixture of
compounds B and C gave coumarin derivative A in very good yield (95%).
4.1.2. Photocatalysis
It is worth speaking about another emerging strategy in organic synthesis: photocatalysis. In
2015, Metternich and Gilmour utilized this approach to emulate coumarins biosynthesis, using
(−)-riboflavin as a photocatalyst [291]. In this work, two discrete activation modes of (−)-riboflavin
were sequentially exploited to induce the isomerization and cyclisation of E-cinnamic acids used as
starting material (Scheme 3), thus overcoming the use of phenol-derived and pre-functionalized aryl
rings as starting materials.
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Similarly, in 2019, Song and co-workers reported a one-pot photoredox-catalyzed protocol
to achieve a series of 3-fluoroalkylated coumarins starting from ortho-hydroxycinnamic esters
(Scheme 4) [292]. ortho-Hydroxycinnamic esters and BrCF2COR’ (or other commercially available
perfluoroalkylated radical resources) were exposed to 30W blue LEDs irradiation under argon
atmosphere for 12 h.; fac-Ir(ppy)3 was found to be the best among the tested catalysts, whereas CH3CN,
DMF, DMSO and THF were all suitable solvents for this reaction. K2CO3, Et3N and DIPEA were all
able to neutralize HBr produced during the process. This procedure gave 3-fluoroalkylated coumarins
in good yields on milligram and gram scales.
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2015, Metternich and Gilmour utilized this approach to emulate coumarins biosynthesis, using (−)-
riboflavin as a photocatalyst [291]. In this work, two discrete activation modes of (−)-riboflavin were 
sequentially exploited to induce the isomerization and cyclisation of E-cinnamic acids used as 
starting material (Scheme 3), thus overcoming the use of phenol-derived and pre-functionalized aryl 
rings as starting materials.  
 
 
 
 
 
Scheme 3. (a) Photocatalyzed synthesis of coumarins; (b) Chemical structure of (-) Riboflavin. 
Similarly, in 2019, Song and co-workers reported a one-pot photoredox-catalyzed protocol to 
achieve a series of 3-fluoroalkylated coumarins starting from ortho-hydroxycinnamic esters (Scheme 
4) [292]. ortho-Hydroxycinnamic esters and BrCF2COR’ (or other commercially available 
perfluoroalkylated radical resources) were exposed to 30W blue LEDs irradiation under argon 
atmosphere for 12 h.; fac-Ir(ppy)3 was found to be the best among the tested catalysts, whereas 
CH3CN, DMF, DMSO and THF were all suitable solvents for this reaction. K2CO3, Et3N and DIPEA 
were all able to neutralize HBr produced during the process. This procedure gave 3-fluoroalkylated 
coumarins in good yields on milligram and gram scales. 
 
 
 
 
Scheme 4. Photoredox-catalyzed synthesis of 3-fluoroalkylated coumarins. 
Another example is the bichromatic synthesis of coumarins proposed by Eivgi and collaborators 
in 2017 [293]. In this work, 2-nitrobenzyl-protected 2-hydroxystyrenes and acrylates underwent a UV-
A (380 nm) photoinduced cross metathesis (CM) reaction, in the presence of ruthenium as a catalyst. 
In this step a 1-pyrenecarboxaldheyde solution was used as a UV filter, without whom the catalyst 
would be permanently inactivated due to phenol deprotection and phenolate chelation to the 
ruthenium. After CM, the UV filter was removed and irradiation with UV-C light (254 nm) led to 
more complex structures, such as coumarins. In fact, irradiation with UV-C light started a three-
reactions chain—photodeprotection of the intermediate, E/Z isomerization and cyclization to form 
the desired coumarins (Scheme 5).  
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Another example is the bichromatic synthesis of coumarins proposed by Eivgi and collaborators
in 2017 [293]. In this work, 2-nitrobenzyl-protected 2-hydroxystyrenes and acrylates underwent a
UV-A (380 nm) photoinduced c ss metathesi (CM) reaction, in the presence of ruthenium as a
catalyst. In this step a 1-pyrenecarboxaldheyde solution was used a UV filter, without whom the
catalyst would be permanently inactivated due to phen l deprotection and phenolate chelation to the
ruthenium. After CM, the UV filter was removed and irra i tion with UV-C light (254 n ) led to more
complex structures, such as oumarins. In fact, irradiation with UV-C light started a three-reactions
chain—photodeprotection of the intermediate, E/Z isomerization and cyclization to form the desired
coumarins (Scheme 5).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 61 of 83 
 
 
 
 
 
 
 
 
 
Scheme 5. (a) Bichromatic synthesis of coumarins; (b) chemical structure of catalyst A. 
4.1.3. Solvent-Free Reactions 
Chemists usually carry out reactions in solution, following the Aristotelian principle “Corpora 
non agunt nisi fluida seu soluta” or in other and more contemporary words “Compounds do not react 
unless fluid or if dissolved” [294]. However, this is not always completely accurate, because many 
solventless reactions proceed efficiently. An enhancement in kinetics, owed to the different 
concentrations of reactants given the lack of solvents, bring actually to a higher reactivity and, where 
necessary, milder experimental conditions. At the same time, the absence of solvents provides the 
chance to heat over the boiling point of the most common solvents and to exploit the benefits of 
microwave assisted irradiation. The occurrence of efficient solid-state reactions shows that the 
reacting molecules are able to move freely in the solid state, whereas monitoring of the reaction is 
possible thanks IR and UV spectra in the solid state [295,296]. The most remarkable advantage of 
solvent-free reaction, in all probability, is the noteworthy cut in the waste production associated with 
solvents handling, resulting in a more effective and ecological chemical process. There are three 
solvent-free techniques: (1) reactions conducted on mineral supports, (2) reaction without any 
solvent, support or catalyst and (3) solid-liquid phase transfer catalysis [297]. 
The experimental conditions required for the classical synthesis of coumarin derivatives are, in 
some cases, drastic, as in the production of hymecromone via Pechmann condensation where the 
final compound is obtain by stirring a mixture of resorcinol and ethyl acetoacetate in concentrated 
H2SO4 for 12–24 h [295]. Solvent-free reactions seemed to be a more ecological option. Consequently, 
in 2001, Sugino and Tanaka proposed the synthesis of several coumarin derivatives both via 
Pechmann and Knoevenagel condensation reactions [298]. For example, p-toluensolfonic acid was 
employed as a catalyst and the reaction mixture was heated at 60 °C for 10 min. without solvent, 
giving after the work-up 7-hydroxy-4-methylcoumarin in 98% yield (Scheme 6). 
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4.1.3. Solvent-Free Reactions
Chemists usually carry out reactions in solution, following the Aristotelian principle “Corpora non
agunt nisi fluida seu soluta” r in other and more contemporary words “Compounds do not react unless
fluid or if dissolved” [294]. However, this is not always completely accurate, because many solventless
reactions proceed efficiently. An enhancement in kinetics, owed to the different concentrations of
reactants given the lack of solvents, bring actually to a higher reactivity and, where necessary, milder
experimental conditions. At the same time, the absence of solvents provides the chance to heat over the
boiling point of the most common solvents and to exploit the benefits of microwave assisted irradiation.
The occurrence of efficient solid-state reactions shows that the reacting molecules are able to move
freely in the solid state, whereas monitoring of the reaction is possible thanks IR and UV spectra in the
solid state [295,296]. The most remarkable advantage of solvent-free reaction, in all probability, is the
noteworthy cut in the waste production associated with solvents handling, resulting in a more effective
and ecological chemical process. There are three solvent-free techniques: (1) reactions conducted
on mineral supports, (2) reaction without any solvent, support or catalyst and (3) solid-liquid phase
transfer catalysis [297].
The experimental conditions required for the classical synthesis of coumarin derivatives are, in
some cases, drastic, as in the production of hymecromone via Pechmann condensation where the final
compound is obtain by stirring a mixture of resorcinol and ethyl acetoacetate in concentrated H2SO4
for 12–24 h [295]. Solvent-free reactions seemed to be a more ecological option. Consequently, in 2001,
Sugino and Tanaka proposed the synthesis of several coumarin derivatives both via Pechmann and
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Knoevenagel condensation reactions [298]. For example, p-toluensolfonic acid was employed as a
catalyst and the reaction mixture was heated at 60 ◦C for 10 min. without solvent, giving after the
work-up 7-hydroxy-4-methylcoumarin in 98% yield (Scheme 6).
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Scheme 6. Solvent-free synthesis of 7-hydroxy-4-methylcoumarin.
Knoevenagel condensation was also studied under solventless conditions and efficiently brought
to the production of both coumarins and benzocoumarin derivatives [298].
Another methodology was proposed in 2012 by Kalita and Kumar, that exploited the Pechmann
reaction using trifluoromethanesulfonic acid functionalized Zr-TMS (Zr-TMS, zirconia-based transition
metal oxide mesoporous molecular sieves) catalysts, under solvent-free heterogeneous catalytic
conditions. The product selectivity was always found to be about 100% (Scheme 7) [296].
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More recently, a novel series of hetero-annulated coumarins was obtained by Ebrahimi and 
colleagues through a one-pot reaction under solvent-free conditions and evaluated as AChE/BuChE 
inhibitors. As acidic catalyst nano-silica sulfuric acid was employed and the versatility of the system 
was assayed on appropriated benzaldehydes, dimedone and 4-hydroxycoumarin (Scheme 8) [299]. 
Also noteworthy is the application, once again, of a reusable heterogeneous catalyst, which 
contributed to the general environmental sustainability of the process thanks to the possible recovery 
and reuse [300].  
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Another solventless procedure worth noting is the one presented by Kour and Paul, which 
exploited Lewis acid grafted sulfonated carbon@titania composite as catalyst for the Pechmann 
condensation. This particular kind of catalyst and its efficacy had been already studied by the team 
for the synthesis of 4H-pyrimido[2,1-b]benzothiazoles and benzoxanthenones under solvent-free 
conditions, so the one-pot synthesis of coumarin derivatives was the natural next step (Scheme 9) 
[301,302]. Because the catalyst reusability contributes to reduce the cost of the practical application 
processes, the reusability of the catalyst was investigated in the Pechmann condensation. The catalyst, 
recovered by filtration, after five catalytic runs had a mild decrease in the catalytic activity and 
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Scheme 7. Solvent-free Pechmann condensation with Zr-TMS-TFA as catalyst.
More recently, a novel series of hetero-annulated coumarins was obtained by Ebrahimi and
colleagues through a one-pot reaction under solvent-free conditions and evaluated as AChE/BuChE
inhibitors. As acidic catalyst nano-silica sulfuric acid was employed and the versatility of the system
was assayed on appropriated benzaldehydes, dimedone and 4-hydroxycoumarin (Scheme 8) [299]. Also
noteworthy is the application, once again, of a reusable heterogeneous catalyst, which contributed to
the general environmental sustainability of the process thanks to the possible recovery and reuse [300].
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Scheme 8. Solvent-free synthesis of hetero-annulated coumarins.
Another solventless procedure worth noting is the one presented by Kour and Paul, which exploited
Lewis acid grafted sulfonated carbon@titania composite as catalyst for the Pechmann condensation.
This particular kind of catalyst and its efficacy had been already studied by the team for the synthesis
of 4H-pyrimido[2,1-b]benzothiazoles and benzoxanthenones under solvent-free conditions, so the
Int. J. Mol. Sci. 2020, 21, 4618 62 of 81
one-pot synthesis of coumarin derivatives was the natural next step (Scheme 9) [301,302]. Because the
catalyst reusability contributes to reduce the cost of the practical application processes, the reusability
of the catalyst was investigated in the Pechmann condensation. The catalyst, recovered by filtration,
after five catalytic runs had a mild decrease in the catalytic activity and exhibited almost the same TG
curve as the fresh one, depicting that the present heterogeneous system showed high thermal stability
after successive reaction cycles [302].
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In order to obtain a different and ecological procedure for the synthesis of 3-substituted 
coumarins via Knoevenagel condensation, Ghomi and Akbarzadeh developed a procedure starting 
from various salicylaldehydes and 1,3-dicarbonyl compounds. They used MgFe2O4 nanoparticles as 
an efficient catalyst under solvent-free condition and ultrasound irradiation (Scheme 10).  
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and microjet generated by the cavitation. Furthermore, with this method, MgFe2O4 nanoparticles 
were dispersed in the reaction and provided more sites for the construction of cavity over their 
surface. The catalyst was recovered via magnetic separation and reused up to 6 cycles without 
relevant loss of activity [303]. 
The convenience given by the removal of the catalyst by means of an external magnetic field is 
a significant improvement in the work-up of a reaction mixture. Consequently, another magnetic 
nano structured catalyst was employed for the synthesis of coumarin nucleus, this time through 
Pechmann condensation. In 2019, Pakdel and co-workers proposed the synthesis of coumarin 
derivatives by leveraging Fe3O4@Boehmite-NH2-CoII NPs as a catalyst, under solvent-free conditions 
that resulted the best choice comparing the results obtained with classic solvents. The catalyst could 
be recovered easily and reused up to six times. However, no desired coumarin derivatives were 
observed in the case of phenols bearing electron-withdrawing substituents (such as -Cl and –NO2), 
behavior attributed to the proposed mechanism of the reaction [304]. 
In the field of solvent-free reactions, the application of ionic liquids as catalyst for the synthesis 
of coumarin scaffolds deserves a stand-alone status. Ionic liquids (ILs) have become increasingly 
popular in the last decades as a safer alternative to classic solvent systems, in a perspective of more 
sustainable chemical processes. Most ILs possess a number of properties that made them appealing, 
proving to be non-flammable, to possess a negligible vapor-pressure, that means that solvent 
evaporation is eliminated and to dissolve a wide range of organic and inorganic compounds [305]. 
Furthermore, since ionic liquids are low-melting salts, they are made at least from two components 
which can be varied (the anion and the cation), thus the solvents could be designed with a particular 
end use in mind or possessing a particular set of properties [306]. However, their use in large 
quantities is restricted by some limitations like biodegradability, toxicity and high costs [307–309]. 
Mahato and colleagues in 2017 used ionic liquids as an acidic catalyst in the regioselective synthesis 
of pyrano[3,2-c] coumarins under solvent-free conditions. In particular, given the fact that Brønsted 
acidic ion liquids (BAILs) acquired recognition in the field of catalysis, the research team reported 
the catalytic effect of 1-butane sulfonic acid-3-methylimidazolium tosylate, [BSMIM]OTs (BAIL-1), 
on the tandem reaction between 4-hydroxycoumarin and α,β-unsaturated carbonyl compounds for 
the formation of pyrano[3,2-c]coumarins (Scheme 10) [310,311]. In addition to the high yields and the 
regioselectivity, this procedure allowed to avoid column chromatography for further purification. 
Scheme 9. Lewis acid grafted sulfonated carbon@titania composite as catalyst for the
Pechmann condensation.
In order to obtain a different and ecological procedure for the synthesis of 3-substituted coumarins
via Knoevenagel condensation, Ghomi and Akbarzadeh developed a procedure starting from various
salicylaldehydes and 1,3-dicarbonyl compounds. They used MgFe2O4 nanoparticles as an efficient
catalyst under solvent-free condition and ultrasound irradiation (Scheme 10).
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Noroozizadeh and co-workers focused their efforts on the synthesis of bis-coumarins thanks to 
a different catalyst, acetic acid functionalized poly(4-vinylpyridinum) bromide (APVPB), in 
continuous of a previous work of the research team on the preparation of Brønsted acidic ionic liquids 
and solid salts [312,313]. The aim was the development of a novel and efficient procedure for the 
synthesis of bis-coumarins which lacked the classical drawbacks as the use of solvents, high costs and 
low yields [314].  
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Scheme 10. Ionic liquids as an acidic catalyst in the regioselective synthesis of pyrano[3,2-c] coumarins
under solvent-free conditions.
Basically, ultrasound irradiation increased the dimension of the single bubbles together with the
number of active cavitation bubbl s. The resulting effect was expected to be a higher maximum collapse
temperature and a faster synthesis of oumarin compounds by Knoevenagel reaction. Comparing
ultrasound irr diation to c nventional heating the research team dem nstrated th t the first method
llowed to obtain higher yields in shor er times, probably because of th shock wave and microjet
ge erated by the cavitation. Furthermore, with this method, MgFe2O4 nanoparticles were disperse
in the reaction and provided more sites for the construction of cavity over their surface. The catalyst
was recovered via magnetic separation and reused up to 6 cycles without relevant loss of activity [303].
The c nvenience given by he removal of the catalyst by means of an external magnetic field is a
significant improvement in the work-up of a reaction mixture. Consequently, another magnetic nano
structured catalyst was employed for the synthesis of coumarin nucleus, this time through Pechmann
condensation. In 2019, Pakdel and co-workers proposed the synthesis of coumarin derivatives by
leveraging Fe3O4@Boehmite-NH2-CoII NPs as a catalyst, under solvent-free conditions that resulted
the best choice comparing the results obtained with classic solvents. The catalyst could be recovered
easily and reused up to six times. However, no desired coumarin derivatives were observed in the case
of phenols bearing electron-withdrawing substituents (such as -Cl and –NO2), behavior attributed to
the proposed mechanism of the reaction [304].
In the field of solvent-free reactions, the application of ionic liquids as catalyst for the synthesis of
coumarin scaffolds deserves a stand-alone status. Ionic liquids (ILs) have become increasingly popular
in the last decades as a safer alternative to classic solvent systems, in a perspective of more sustainable
chemical processes. Most ILs possess a number of properties that made them appealing, proving
to be non-flammable, to possess a negligible vapor-pressure, that means that solvent evaporation is
eliminated and to dissolve a wide range of organic and inorganic compounds [305]. Furthermore,
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since ionic liquids are low-melting salts, they are made at least from two components which can
be varied (the anion and the cation), thus the solvents could be designed with a particular end use
in mind or possessing a particular set of properties [306]. However, their use in large quantities
is restricted by some limitations like biodegradability, toxicity and high costs [307–309]. Mahato
and colleagues in 2017 used ionic liquids as an acidic catalyst in the regioselective synthesis of
pyrano[3,2-c] coumarins under solvent-free conditions. In particular, given the fact that Brønsted acidic
ion liquids (BAILs) acquired recognition in the field of catalysis, the research team reported the catalytic
effect of 1-butane sulfonic acid-3-methylimidazolium tosylate, [BSMIM]OTs (BAIL-1), on the tandem
reaction between 4-hydroxycoumarin and α,β-unsaturated carbonyl compounds for the formation of
pyrano[3,2-c]coumarins (Scheme 10) [310,311]. In addition to the high yields and the regioselectivity, this
procedure allowed to avoid column chromatography for further purification. Moreover, given the mild
experimental conditions, there were no by-products attributable to decomposition or polymerization.
Noroozizadeh and co-workers focused their efforts on the synthesis of bis-coumarins thanks to a
different catalyst, acetic acid functionalized poly(4-vinylpyridinum) bromide (APVPB), in continuous
of a previous work of the research team on the preparation of Brønsted acidic ionic liquids and solid
salts [312,313]. The aim was the development of a novel and efficient procedure for the synthesis
of bis-coumarins which lacked the classical drawbacks as the use of solvents, high costs and low
yields [314].
4.1.4. Microwave Assisted Reactions
Temperature is a key parameter in almost the totality of chemical reactions involving both
inorganic and organic compounds. Generally, most organic reactions are performed heating by
traditional heat transfer equipment like oil baths, sand baths and heating jackets. The drawbacks
associated with these heating techniques are the slowness, the possible development of temperature
gradient within the sample and consequent local overheating that could lead to the formation of
by-products. Microwave technology started to emerge in inorganic chemistry since the late 1970s
and almost a decade after attracted the attention of organic chemists [315]. Compared to the
traditional heating, microwave dielectric heating has several advantages: (1) higher heating rates,
(2) no direct contact between the source of energy and the reacting chemicals, (3) possible selective
heating, because reacting chemicals interact differently with the commonly used microwave radiations
and (4) rapid increase of the temperature also above boiling point in pressurized systems [316].
Microwave irradiation is often associated with other technologies, such as ionic liquids and neat
reactions (already mentioned in the previous paragraph) [295,317]. In the late 1990s progresses in the
classic coumarins synthesis via microwave irradiation were reported by Singh and co-workers, who
confirmed a reduction in reaction time of the Pechmann condensation and by Saidi and colleagues,
who demonstrated the improvement in the synthesis of pyranocoumarins and furanocoumarins
through Claisen rearrangement [317,318]. Ten years later, Valizadeh and Shockravi pushed further
the opportunities given by microwave heating combining it with a task-specific imidazolium-based
phosphinite ionic liquid (IL-OPPh2) for the synthesis of E-cinnamates and coumarin derivatives via
the one-pot Horner–Wadsworth–Emmons–type reaction (Scheme 11).
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The same reactions were in parallel conducted with traditional heating and microwave irradiation:
the former technique showed considerably longer reaction times (13–16 h vs. 10–12 min) and lower
yields (65–60% vs. 79–83%). Furthermore, IL-OPPh2 worked at the same time as reaction medium and
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reagent as the research team already demonstrated in a previous study focused on the synthesis of
coumarin nucleus via Knoevenagel and Witting reactions in ionic liquids [319,320].
In 2016, Fiorito and colleagues merged the advantages of solvent-free reactions with microwave
heating for the synthesis of several coumarin derivatives. They started from variously substituted
phenols and propiolic acids in the presence of ytterbium triflate hydrate 10% mol as catalyst [321].
During the last thirty years, triflates of metals belonging to the lanthanide series have been regarded
as effective water tolerant recyclable Lewis acids. These metals have been discovered to catalyze
different carbon–carbon and carbon–heteroatom bond formation reactions, providing the desired
products in excellent yields by means of a green chemical approach [322,323]. Furthermore, Wang
and colleagues already employed this particular catalyst for the synthesis of 4-methylcoumarins
via Pechmann condensation [324]. Fiorito and co-workers developed for the first time a synthetic
procedure to obtain different substituted coumarins in 2 min. under microwave irradiation in 91-98%
yields [321]. Moreover, the research team recovered the ytterbium triflate catalyst and demonstrated
that no loss of activity occurred during several cycles.
In the same year, Bouasla et al. compared the efficacy of different heterogeneous acidic catalysts
in the Pechmann synthesis of 4-methylcoumarin and 7-hydroxy-4-methylcoumarin when coupled
by microwave heating. The efficacy of different Amberylst-type catalyst in the Pechmann synthesis
of 7-hydroxy-4-methylcoumarin was already pointed out by Sabou and colleagues in 2005 [325].
Therefore, the catalytic performance of Amberlyst-15 was compared with zeolite H-β and sulfonic acid
functionalized hybrid material TS-OS-SO3H, performing the reaction under solvent-free conditions, at
130 ◦C for 20 min in a microwave reaction tube. Amberlyst-15 showed a higher catalytic activity (97%
yield against 21–44% obtained with two others catalysts) due to its high density of acid centers [326].
It is also worth mentioning the work of Konrádová et al., who in 2017 developed an interesting
protecting-group-free method starting from commercially available aromatic aldehydes and using a
microwave promoted Wittig reaction of a stabilized ylide for the synthesis of different natural products,
including coumarins. After the optimization of the experimental parameters and the development
of a general synthetic methodology for the synthesis of different substitute coumarin derivatives
(Scheme 12a), the method was further developed to incorporate a Claisen rearrangement step. In
order to demonstrate the synthetic utility and versatility of the developed method, the research team
performed the total synthesis of two coumarins, one of which being osthole, a natural coumarin
derivative already mentioned in the anti-inflammatory paragraph (Scheme 12b) [327].
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A broad range of indolo[2,3-c] coumarins have been obtained in good yields (46–88%) by Gu and
co-workers in 2019 under microwave-assisted base-free intramolecular cross dehydrogenative coupling
using palladium catalyst. The advantages of this methodologies compared to classic synthesis of
coumarin lactone ring were both atom economy and step efficiency, combined with C-H/C-H coupling
without pre-functionalization [328].
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5. Conclusions
The coumarin nucleus has been gaining increasing attention in the last years because of the variety
of its applications both in medicinal chemistry and in agri-food sectors. In this review, we presented
a collection of recent works that highlight the wide range of pharmacological activities ascribable
to coumarins (antioxidant, antibacterial, antifungal, antiviral, anti-proliferative, anti-inflammatory,
antidiabetics, anticoagulant and anti-neurodegenerative) and the possibility to easily modify and
decorate this natural scaffold to perform structure activity relationships studies. The coumarin nucleus
possesses some fundamental properties that ensure it an advisable role in the design of new biologically
active derivatives, mainly due to its stability, low molecular weight and to the easiness to decorate it
for increasing pharmacodynamic and pharmacokinetic properties.
Coumarin scaffold has been a valuable source of inspiration in the design of novel biologically
active compounds and its role as a starting point is very attractive. This natural core is present in a
number of currently available drugs used in the treatment of various diseases. For instance, the use
of warfarin, acenocumarol and phenprocoumon in the treatment and prevention of thromboembolic
diseases is now well established. Other examples include the use of hymecromone as choleretic agent
and that of the antihelminthic haloxon in veterinary medicine. Even though the coumarin nucleus
presents an impressive number of biological activities, its presence among marketed drugs is not
widespread yet. Further efforts are needed in order to achieve coumarin-based compounds with
appreciable pharmacokinetic properties, along with high efficacy and a low toxicity profile.
Moreover, in this review we discussed coumarin photoproperties and their applications as
photocleavable protecting groups and fluorescent probes. Finally, we analyzed the latest updates
in coumarin synthesis from both chemical and technological points of view. One of the most
interesting approaches that emerged from this study is the design and use of coumarin-containing
hybrid compounds.
It is our hope that this review will contribute to further development in the investigation and
exploitation of coumarins’ potential.
Author Contributions: Conceptualization, A.P.; original draft preparation, F.A. and C.P.; writing—review and
editing, S.D., A.P. and L.T.; supervision, A.P. and L.T. All authors have read and agreed to the published version of
the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Borges, F.; Roleira, F.; Milhanzes, N.; Santana, L.; Uriarte, E. Simple coumarins and analogues in medicinal
chemistry: Occurrence, synthesis and biological activity. Curr. Med. Chem. 2005, 12, 887–916. [CrossRef]
2. Hoult, J.R.S.; Payá, M. Pharmacological and biochemical actions of simple coumarins: Natural products with
therapeutic potential. Gen. Pharmacol. 1996, 27, 713–722. [CrossRef]
3. Kummerle, A.E.; Vitorio, F.; Franco, D.P.; Pereira, T.M. Coumarin Compounds in Medicinal Chemistry: Some
Important Examples from the Last Year. Curr. Top. Med. Chem. 2018, 18, 124–128. [CrossRef]
4. Barot, K.P.; Jain, S.V.; Kremer, L.; Singh, S.; Ghate, M.D. Recent advances and therapeutic journey of coumarins:
Current status and perspectives. Med. Chem. Res. 2015, 24, 2771–2798. [CrossRef]
5. IUPAC. Nomenclature of Organic Chemistry; Pergamon Press: Oxford, UK, 1979.
6. Zhu, J.J.; Jiang, J.G. Pharmacological and Nutritional Effects of Natural Coumarins and Their
Structure–Activity Relationships. Mol. Nutr. Food Res. 2018, 62. [CrossRef]
7. Stefanachi, A.; Leonetti, F.; Pisani, L.; Catto, M.; Carotti, A. Coumarin: A natural, privileged and versatile
scaffold for bioactive compounds. Molecules 2018, 23, 250. [CrossRef] [PubMed]
8. Srikrishna, D.; Godugu, C.; Dubey, P.K. A Review on Pharmacological Properties of Coumarins. Mini Rev.
Med. Chem. 2016, 18. [CrossRef] [PubMed]
9. Santra, H.K.; Banerjee, D. Natural Products as Fungicide and Their Role in Crop Protection. In Natural
Bioactive Products in Sustainable Agriculture; Singh, J., Yadav, A., Eds.; Springer: Singapore, 2020; pp. 131–219.
Int. J. Mol. Sci. 2020, 21, 4618 66 of 81
10. Mark, R.; Lyu, X.; Lee, J.J.L.; Parra-Saldívar, R.; Chen, W.N. Sustainable production of natural phenolics for
functional food applications. J. Funct. Foods 2019, 57, 233–254. [CrossRef]
11. DellaGreca, M.; Fiorentino, A.; Isidori, M.; Previtera, L.; Temussi, F.; Zarrelli, A. Benzocoumarins from the
rhizomes of Juncus acutus. Tetrahedron 2003, 59, 4821–4825. [CrossRef]
12. Tasior, M.; Kim, D.; Singha, S.; Krzeszewski, M.; Ahn, K.H.; Gryko, D.T. pi-Expanded Coumarins: Synthesis,
Optical Properties and Applications. R. Soc. Chem. 2014, 3, 1421–1446. [CrossRef]
13. Zhang, Z.R.; Leung, W.N.; Cheung, H.Y.; Chan, C.W. Osthole: A Review on Its Bioactivities, Pharmacological
Properties and Potential as Alternative Medicine. Evid. Based Complement. Altern. Med. 2015, 2015. [CrossRef]
[PubMed]
14. Bourgaud, F.; Hehn, A.; Larbat, R.; Doerper, S.; Gontier, E.; Kellner, S.; Matern, U. Biosynthesis of coumarins
in plants: A major pathway still to be unravelled for cytochrome P450 enzymes. Phytochem. Rev. 2006, 5,
293–308. [CrossRef]
15. Chakthong, S.; Weaaryee, P.; Puangphet, P.; Mahabusarakam, W.; Plodpai, P.; Voravuthikunchai, S.P.;
Kanjana-Opas, A. Alkaloid and coumarins from the green fruits of Aegle marmelos. Phytochemistry 2012, 75,
108–113. [CrossRef] [PubMed]
16. Basile, A.; Sorbo, S.; Spadaro, V.; Bruno, M.; Maggio, A.; Faraone, N.; Rosselli, S. Antimicrobial and
antioxidant activities of coumarins from the roots of Ferulago campestris (apiaceae). Molecules 2009, 14,
939–952. [CrossRef]
17. Patil, A.D.; Freyer, A.J.; Eggleston, D.S.; Haltiwanger, R.C.; Bean, M.F.; Taylor, P.B.; Caranfa, M.J.; Breen, A.L.;
Bartus, H.R. The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian
tree, Calophyllum inophyllum Linn. J. Med. Chem. 1993, 36, 4131–4138. [CrossRef]
18. Wardrop, D.; Keeling, D. The story of the discovery of heparin and warfarin. Br. J. Haematol. 2008, 141,
757–763. [CrossRef]
19. Pal, S.; Chatare, V.; Pal, M. Isocoumarin and Its Derivatives: An Overview on their Synthesis and Applications.
Curr. Org. Chem. 2011, 15, 782–800. [CrossRef]
20. Crombie, L.; Games, D.E.; McCormick, A. Isolation and structure ofmammea A/BA, A/AB and A/BB: A group
of 4-arylcoumarin extractives of Mammea americana L. Tetrahedron Lett. 1966, 7, 145–149. [CrossRef]
21. Egan, D.; O’kennedy, R.; Moran, E.; Cox, D.; Prosser, E.; Thornes, R.D. The pharmacology, metabolism,
analysis and applications of coumarin and coumarin-related compounds. Drug Metab. Rev. 1990, 22, 503–529.
[CrossRef]
22. Leonart, L.P.; Gasparetto, J.C.; Pontes, F.L.D.; Cerqueira, L.B.; De Francisco, T.M.G.; Pontarolo, R.
New metabolites of coumarin detected in human urine using ultra performance liquid
chromatography/quadrupole-time-of-flight tandem mass spectrometry. Molecules 2017, 22, 2031. [CrossRef]
23. Gasparetto, J.C.; Peccinini, R.G.; de Francisco, T.M.; Cerqueira, L.B.; Campos, F.R.; Pontarolo, R. A kinetic
study of the main guaco metabolites using syrup formulation and the identification of an alternative route of
coumarin metabolism in humans. PLoS ONE 2015, 10, e0118922. [CrossRef] [PubMed]
24. Traykova, M.; Kostova, I. Coumarin derivatives and oxidative stress. Int. J. Pharm. 2005, 1, 29–32. [CrossRef]
25. Liu, R.H.; Hotchkiss, J.H. Potential genotoxicity of chronically elevated nitric oxide. Mutat. Res. 1995, 339,
73–89. [CrossRef]
26. Ames, B.N.; Shigenaga, M.K.; Gold, L.S. DNA lesions, inducible DNA repair and cell division: Three key
factors in mutagenesis and carcinogenesis. Environ. Health Perspect. 1993, 101, 35–44. [CrossRef] [PubMed]
27. Andreescu, S.; Hepel, M. Oxidative stress: Diagnosis, prevention and therapy. In ACS Symposium Series;
American Chemical Society: Washington, DC, USA, 2011.
28. Galano, A.; Mazzone, G.; Alvarez-Diduk, R.; Marino, T.; Alvarez-Idaboy, J.R.; Russo, N. Food Antioxidants:
Chemical Insights at the Molecular Level. Annu. Rev. Food Sci. Technol. 2016, 7, 335–352. [CrossRef]
[PubMed]
29. Wahy, A.H.M.E.; Ismail, A.R.; Kana, M.T.H.A.; Negm, N.A. Synthesis and characterization of novel
bis-(4-methylcoumarin) derivatives as photosensitizers in antimicrobial photodynamic therapy. J. Taiwan
Inst. Chem. Eng. 2017, 77, 83–91. [CrossRef]
30. Couttolenc, A.; Díaz-Porras, Á.; Espinoza, C.; Medina, M.E.; Trigos, Á. On the primary and secondary
antioxidant activity from hydroxy-methylcoumarins: Experimental and theoretical studies. J. Phys. Org.
Chem. 2020, 33, 1–10. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 67 of 81
31. Thavasi, V.; Leong, L.P.; Bettens, R.P.A. Investigation of the influence of hydroxy groups on the radical
scavenging ability of polyphenols. J. Phys. Chem. A 2006, 110, 4918–4923. [CrossRef]
32. Medina, M.E.; Iuga, C.; Álvarez-Idaboy, J.R. Antioxidant activity of fraxetin and its regeneration in aqueous
media. A density functional theory study. RSC Adv. 2014, 4, 52920–52932. [CrossRef]
33. Medina, M.E.; Galano, A.; Alvarez-Idaboy, J.R. Theoretical study on the peroxyl radicals scavenging activity
of esculetin and its regeneration in aqueous solution. Phys. Chem. Chem. Phys. 2014, 16, 1197–1207.
[CrossRef]
34. Wang, G.; Liu, Y.; Zhang, L.; An, L.; Chen, R.; Liu, Y.; Luo, Q.; Li, Y.; Wang, H.; Xue, Y. Computational study
on the antioxidant property of coumarin-fused coumarins. Food Chem. 2020, 304, 1–7. [CrossRef] [PubMed]
35. Xi, G.L.; Liu, Z.Q. Coumarin-Fused Coumarin: Antioxidant Story from N,N -Dimethylamino and Hydroxyl
Groups. J. Agric. Food Chem. 2015, 63, 3516–3523. [CrossRef] [PubMed]
36. Li, Q.; Wei, L.; Zhang, J.; Gu, G.; Guo, Z. Significantly enhanced antioxidant activity of chitosan through
chemical modification with coumarins. Polym. Chem. 2019, 10, 1480–1488. [CrossRef]
37. Luan, F.; Li, Q.; Tan, W.; Wei, L.; Zhang, J.; Dong, F.; Gu, G.; Guo, Z. The evaluation of antioxidant and
antifungal properties of 6-amino-6-deoxychitosan in vitro. Int. J. Biol. Macromol. 2018, 107, 595–603.
[CrossRef] [PubMed]
38. Popova, S.A.; Shevchenko, O.G.; Chukicheva, I.Y.; Kutchin, A.V. Synthesis and Biological Evaluation of
Novel Coumarins with tert-Butyl and Terpene Substituents. Chem. Biodivers. 2019, 16. [CrossRef]
39. Pierce, B.A. Genetics. A Conceptual Approach, 3rd ed.; W. H. Freeman and Company: New York, NY, USA,
2010.
40. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [CrossRef]
41. Maleki, E.H.; Bahrami, A.R.; Sadeghian, H.; Matin, M.M. Discovering the structure–activity relationships of
different O-prenylated coumarin derivatives as effective anticancer agents in human cervical cancer cells.
Toxicol. In Vitro 2020, 63, 104745. [CrossRef]
42. Comba, A.; Pasqualini, M.E. Primers on molecular pathways lipoxygenases: Their role as an oncogenic
pathway in pancreatic cancer. Pancreatology 2009, 9, 724–728. [CrossRef]
43. Kelavkar, U.P.; Glasgow, W.; Olson, S.J.; Foster, B.A.; Shappell, S.B. Overexpression of 12/15-lipoxygenase, an
ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 2004, 6, 821–830.
[CrossRef]
44. Iranshahi, M.; Jabbari, A.; Orafaie, A.; Mehri, R.; Zeraatkar, S.; Ahmadi, T.; Alimardani, M.; Sadeghian, H.
Synthesis and SAR studies of mono O-prenylated coumarins as potent 15-lipoxygenase inhibitors. Eur. J.
Med. Chem. 2012, 57, 134–142. [CrossRef]
45. Orafaie, A.; Sadeghian, H.; Bahrami, A.R.; Saboormaleki, S.; Matin, M.M. 5-farnesyloxycoumarin: A potent
15-LOX-1 inhibitor, prevents prostate cancer cell growth. Med. Chem. Res. 2017, 26, 227–234. [CrossRef]
46. Hosseinymehr, M.; Matin, M.M.; Sadeghian, H.; Bahrami, A.R.; Kaseb-Mojaver, N. 8-Farnesyloxycoumarin
induces apoptosis in PC-3 prostate cancer cells by inhibition of 15-lipoxygenase-1 enzymatic activity.
Anticancer Drugs 2016, 27, 854–862. [CrossRef] [PubMed]
47. Halawa, A.H.; Eliwa, E.M.; Hassan, A.A.; Nassar, H.S.; El-Eisawy, R.A.; Ismail, M.; Frese, M.; Shaaban, M.;
El-Agrody, A.M.; Bedair, A.H.; et al. Synthesis, in vitro cytotoxicity activity against the human cervix
carcinoma cell line and in silico computational predictions of new 4-arylamino-3-nitrocoumarin analogues. J.
Mol. Struct. 2020, 1200, 127047. [CrossRef]
48. Herrera-R, A.; Castrillón, W.; Otero, E.; Ruiz, E.; Carda, M.; Agut, R.; Naranjo, T.; Moreno, G.; Maldonado, M.E.;
Cardona-G, W. Synthesis and antiproliferative activity of 3- and 7-styrylcoumarins. Med. Chem. Res. 2018,
27, 1893–1905. [CrossRef]
49. Herrera-R, A.; Naranjo, T.W.; Maldonado, M.E.; Moreno-Q, G.; Yepes, A.; Cardona-G, W. Styrylcoumarin
7-SC2 induces apoptosis in SW480 human colon adenocarcinoma cells and inhibits azoxymethane-induced
aberrant crypt foci formation in BALB/c mice. Med. Chem. Res. 2020, 29, 377–395. [CrossRef]
50. Diao, Q.P.; Guo, H.; Wang, G.Q. Design, Synthesis and In Vitro Anticancer Activities of Diethylene Glycol
Tethered Isatin-1,2,3-triazole-coumarin Hybrids. J. Heterocycl. Chem. 2019, 56, 1667–1671. [CrossRef]
51. Li, Z.H.; Liu, X.Q.; Geng, P.F.; Suo, F.Z.; Ma, J.L.; Yu, B.; Zhao, T.Q.; Zhou, Z.Q.; Huang, C.X.; Zheng, Y.C.;
et al. Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Novel LSD1 Inhibitors. ACS Med. Chem.
Lett. 2017, 8, 384–389. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 68 of 81
52. Yu, H.; Hou, Z.; Tian, Y.; Mou, Y.; Guo, C. Design, synthesis, cytotoxicity and mechanism of novel
dihydroartemisinin-coumarin hybrids as potential anti-cancer agents. Eur. J. Med. Chem. 2018, 151, 434–449.
[CrossRef]
53. Singh, H.; Singh, J.V.; Gupta, M.K.; Saxena, A.K.; Sharma, S.; Nepali, K.; Bedi, P.M.S. Triazole tethered
isatin-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological
investigation and docking studies. Bioorg. Med. Chem. Lett. 2017, 27, 3974–3979. [CrossRef]
54. Xu, Z.; Song, X.F.; Hu, Y.Q.; Qiang, M.; Lv, Z.S. Azide-alkyne cycloaddition towards 1H-1,2,3-triazole-tethered
gatifloxacin and isatin conjugates: Design, synthesis and in vitro anti-mycobacterial evaluation. Eur. J. Med.
Chem. 2017, 138, 66–71. [CrossRef]
55. Cai, G.; Yu, W.; Song, D.; Zhang, W.; Guo, J.; Zhu, J.; Ren, Y.; Kong, L. Discovery of fluorescent
coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors.
Eur. J. Med. Chem. 2019, 174, 236–251. [CrossRef] [PubMed]
56. Aggarwal, B.B.; Kunnumakkara, A.B.; Harikumar, K.B.; Gupta, S.R.; Tharakan, S.T.; Koca, C.; Dey, S.;
Sung, B. Signal transducer and activator of transcription-3, inflammation and cancer: How intimate is the
relationship? Ann. N. Y. Acad. Sci. 2009, 1171, 59–76. [CrossRef] [PubMed]
57. Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev.
Drug Discov. 2008, 7, 168–181. [CrossRef] [PubMed]
58. Alterio, V.; di Fiore, A.; D’Ambrosio, K.; Supuran, C.T.; De Simone, G. Multiple Binding Modes of Inhibitors
to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms? Chem. Rev. 2012,
112, 4421–4468. [CrossRef]
59. Supuran, C.T.; Altamimi, A.S.A.; Carta, F. Carbonic Anhydrase inhibition and the management of glaucoma:
A literature inhibition and the management of glaucoma: A literature. Expert Opin. Ther. Patents 2019, 29,
781–792. [CrossRef]
60. Masini, E.; Carta, F.; Scozzafava, A. Antiglaucoma Carbonic anhydrase inhibitors: A patent review. Expert
Opin. Ther. Patents 2013, 23, 705–716. [CrossRef]
61. Aggarwal, M.; Kondeti, B.; McKenna, R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: A
patent review. Expert Opin. Ther. Patents 2013, 23, 717–724. [CrossRef]
62. Lou, Y.; McDonald, P.C.; Oloumi, A.; Dedhar, S. Targeting tumour hypoxia: Suppression of breast tumor
growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011, 71, 3364–3376. [CrossRef]
63. Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug
Discov. 2011, 10, 767–777. [CrossRef]
64. Maresca, A.; Temperini, C.; Vu, H.; Pham, N.B.; Poulsen, S.A.; Scozzafava, A.; Quinn, R.J.; Supuran, C.T.
Non-zinc mediated inhibition of carbonic anhydrases: Coumarins are a new class of suicide inhibitors. J. Am.
Chem. Soc. 2009, 131, 3057–3062. [CrossRef]
65. Maresca, A.; Temperini, C.; Pochet, L.; Masereel, B.; Scozzafava, A.; Supuran, C.T. Deciphering the Mechanism
of Carbonic Anhydrase Inhibition with Coumarins and Thiocoumarins. J. Med. Chem. 2010, 53, 335–344.
[CrossRef] [PubMed]
66. Maresca, A.; Scozzafava, A.; Supuran, C.T. 7,8-Disubstituted- but not 6,7-disubstituted coumarins selectively
inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones
I and II in the low nanomolar/subnanomolar range. Bioorg. Med. Chem. Lett. 2010, 20, 7255–7258. [CrossRef]
[PubMed]
67. Touisni, N.; Maresca, A.; McDonald, P.C.; Lou, Y.; Scozzafava, A.; Dedhar, S.; Winum, J.Y.; Supuran, C.T.
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast
tumors. J. Med. Chem. 2011, 54, 8271–8277. [CrossRef] [PubMed]
68. Ferraroni, M.; Carta, F.; Scozzafava, A.; Supuran, C.T. Thioxocoumarins Show an Alternative Carbonic
Anhydrase Inhibition Mechanism Compared to Coumarins. J. Med. Chem. 2016, 59, 462–473. [CrossRef]
[PubMed]
69. De Luca, L.; Mancuso, F.; Ferro, S.; Buemi, M.R.; Angeli, A.; Del Prete, S.; Capasso, C.; Supuran, C.T.; Gitto, R.
Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively
target human CA IX and CA XII carbonic anhydrases. Eur. J. Med. Chem. 2018, 143, 276–282. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 69 of 81
70. Fois, B.; Distinto, S.; Meleddu, R.; Deplano, S.; Maccioni, E.; Floris, C.; Rosa, A.; Nieddu, M.; Caboni, P.;
Sissi, C.; et al. Coumarins from Magydaris pastinacea as inhibitors of the tumour-associated carbonic
anhydrases IX and XII: Isolation, biological studies and in silico evaluation. J. Enzyme Inhib. Med. Chem.
2020, 35, 539–548. [CrossRef]
71. Buran, K.; Bua, S.; Poli, G.; Bayram, F.E.Ö.; Tuccinardi, T.; Supuran, C.T. Novel 8-substituted coumarins that
selectively inhibit human carbonic anhydrase IX and XII. Int. J. Mol. Sci. 2019, 20, 1208. [CrossRef]
72. Krasavin, M.; Žalubovskis, R.; Granda¯ne, A.; Domracˇeva, I.; Zhmurov, P.; Supuran, C.T. Sulfocoumarins as
dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase. J. Enzyme
Inhib. Med. Chem. 2020, 35, 506–510. [CrossRef]
73. Kurt, B.Z.; Dag, A.; Dog˘an, B.; Durdagi, S.; Angeli, A.; Nocentini, A.; Supuran, C.T.; Sonmez, F. Synthesis,
biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase
IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma. Bioorg. Chem. 2019, 87,
838–850. [CrossRef] [PubMed]
74. Narella, S.G.; Shaik, M.G.; Mohammed, A.; Alvala, M.; Angeli, A.; Supuran, C.T. Synthesis and biological
evaluation of coumarin-1,3,4-oxadiazole hybrids as selective carbonic anhydrase IX and XII inhibitors. Bioorg.
Chem. 2019, 87, 765–772. [CrossRef] [PubMed]
75. Bassetti, M.; Merelli, M.; Temperoni, C.; Astilean, A. New antibiotics for bad bugs: Where are we? Ann. Clin.
Microbiol. Antimicrob. 2013, 12, 1–15. [CrossRef] [PubMed]
76. Brown, E.D.; Wright, G.D. Antibacterial drug discovery in the resistance era. Nature 2016, 529, 336–343.
[CrossRef] [PubMed]
77. Cowan, M.M. Plant products as antimicrobial agents. Clin. Microbiol. Rev. 1999, 12, 564–582. [CrossRef]
[PubMed]
78. De Souza, S.M.; Delle Monache, F.; Smânia, A. Antibacterial activity of coumarins. Z. Naturforsch. Sect. C J.
Biosci. 2005, 60, 693–700. [CrossRef]
79. Nagamallu, R.; Srinivasan, B.; Ningappa, M.B.; Kariyappa, A.K. Synthesis of novel coumarin appended
bis(formylpyrazole) derivatives: Studies on their antimicrobial and antioxidant activities. Bioorg. Med. Chem.
Lett. 2016, 26, 690–694. [CrossRef]
80. Chougala, B.M.; Samundeeswari, S.; Holiyachi, M.; Naik, N.S.; Shastri, L.A.; Dodamani, S.; Jalalpure, S.;
Dixit, S.R.; Joshi, S.D.; Sunagar, V.A. Green, unexpected synthesis of bis-coumarin derivatives as potent
anti-bacterial and anti-inflammatory agents. Eur. J. Med. Chem. 2018, 143, 1744–1756. [CrossRef]
81. Rice, L.B. Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE.
J. Infect. Dis. 2008, 197, 1079–1081. [CrossRef]
82. Naik, N.S.; Shastri, L.A.; Joshi, S.D.; Sunagar, V.; Dixit, S.R.; Chougala, B.M.; Samundeeswari, S.; Holiyachi, M.;
Shaikh, F.; Madar, J.; et al. 3,4-Dihydropyrimidinone-coumarin analogues as a new class of selective agent
against S. aureus: Synthesis, biological evaluation and molecular modelling study. Bioorg. Med. Chem. 2017,
25, 1413–1422. [CrossRef]
83. Chavan, R.R.; Hosamani, K.M. Microwave-assisted synthesis, computational studies and antibacterial/
anti-inflammatory activities of compounds based on coumarin-pyrazole hybrid. R. Soc. Open Sci. 2018, 5.
[CrossRef]
84. Rahman, A.; Choudhary, M.I.; Thomsen, W.J. Bioassay Techniques for Drug Develompent, 1st ed.; Harwood
Academic Publishers: Amsterdam, The Netherlands, 2001.
85. Madeiro, S.A.L.; Borges, N.H.P.B.; Souto, A.L.; de Figueiredo, P.T.R.; Siqueira-Junior, J.P.; Tavares, J.F.
Modulation of the antibiotic activity against multidrug resistant strains of coumarins isolated from Rutaceae
species. Microb. Pathog. 2017, 104, 151–154. [CrossRef]
86. Widelski, J.; Luca, S.V.; Skiba, A.; Chinou, I.; Marcourt, L.; Wolfender, J.L.; Skalicka-Wozniak, K. Isolation and
antimicrobial activity of coumarin derivatives from fruits of peucedanum luxurians tamamsch. Molecules
2018, 23, 1222. [CrossRef]
87. Liu, H.; Ren, Z.L.; Wang, W.; Gong, J.X.; Chu, M.J.; Ma, Q.W.; Wang, J.C.; Lv, X.H. Novel coumarin-pyrazole
carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.
Eur. J. Med. Chem. 2018, 157, 81–87. [CrossRef] [PubMed]
88. Brown, G.D.; Denning, D.W.; Gow, N.A.R.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human
fungal infections. Sci. Transl. Med. 2012, 4, 1–10. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4618 70 of 81
89. GAFFI Fungal Disease Frequency|Gaffi—Global Action Fund for Fungal Infections. Available online:
https://www.gaffi.org/why/fungal-disease-frequency/ (accessed on 21 March 2020).
90. How Common are Fungal Diseases?—Fungal Infection Trust. Available online: https://www.
fungalinfectiontrust.org/how-common-are-fungal-diseases (accessed on 21 March 2020).
91. Bartlett, J.G. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective
nationwide surveillance study. Infect. Dis. Clin. Pract. 2004, 12, 376. [CrossRef]
92. Pfaller, M.A.; Diekema, D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin.
Microbiol. Rev. 2007, 20, 133–163. [CrossRef]
93. Shi, Y.; Zhou, C.H. Synthesis and evaluation of a class of new coumarin triazole derivatives as potential
antimicrobial agents. Bioorg. Med. Chem. Lett. 2011, 21, 956–960. [CrossRef] [PubMed]
94. Shaikh, M.H.; Subhedar, D.D.; Kalam Khan, F.A.; Sangshetti, J.N.; Shingate, B.B. 1,2,3-Triazole incorporated
coumarin derivatives as potential antifungal and antioxidant agents. Chin. Chem. Lett. 2016, 27, 295–301.
[CrossRef]
95. Tiwari, S.; Seijas, J.; Vazquez-Tato, M.; Sarkate, A.; Karnik, K.; Nikalje, A. Facile Synthesis of Novel Coumarin
Derivatives, Antimicrobial Analysis, Enzyme Assay, Docking Study, ADMET Prediction and Toxicity Study.
Molecules 2017, 22, 1172. [CrossRef]
96. Elias, R.; Benhamou, R.I.; Jaber, Q.Z.; Dorot, O.; Zada, S.L.; Oved, K.; Pichinuk, E.; Fridman, M. Antifungal
activity, mode of action variability and subcellular distribution of coumarin-based antifungal azoles. Eur. J.
Med. Chem. 2019, 179, 779–790. [CrossRef]
97. Dikpınar, T.; Süzgeç-Selçuk, S.; Çelik, B.Ö.; Urus¸ak, E.A. Antimicrobial activity of rhizomes of Ferulago
trachycarpa Boiss. and bioguided isolation of active coumarin constituents. Ind. Crops Prod. 2018, 123,
762–767. [CrossRef]
98. Lee, J.H.; Kim, Y.G.; Cho, H.S.; Ryu, S.Y.; Cho, M.H.; Lee, J. Coumarins reduce biofilm formation and the
virulence of Escherichia coli O157:H7. Phytomedicine 2014, 21, 1037–1042. [CrossRef] [PubMed]
99. Reen, F.J.; Gutiérrez-Barranquero, J.A.; Parages, M.L.; O’Gara, F. Coumarin: A novel player in microbial
quorum sensing and biofilm formation inhibition. Appl. Microbiol. Biotechnol. 2018, 102, 2063–2073.
[CrossRef] [PubMed]
100. Xu, K.; Wang, J.L.; Chu, M.P.; Jia, C. Activity of coumarin against Candida albicans biofilms. J. Mycol. Med.
2019, 29, 28–34. [CrossRef] [PubMed]
101. Barry, A.L.; Thornsberry, J.C. Susceptibility tests: Diffusion test procedures. In Manual of Clinical Microbiology,
4th ed.; Balows, A., Hausler, W.H., Jr., Shadomy, J., Lenette, E.H., Eds.; American Society of Microbiology:
Washington, DC, USA, 1985; pp. 978–987.
102. Dharavath, R.; Nagaraju, N.; Reddy, M.R.; Ashok, D.; Sarasija, M.; Vijjulatha, M.; T, V.; Jyothi, K.; Prashanthi, G.
Microwave-assisted synthesis, biological evaluation and molecular docking studies of new coumarin-based
1,2,3-triazoles. RSC Adv. 2020, 10, 11615–11623. [CrossRef]
103. WHO Coronavirus (COVID-19) Events as They Happen. Available online: https://www.who.int/emergencies/
diseases/novel-coronavirus-2019/events-as-they-happen (accessed on 21 March 2020).
104. Mishra, S.; Pandey, A.; Manvati, S. Coumarin: An emerging antiviral agent. Heliyon 2020, 6, e03217.
[CrossRef]
105. Lilly Ganju, S.S. Plant Derived Antivirals: A Potential Source of Drug Development. J. Virol. Antivir. Res.
2013, 2. [CrossRef]
106. Kwon, J.E.; Lee, Y.G.; Kang, J.H.; Bai, Y.F.; Jeong, Y.J.; Baek, N.I.; Seo, Y.J.; Kang, S.C. Anti-viral activity
of compounds from Agrimonia pilosa and Galla rhois extract mixture. Bioorg. Chem. 2019, 93, 103320.
[CrossRef]
107. Guo, H.; Wan, X.; Niu, F.; Sun, J.; Shi, C.; Ye, J.M.; Zhou, C. Evaluation of antiviral effect and toxicity of
total flavonoids extracted from Robinia pseudoacacia cv. idaho. Biomed. Pharmacother. 2019, 118, 109335.
[CrossRef]
108. Dewi, B.E.; Ratningpoeti, E.; Desti, H.; Angelina, M. In vitro and in silico study to evaluate the effectiveness
of quercitrin as antiviral drug to dengue virus. AIP Conf. Proc. 2019, 2193. [CrossRef]
109. Sahuc, M.; Sahli, R.; Rivière, C.; Pène, V.; Lavie, M. Vandeputte, Dehydrojuncusol, a Natural Phenanthrene
Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. J.
Virol. 2019, 93, 1–15. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 71 of 81
110. Teplova, V.V.; Isakova, E.P.; Klein, O.I.; Dergachova, D.I.; Gessler, N.N.; Deryabina, Y.I. Natural Polyphenols:
Biological Activity, Pharmacological Potential, Means of Metabolic Engineering (Review). Appl. Biochem.
Microbiol. 2018, 54, 221–237. [CrossRef]
111. Campagna, M.; Rivas, C. Antiviral activity of resveratrol. Biochem. Soc. Trans. 2010, 38, 50–53. [CrossRef]
[PubMed]
112. Hassan, M.Z.; Osman, H.; Ali, M.A.; Ahsan, M.J. Therapeutic potential of coumarins as antiviral agents. Eur.
J. Med. Chem. 2016, 123, 236–255. [CrossRef] [PubMed]
113. Liu, Y.P.; Yan, G.; Xie, Y.T.; Lin, T.C.; Zhang, W.; Li, J.; Wu, Y.J.; Zhou, J.Y.; Fu, Y.H. Bioactive prenylated
coumarins as potential anti-inflammatory and anti-HIV agents from Clausena lenis. Bioorg. Chem. 2020, 97,
103699. [CrossRef]
114. Liu, Y.P.; Liu, Q.L.; Zhang, X.L.; Niu, H.Y.; Guan, C.Y.; Sun, F.K.; Xu, W.; Fu, Y.H. Bioactive monoterpene
indole alkaloids from Nauclea officinalis. Bioorg. Chem. 2019, 83, 1–5. [CrossRef]
115. Liu, Y.P.; Zhao, W.H.; Feng, X.Y.; Zhang, Z.J.; Zong, K.; Sun, Z.G.; Zheng, Y.T.; Fu, Y.H. Novel tetrahydrofuran
derivatives from Trigonostemon howii with their potential anti-HIV-1 activities. Bioorg. Chem. 2018, 79,
111–114. [CrossRef]
116. Liu, Y.P.; Yan, G.; Guo, J.M.; Liu, Y.Y.; Li, Y.J.; Zhao, Y.Y.; Qiang, L.; Fu, Y.H. Prenylated Coumarins from the
Fruits of Manilkara zapota with Potential Anti-inflammatory Effects and Anti-HIV Activities. J. Agric. Food
Chem. 2019, 67, 11942–11947. [CrossRef]
117. Jesumoroti, O.J.; Faridoon; Mnkandhla, D.; Isaacs, M.; Hoppe, H.C.; Klein, R. Evaluation of novel
N′-(3-hydroxybenzoyl)-2-oxo-2H-chromene-3-carbohydrazide derivatives as potential HIV-1 integrase
inhibitors. Medchemcomm 2019, 10, 80–88. [CrossRef]
118. Goldgur, Y.; Dyda, F.; Hickman, A.B.; Jenkins, T.M.; Craigie, R.; Davies, D.R. Three new structures of the
core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. USA 1998, 95,
9150–9154. [CrossRef]
119. Neamati, N.; Sunder, S.; Pommier, Y. Design and discovery of HIV-1 integrase inhibitors. Drug Discov. Today
1997, 2, 487–498. [CrossRef]
120. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G.W.A.; Pommier, Y.; Burke, T.R.
Hydrazide-Containing Inhibitors of HIV-1 Integrase. J. Med. Chem. 1997, 2623, 937–941. [CrossRef]
[PubMed]
121. Park, J.H.; Lee, S.U.; Kim, S.H.; Shin, S.Y.; Lee, J.Y.; Shin, C.G.; Yoo, K.H.; Lee, Y.S. Chromone and chromanone
derivatives as strand transfer inhibitors of HIV-1 integrase. Arch. Pharm. Res. 2008, 31, 1–5. [CrossRef]
[PubMed]
122. McColl, D.J.; Chen, X. Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral
therapy. Antiviral Res. 2010, 85, 101–118. [CrossRef] [PubMed]
123. WHO -Up to 650 000 People Die of Respiratory Diseases Linked to Seasonal Flu Each
Year. Available online: https://www.who.int/news-room/detail/14-12-2017-up-to-650-000-people-die-of-
respiratory-diseases-linked-to-seasonal-flu-each-year (accessed on 21 March 2020).
124. Kilbourne, E.D. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 2006, 12, 9–14. [CrossRef]
[PubMed]
125. Osman, H.; Yusufzai, S.K.; Khan, M.S.; Abd Razik, B.M.; Sulaiman, O.; Mohamad, S.; Gansau, J.A.; Ezzat, M.O.;
Parumasivam, T.; Hassan, M.Z. New thiazolyl-coumarin hybrids: Design, synthesis, characterization, X-ray
crystal structure, antibacterial and antiviral evaluation. J. Mol. Struct. 2018, 1166, 147–154. [CrossRef]
126. Arshad, A.; Osman, H.; Bagley, M.C.; Lam, C.K.; Mohamad, S.; Zahariluddin, A.S.M. Synthesis and
antimicrobial properties of some new thiazolyl coumarin derivatives. Eur. J. Med. Chem. 2011, 46, 3788–3794.
[CrossRef]
127. Reddy, G.M.; Garcia, J.R.; Reddy, V.H.; de Andrade, A.M.; Camilo, A.; Pontes Ribeiro, R.A.; de
Lazaro, S.R. Synthesis, antimicrobial activity and advances in structure-activity relationships (SARs) of novel
tri-substituted thiazole derivatives. Eur. J. Med. Chem. 2016, 123, 508–513. [CrossRef]
128. Pavurala, S.; Vaarla, K.; Kesharwani, R.; Naesens, L.; Liekens, S.; Vedula, R.R. Bis coumarinyl bis
triazolothiadiazinyl ethane derivatives: Synthesis, antiviral activity evaluation and molecular docking
studies. Synth. Commun. 2018, 48, 1494–1503. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 72 of 81
129. Bizzarri, B.M.; Botta, L.; Capecchi, E.; Celestino, I.; Checconi, P.; Palamara, A.T.; Nencioni, L.; Saladino, R.
Regioselective IBX-Mediated Synthesis of Coumarin Derivatives with Antioxidant and Anti-influenza
Activities. J. Nat. Prod. 2017, 80, 3247–3254. [CrossRef]
130. Tsay, S.C.; Lin, S.Y.; Huang, W.C.; Hsu, M.H.; Hwang, K.C.; Lin, C.C.; Horng, J.C.; Chen, I.C.; Hwu, J.R.;
Shieh, F.K.; et al. Synthesis and structure-activity relationships of imidazole-coumarin conjugates against
hepatitis C virus. Molecules 2016, 21, 228. [CrossRef]
131. Huang, S.X.; Mou, J.F.; Luo, Q.; Mo, Q.H.; Zhou, X.L.; Huang, X.; Xu, Q.; Tan, X.D.; Chen, X.; Liang, C.Q.
Anti-Hepatitis B Virus Activity of Esculetin from Microsorium fortunei in Vitro and in Vivo. Molecules 2019, 24,
3475. [CrossRef] [PubMed]
132. Taramelli, D.; Miglietta, A.; D’Alessandro, S.; Corbett, Y. Risposta del tessuto al danno. In Patologia Generale e
Fisiopatologia, 2nd ed.; Celotti, F., Ed.; EdiSES: Napoli, Italy, 2013; pp. 86–127.
133. Medzhitov, R. Origin and physiological roles of inflammation. Nature 2008, 454, 428–435. [CrossRef]
[PubMed]
134. Vane, J.; Botting, R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 1987,
89–96. [CrossRef]
135. Gaddi, A.; Cicero, A.F.G.; Pedro, E.J. Clinical perspectives of anti-inflammatory therapy in the elderly: The
lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch. Gerontol. Geriatr. 2004, 38, 201–212.
[CrossRef]
136. Sanghi, S.; MacLaughlin, E.; Jewell, C.; Chaffer, S.; Naus, P.; Watson, L.; Dostal, D. Cyclooxygenase-2
Inhibitors: A Painful Lesson. Cardiovasc. Hematol. Disord. Targets 2012, 6, 83–98. [CrossRef]
137. Schjerning Olsen, A.M.; Fosbøl, E.L.; Lindhardsen, J.; Folke, F.; Charlot, M.; Selmer, C.; Lamberts, M.; Bjerring
Olesen, J.; Køber, L.; Hansen, P.R.; et al. Duration of treatment with nonsteroidal anti-inflammatory drugs
and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction:
A nationwide cohort study. Circulation 2011, 123, 2226–2235. [CrossRef]
138. Woods, K.W.; McCroskey, R.W.; Michaelides, M.R.; Wada, C.K.; Hulkower, K.I.; Bell, R.L. Thiazole analogues
of the NSAID indomethacin as selective COX-2 inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1325–1328.
[CrossRef]
139. El-Gamal, M.I.; Oh, C.H. Synthesis, in vitro antiproliferative activity and in silico studies of fused tricyclic
coumarin sulfonate derivatives. Eur. J. Med. Chem. 2014, 84, 68–76. [CrossRef]
140. Unsal-Tan, O.; Ozadali, K.; Piskin, K.; Balkan, A. Molecular modeling, synthesis and screening of some new
4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity. Eur. J. Med. Chem. 2012, 57,
59–64. [CrossRef]
141. Rambabu, D.; Mulakayala, N.; Ismail; Ravi Kumar, K.; Pavan Kumar, G.; Mulakayala, C.; Kumar, C.S.;
Kalle, A.M.; Basaveswara Rao, M.V.; Oruganti, S.; et al. Synthesis and pharmacological evaluation of
N-substituted 2-(2-oxo-2H-chromen-4-yloxy)propanamide as cyclooxygenase inhibitors. Bioorg. Med. Chem.
Lett. 2012, 22, 6745–6749. [CrossRef]
142. Kontogiorgis, C.A.; Hadjipavlou-Litina, D.J. Synthesis and antiinflammatory activity of coumarin derivatives.
J. Med. Chem. 2005, 48, 6400–6408. [CrossRef] [PubMed]
143. Dawood, D.H.; Batran, R.Z.; Farghaly, T.A.; Khedr, M.A.; Abdulla, M.M. New Coumarin Derivatives as
Potent Selective COX-2 Inhibitors: Synthesis, Anti-Inflammatory, QSAR and Molecular Modeling Studies.
Arch. Pharm. 2015, 348, 875–888. [CrossRef] [PubMed]
144. Ford-Hutchinson, A.W.; Gresser, M.; Young, R.N. 5-Lipoxygenase. Annu. Rev. Biochem. 1994, 63, 383–417.
[CrossRef] [PubMed]
145. Werz, O.; Steinhilber, D. Development of 5-lipoxygenase inhibitors—Lessons from cellular enzyme regulation.
Biochem. Pharmacol. 2005, 70, 327–333. [CrossRef]
146. Srivastava, P.; Vyas, V.K.; Variya, B.; Patel, P.; Qureshi, G.; Ghate, M. Synthesis, anti-inflammatory, analgesic,
5-lipoxygenase (5-LOX) inhibition activities and molecular docking study of 7-substituted coumarin
derivatives. Bioorg. Chem. 2016, 67, 130–138. [CrossRef]
147. Liu, B.Y.; Zhang, C.; Zeng, K.W.; Li, J.; Guo, X.Y.; Zhao, M.B.; Tu, P.F.; Jiang, Y. Anti-Inflammatory Prenylated
Phenylpropenols and Coumarin Derivatives from Murraya exotica. J. Nat. Prod. 2018, 81, 22–33. [CrossRef]
148. Courtois, G. The NF-κB signaling pathway in human genetic diseases. Cell. Mol. Life Sci. 2005, 62, 1682–1691.
[CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 73 of 81
149. Karin, M.; Ben-Neriah, Y. Phosphorilation meets ubiquitination: The control of NF-kB activity. Annu. Rev.
Immunol. 2000, 621–663. [CrossRef]
150. Fan, H.; Gao, Z.; Ji, K.; Li, X.; Wu, J.; Liu, Y.; Wang, X.; Liang, H.; Liu, Y.; Li, X.; et al. The in vitro and in vivo
anti-inflammatory effect of osthole, the major natural coumarin from Cnidium monnieri (L.) Cuss, via the
blocking of the activation of the NF-κB and MAPK/p38 pathways. Phytomedicine 2019, 58, 152864. [CrossRef]
151. Mu, C.; Wu, M.; Li, Z. Anti-Inflammatory Effect of Novel 7-Substituted Coumarin Derivatives through
Inhibition of NF-κB Signaling Pathway. Chem. Biodivers. 2019, 16, e1800559. [CrossRef]
152. Alzheimer-Riese. s.d. Available online: https://www.alzheimer-riese.it/ (accessed on 20 June 2018).
153. Vitthalrao, B.K.; Sunanda, V.K.; Sharad, G.J. Alzheimer’s disease: Overview. Int. Acad. Inst. Sci. Technol.
2016, 3, 23–38.
154. Bartus, R.T.; Dean, R.L.; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction.
Science 1982, 217, 408–417. [CrossRef] [PubMed]
155. Furukawa-Hibi, Y.; Alkam, T.; Nitta, A.; Matsuyama, A.; Mizoguchi, H.; Suzuki, K.; Moussaoui, S.; Yu, Q.S.;
Greig, N.H.; Nagai, T.; et al. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by
amyloid-β peptide in mice. Behav. Brain Res. 2011, 225, 222–229. [CrossRef] [PubMed]
156. Querfurth, H.W.; Laferla, F.M. Mechanisms of disease: Alzheimer’s disease. N. Engl. J. Med. 2010, 362,
329–344. [CrossRef] [PubMed]
157. Vassar, R.; Kandalepas, P. The b-secretase enzyme BACE1 as a therapeutic target for Alzheimer’s disease.
Alzheimers Res. Ther. 2011, 3, 20–26. [CrossRef]
158. Karakaya, S.; Koca, M.; Sytar, O.; Dursunoglu, B.; Ozbek, H.; Duman, H.; Guvenalp, Z.; Kılıc, C.S. Antioxidant
and anticholinesterase potential of Ferulago cassia with farther bio-guided isolation of active coumarin
constituents. S. Afr. J. Bot. 2019, 121, 536–542. [CrossRef]
159. Ellman, G.L.; Courtney, K.D.; Andresjr, V.; Featherstone, R.M. A new and rapid colorimetric determination
of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88–95. [CrossRef]
160. Najafi, Z.; Mahdavi, M.; Saeedi, M.; Karimpour-Razkenari, E.; Edraki, N.; Sharifzadeh, M.; Khanavi, M.;
Akbarzadeh, T. Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer’s compounds:
In vitro and in vivo biological evaluation and docking study. Bioorg. Chem. 2019, 83, 303–316. [CrossRef]
161. De Souza, L.G.; Rennã, M.N.; Figueroa-Villar, J.D. Coumarins as cholinesterase inhibitors: A review. Chem.
Biol. Interact. 2016, 254, 11–23. [CrossRef]
162. Najafi, Z.; Mahdavi, M.; Saeedi, M.; Karimpour-Razkenari, E.; Asatouri, R.; Vafadarnejad, F.; Moghadam, F.H.;
Khanavi, M.; Sharifzadeh, M.; Akbarzadeh, T. Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological
evaluation and docking study of cholinesterase inhibitors. Eur. J. Med. Chem. 2017, 125, 1200–1212.
[CrossRef]
163. Rastegari, A.; Nadri, H.; Mahdavi, M.; Moradi, A.; Mirfazli, S.S.; Edraki, N.; Moghadam, F.H.; Larijani, B.;
Akbarzadeh, T.; Saeedi, M. Design, synthesis and anti-Alzheimer’s activity of novel 1,2,3-triazole-chromenone
carboxamide derivatives. Bioorg. Chem. 2019, 83, 391–401. [CrossRef] [PubMed]
164. Asadipour, A.; Alipour, M.; Jafari, M.; Khoobi, M.; Emami, S.; Nadri, H.; Sakhteman, A.; Moradi, A.;
Sheibani, V.; Homayouni Moghadam, F.; et al. Novel coumarin-3-carboxamides bearing N-benzylpiperidine
moiety as potent acetylcholinesterase inhibitors. Eur. J. Med. Chem. 2013, 70, 623–630. [CrossRef] [PubMed]
165. Iraji, A.; Firuzi, O.; Khoshneviszadeh, M.; Tavakkoli, M.; Mahdavi, M.; Nadri, H.; Edraki, N.; Miri, R.
Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole
with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer’s disease. Eur. J.
Med. Chem. 2017, 141, 690–702. [CrossRef] [PubMed]
166. De Souza, G.A.; da Silva, S.J.; de Nigris Del Cistia, C.; Pitasse-Santos, P.; de Oliveira Pires, L.; Passos, Y.M.;
Cordeiro, Y.; Cardoso, C.M.; Castro, R.N.; Sant’Anna, C.M.R.; et al. Discovery of novel dual-active
3-(4-(dimethylamino)phenyl)-7-aminoalcoxy-coumarin as potent and selective acetylcholinesterase inhibitor
and antioxidant. J. Enzyme Inhib. Med. Chem. 2019, 34, 631–637. [CrossRef]
167. Yang, J.; Zhang, P.; Hu, Y.; Liu, T.; Sun, J.; Wang, X. Synthesis and biological evaluation of 3-arylcoumarins as
potential anti-Alzheimer’s disease agents. J. Enzyme Inhib. Med. Chem. 2019, 34, 651–656. [CrossRef]
168. Knez, D.; Sova, M.; Košak, U.; Gobec, S. Dual inhibitors of cholinesterases and monoamine oxidases for
Alzheimer’s disease. Future Med. Chem. 2017, 9, 811–832. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 74 of 81
169. Joubert, J.; Foka, G.B.; Repsold, B.P.; Oliver, D.W.; Kapp, E.; Malan, S.F. Synthesis and evaluation of
7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for
the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2017, 125, 853–864. [CrossRef]
170. Shi, D.H.; Min, W.; Song, M.Q.; Si, X.X.; Li, M.C.; Zhang, Z.Y.; Liu, Y.W.; Liu, W.W. Synthesis, characterization,
crystal structure and evaluation of four carbazole-coumarin hybrids as multifunctional agents for the
treatment of Alzheimer’s disease. J. Mol. Struct. 2020, 1209, 127897. [CrossRef]
171. Tang, Y.-Z.; Liu, Z.-Q. Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis
of human erythrocytes. Biorgan. Maed. Chem. 2007, 15, 1903–1913. [CrossRef]
172. Yang, W.; Wong, Y.; Ng, O.T.W.; Bai, L.P.; Kwong, D.W.J.; Ke, Y.; Jiang, Z.H.; Li, H.W.; Yung, K.K.L.; Wong, M.S.
Inhibition of beta-amyloid peptide aggregation by multifunctional carbazole-based fluorophores. Angew.
Chem. Int. Ed. 2012, 51, 1804–1810. [CrossRef]
173. Fang, L.; Fang, X.; Gou, S.; Lupp, A.; Lenhardt, I.; Sun, Y.; Huang, Z.; Chen, Y.; Zhang, Y.; Fleck, C. Design,
synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer
agents. Eur. J. Med. Chem. 2014, 76, 376–386. [CrossRef] [PubMed]
174. Li, Y.; Qiang, X.; Luo, L.; Yang, X.; Xiao, G.; Liu, Q.; Ai, J.; Tan, Z.; Deng, Y. Aurone Mannich base derivatives
as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and
neuroprotective properties for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2017, 126, 762–775.
[CrossRef] [PubMed]
175. McNamara, J.O. Cellular and molecular basis of epilepsy. J. Neurosci. 1994, 14, 3413–3425. [CrossRef]
[PubMed]
176. Aboul-Enein, M.N.; El-Azzouny, A.A.; Attia, M.I.; Maklad, Y.A.; Aboutabl, M.E.;
Ragab, F.; El-Hamid, W.H.A.A. Anticonvulsant profiles of certain new 6-Aryl-9-substituted-
6,9-diazaspiro-[4.5]decane-8,10-diones and 1-Aryl-4-substituted- 1,4-diazaspiro[5.5]undecane-3,5-diones. Int.
J. Mol. Sci. 2014, 15, 16911–16935. [CrossRef] [PubMed]
177. Kamin´ski, K.; Rapacz, A.; Łuszczki, J.J.; Latacz, G.; Obniska, J.; Kiec´-Kononowicz, K.;
Filipek, B. Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from
N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
Bioorg. Med. Chem. 2015, 23, 2548–2561. [CrossRef]
178. Abd-Allah, W.H.; Aboutabl, M.E.; Aboul-Enein, M.N.; El-Azzouny, A.A.S. Synthesis, molecular modeling
studies and anticonvulsant activity of certain (1-(benzyl (aryl) amino) cyclohexyl) methyl esters. Bioorg.
Chem. 2017, 71, 135–145. [CrossRef]
179. Sahu, M.; Siddiqui, N.; Naim, M.J.; Alam, O.; Yar, M.S.; Sharma, V.; Wakode, S. Design, Synthesis and
Docking Study of Pyrimidine–Triazine Hybrids for GABA Estimation in Animal Epilepsy Models. Arch.
Pharm. 2017, 350, 1–18. [CrossRef]
180. Abd-Allah, W.H.; Osman, E.E.A.; Anwar, M.A.E.M.; Attia, H.N.; El Moghazy, S.M. Design, synthesis and
docking studies of novel benzopyrone derivatives as anticonvulsants. Bioorg. Chem. 2020, 98, 103738.
[CrossRef]
181. Aboutabl, M.E.; Hassan, R.M.; El-Azzouny, A.A.S.; Aboul-Enein, M.N.; Abd-Allah, W.H. Design and
synthesis of novel parabanic acid derivatives as anticonvulsants. Bioorg. Chem. 2020, 94, 103473. [CrossRef]
182. Partap, S.; Yar, M.S.; Hassan, M.Z.; Akhtar, M.J.; Siddiqui, A.A. Design, Synthesis and Pharmacological
Screening of Pyridazinone Hybrids as Anticonvulsant Agents. Arch. Pharm. 2017, 350, 1–14. [CrossRef]
183. Mohammadi-Khanaposhtani, M.; Ahangar, N.; Sobhani, S.; Masihi, P.H.; Shakiba, A.; Saeedi, M.;
Akbarzadeh, T. Design, synthesis, in vivo and in silico evaluation of new coumarin-1,2,4-oxadiazole
hybrids as anticonvulsant agents. Bioorg. Chem. 2019, 89, 102989. [CrossRef] [PubMed]
184. Ahangar, N.; Ayati, A.; Alipour, E.; Pashapour, A.; Foroumadi, A.; Emami, S.
1-[(2-arylthiazol-4-yl)methyl]azoles as a new class of anticonvulsants: Design, synthesis, in vivo
screening and in silico drug-like properties. Chem. Biol. Drug Des. 2011, 78, 844–852. [CrossRef] [PubMed]
185. Lankau, H.J.; Unverferth, K.; Grunwald, C.; Hartenhauer, H.; Heinecke, K.; Bernöster, K.; Dost, R.; Egerland, U.;
Rundfeldt, C. New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity. Eur. J.
Med. Chem. 2007, 42, 873–879. [CrossRef] [PubMed]
186. Faizi, M.; Sheikhha, M.; Ahangar, N.; Ghomi, H.T.; Shafaghi, B.; Shafiee, A.; Tabatabai, S.A. Design, synthesis
and pharmacological evaluation of novel 2-[2-(2-Chlorophenoxy) phenyl]-1,3,4-oxadiazole derivatives as
benzodiazepine receptor agonists. Iran. J. Pharm. Res. 2012, 11, 83–90. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4618 75 of 81
187. Mohammadi-Khanaposhtani, M.; Shabani, M.; Faizi, M.; Aghaei, I.; Jahani, R.; Sharafi, Z.; Shamsaei
Zafarghandi, N.; Mahdavi, M.; Akbarzadeh, T.; Emami, S.; et al. Design, synthesis, pharmacological
evaluation and docking study of new acridone-based 1,2,4-oxadiazoles as potential anticonvulsant agents.
Eur. J. Med. Chem. 2016, 112, 91–98. [CrossRef] [PubMed]
188. Zolfagharian, F.; Razavi, B.M.; Hosseinzadeh, H. Anticonvulsant effect of Satureja hortensis aerial parts
extracts in mice. Avicenna J. Phytomed. 2016, 6, 305–312. [CrossRef]
189. Mokrov, G.V.; Savel’ev, V.L.; Voronina, T.A.; Litvinova, S.A.; Kovalev, I.G.; Nerobkova, L.N.;
Dmitrienko, A.O.; Gudasheva, T.A.; Seredenin, S.B. Synthesis and Anticonvulsant Activity of N-Substituted
4-Amino-3-Nitrocoumarins. Pharm. Chem. J. 2019, 53, 118–124. [CrossRef]
190. Wadelius, M.; Pirmohamed, M. Pharmacogenetics of warfarin: Current status and future challenges.
Pharmacogen. J. 2007, 7, 99–111. [CrossRef]
191. Kamali, F.; Pirmohamed, M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br. J.
Clin. Pharmacol. 2006, 61, 746–751. [CrossRef]
192. Pirmohamed, M. Warfarin: Almost 60 years old and still causing problems. Br. J. Clin. Pharmacol. 2006, 62,
509–511. [CrossRef]
193. Trailokya, A. Acenocoumarol in Thromoembolic Disorders. Cardiovasc. Pharmacol. Open Access 2015, 4.
[CrossRef]
194. Lippi, G.; Gosselin, R.; Favaloro, E.J. Current and Emerging Direct Oral Anticoagulants: State-of-the-Art.
Semin. Thromb. Hemost. 2019, 45, 490–501. [CrossRef] [PubMed]
195. Székely, O.; Miyazawa, K.; Lip, G.Y.H. Current and emerging pharmacotherapy for ischemic stroke prevention
in patients with atrial fibrillation. Expert Opin. Pharmacother. 2018, 19, 1999–2009. [CrossRef] [PubMed]
196. Bavisotto, L.M.; Ellis, D.J.; Milner, P.G.; Combs, D.L.; Irwin, I.; Canafax, D.M. Tecarfarin, a novel vitamin K
reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration
of fluconazole in healthy participants. J. Clin. Pharmacol. 2011, 51, 561–574. [CrossRef] [PubMed]
197. Albrecht, D.; Ellis, D.; Canafax, D.M.; Combs, D.; Druzgala, P.; Milner, P.G.; Midei, M.G. Pharmacokinetics
and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. Thromb. Haemost.
2017, 117, 706–717. [CrossRef] [PubMed]
198. Albrecht, D.; Turakhia, M.P.; Ries, D.; Marbury, T.; Smith, W.; Dillon, D.; Milner, P.G.; Midei, M.G.
Pharmacokinetics of tecarfarin and warfarin in patients with severe chronic kidney disease. Thromb. Haemost.
2017, 117, 2026–2033. [CrossRef] [PubMed]
199. Bang, N.C.; Abyshev, A.Z.; Ivkin, D.Y. Synthesis and In Vivo Evaluation of New Coumarin Conjugates as
Potential Indirect-Action Anticoagulants. Pharm. Chem. J. 2019, 53, 419–422. [CrossRef]
200. Montagut-Romans, A.; Boulven, M.; Jacolot, M.; Moebs-Sanchez, S.; Hascoët, C.; Hammed, A.; Besse, S.;
Lemaire, M.; Benoit, E.; Lattard, V.; et al. Synthesis and biological evaluation of C-3 aliphatic coumarins as
vitamin K antagonists. Bioorg. Med. Chem. Lett. 2017, 27, 1598–1601. [CrossRef]
201. Gebauer, M. Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg. Med. Chem.
2007, 15, 2414–2420. [CrossRef]
202. Au, N.; Rettie, A.E. Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug Metab. Rev. 2008, 40,
355–375. [CrossRef]
203. Lei, L.; Xue, Y.B.; Liu, Z.; Peng, S.S.; He, Y.; Zhang, Y.; Fang, R.; Wang, J.P.; Luo, Z.W.; Yao, G.M. Coumarin
derivatives from Ainsliaea fragrans and their anticoagulant activity. Sci. Rep. 2015, 5, 1–9. [CrossRef]
204. World Health Organization (WHO). Diabetic. Available online: http://www.who.int/diabetic/en/ (accessed
on 18 March 2020).
205. Lebovitz, H.A. A new oral therapy for diabetes management: Alpha-glucosidase inhibition with acarbose.
Clin. Diabetes 1995, 13, 99–103. [CrossRef]
206. Playford, R.J.; Pither, C.; Gao, R.; Middleton, S.J. Use of the alpha-glucosidase inhibitor acarbose in patients
with ‘Middleton syndrome’: Normal gastric anatomy but with accelerated gastric emptying causing
postprandial reactive hypoglycemia and diarrhea. Can. J. Gastroenterol. 2013, 27, 403–404. [CrossRef]
[PubMed]
207. Mentes¸e, E.; Baltas¸, N.; Bekircan, O. Synthesis and kinetics studies of
N′-(2-(3,5-disubstituted-4H-1,2,4-triazol-4-yl)acetyl)-6/7/8-substituted-2-oxo-2H-chromen-3-carbohydrazide
derivatives as potent antidiabetic agents. Arch. Pharm. 2019, 352, 2–8. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4618 76 of 81
208. Kharb, R.; Sharma, P.C.; Yar, M.S. Pharmacological significance of triazole scaffold. J. Enzyme Inhib. Med.
Chem. 2011, 26, 1–21. [CrossRef]
209. Kaur, P.; Chawla, A. 1,2,4-Triazole: A Review of Pharmacological Activities. Int. Res. J. Pharm. 2017, 8, 10–29.
[CrossRef]
210. Pillai, R.R.; Karrouchi, K.; Fettach, S.; Armakovic´, S.; Armakovic´, S.J.; Brik, Y.; Taoufik, J.; Radi, S.; El Abbes
Faouzi, M.; Ansar, M. Synthesis, spectroscopic characterization, reactive properties by DFT calculations,
molecular dynamics simulations and biological evaluation of Schiff bases tethered 1,2,4-triazole and pyrazole
rings. J. Mol. Struct. 2019, 1177, 47–54. [CrossRef]
211. Dhameja, M.; Gupta, P. Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.
Eur. J. Med. Chem. 2019, 176, 343–377. [CrossRef]
212. Taha, M.; Shah, S.A.A.; Afifi, M.; Imran, S.; Sultan, S.; Rahim, F.; Khan, K.M. Synthesis, α-glucosidase
inhibition and molecular docking study of coumarin based derivatives. Bioorg. Chem. 2018, 77, 586–592.
[CrossRef]
213. Salar, U.; Taha, M.; Khan, K.M.; Ismail, N.H.; Imran, S.; Perveen, S.; Gul, S.; Wadood, A. Syntheses of new
3-thiazolyl coumarin derivatives, in vitro α-glucosidase inhibitory activity and molecular modeling studies.
Eur. J. Med. Chem. 2016, 122, 196–204. [CrossRef]
214. Hu, Y.; Wang, B.; Yang, J.; Liu, T.; Sun, J.; Wang, X. Synthesis and biological evaluation of 3-arylcoumarin
derivatives as potential anti-diabetic agents. J. Enzyme Inhib. Med. Chem. 2019, 34, 15–30. [CrossRef]
[PubMed]
215. Asgari, M.S.; Mohammadi-Khanaposhtani, M.; Kiani, M.; Ranjbar, P.R.; Zabihi, E.; Pourbagher, R.; Rahimi, R.;
Faramarzi, M.A.; Biglar, M.; Larijani, B.; et al. Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic
agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic and docking studies. Bioorg. Chem. 2019,
92, 103206. [CrossRef] [PubMed]
216. Wang, G.; Peng, Z.; Li, X.; Li, J. Synthesis, in vitro evaluation and molecular docking studies of novel
triazine-triazole derivatives as potential α-glucosidase inhibitors. Eur. J. Med. Chem. 2017, 125, 423–429.
[CrossRef] [PubMed]
217. Ahmed, S.; Nur-e-Alam, M.; Parveen, I.; Coles, S.J.; Hafizur, R.M.; Hameed, A.; Orton, J.B.; Threadgill, M.D.;
Yousaf, M.; Alqahtani, A.M.; et al. Stimulation of insulin secretion by 5-methylcoumarins and its sulfur
analogues isolated from Clutia lanceolata Forssk. Phytochemistry 2020, 170, 112213. [CrossRef] [PubMed]
218. Ford, R.A.; Hawkins, D.R.; Mayo, B.C.; Api, A.M. The in vivo dermal absorption and metabolism of
[4-14C]coumarin by rats and by human volunteers under simulated conditions of use in fragrances. Food
Chem. Toxicol. 2001, 39, 153–162. [CrossRef]
219. Azim, S.A.; Al-Hazmy, S.M.; Ebeid, E.M.; El-Daly, S.A. A new coumarin laser dye
3-(benzothiazol-2-yl)-7-hydroxycoumarin. Opt. Laser Technol. 2005, 37, 245–249. [CrossRef]
220. Vocanson, M.; Valeyrie, M.; Rozières, A.; Hennino, A.; Floc’h, F.; Gard, A.; Nicolas, J.F. Lack of evidence for
allergenic properties of coumarin in a fragrance allergy mouse model. Contact Dermatitis 2007, 57, 361–364.
[CrossRef] [PubMed]
221. Xiao, H.; Chen, K.; Cui, D.; Jiang, N.; Yin, G.; Wang, J.; Wang, R. Two novel aggregation-induced emission
active coumarin-based Schiff bases and their applications in cell imaging. New J. Chem. 2014, 38, 2386–2393.
[CrossRef]
222. Srinivasan, G.; Chen, J.; Parisi, J.; Brückner, C.; Yao, X.; Lei, Y. An Injectable PEG-BSA-Coumarin-GOx
Hydrogel for Fluorescence Turn-on Glucose Detection. Appl. Biochem. Biotechnol. 2015, 177, 1115–1126.
[CrossRef]
223. Song, P.P.; Zhao, J.; Liu, Z.L.; Duan, Y.B.; Hou, Y.P.; Zhao, C.Q.; Wu, M.; Wei, M.; Wang, N.H.; Lv, Y.; et al.
Evaluation of antifungal activities and structure–activity relationships of coumarin derivatives. Pest Manag.
Sci. 2017, 73, 94–101. [CrossRef] [PubMed]
224. Gandioso, A.; Contreras, S.; Melnyk, I.; Oliva, J.; Nonell, S.; Velasco, D.; García-Amorós, J.; Marchán, V.
Development of Green/Red-Absorbing Chromophores Based on a Coumarin Scaffold That Are Useful as
Caging Groups. J. Org. Chem. 2017, 82, 5398–5408. [CrossRef] [PubMed]
225. Gualandi, A.; Rodeghiero, G.; Della Rocca, E.; Bertoni, F.; Marchini, M.; Perciaccante, R.; Jansen, T.P.;
Ceroni, P.; Cozzi, P.G. Application of coumarin dyes for organic photoredox catalysis. Chem. Commun. 2018,
54, 10044–10047. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4618 77 of 81
226. Liu, D.; Yang, F.; Xiong, F.; Gu, N. The smart drug delivery system and its clinical potential. Theranostics
2016, 6, 1306–1323. [CrossRef] [PubMed]
227. Silva, J.M.; Silva, E.; Reis, R.L. Light-triggered release of photocaged therapeutics—Where are we now? J.
Control. Release 2019, 298, 154–176. [CrossRef] [PubMed]
228. Yang, Y.; Mu, J.; Xing, B. Photoactivated drug delivery and bioimaging. Wiley Interdiscip. Rev. Nanomed.
Nanobiotechnol. 2017, 9, e1408. [CrossRef]
229. Velema, W.A.; Szymanski, W.; Feringa, B.L. Photopharmacology: Beyond proof of principle. J. Am. Chem.
Soc. 2014, 136, 2178–2191. [CrossRef]
230. Brieke, C.; Rohrbach, F.; Gottschalk, A.; Mayer, G.; Heckel, A. Light-controlled tools. Angew. Chem. Int. Ed.
2012, 51, 8446–8476. [CrossRef]
231. Fournier, L.; Aujard, I.; Le Saux, T.; Maurin, S.; Beaupierre, S.; Baudin, J.B.; Jullien, L. Coumarinylmethyl
caging groups with redshifted absorption. Chem. A Eur. J. 2013, 19, 17494–17507. [CrossRef]
232. Fournier, L.; Gauron, C.; Xu, L.; Aujard, I.; Le Saux, T.; Gagey-Eilstein, N.; Maurin, S.; Dubruille, S.;
Baudin, J.B.; Bensimon, D.; et al. A blue-absorbing photolabile protecting group for in vivo chromatically
orthogonal photoactivation. ACS Chem. Biol. 2013, 8, 1528–1536. [CrossRef]
233. Bojtár, M.; Kormos, A.; Kis-Petik, K.; Kellermayer, M.; Kele, P. Green-Light Activatable, Water-Soluble
Red-Shifted Coumarin Photocages. Org. Lett. 2019, 21, 9410–9414. [CrossRef]
234. Iturmendi, A.; Theis, S.; Maderegger, D.; Monkowius, U.; Teasdale, I. Coumarin-Caged Polyphosphazenes
with a Visible-Light Driven On-Demand Degradation. Macromol. Rapid Commun. 2018, 39, 1–6. [CrossRef]
235. Sarkar, A.R.; Heo, C.H.; Xu, L.; Lee, H.W.; Si, H.Y.; Byun, J.W.; Kim, H.M. A ratiometric two-photon probe for
quantitative imaging of mitochondrial pH values. Chem. Sci. 2016, 7, 766–773. [CrossRef]
236. Gong, H.L.; Jiang, Y.; Hou, R.C.; Ding, X.Q. A Sensitive and Selective Fluorescent Coumarin-Based Probe
for Detection of Hypochlorite ion and its Application to Cellular Imaging. J. Fluoresc. 2016, 26, 403–406.
[CrossRef] [PubMed]
237. Hu, Z.Q.; Sun, L.L.; Gu, Y.Y.; Jiang, Y. A sensitive and selective fluorescent probe for detection of glutathione
in the presence of Cu2+ and its application to biological imaging. Sens. Actuators B Chem. 2015, 212, 220–224.
[CrossRef]
238. Shangguan, M.; Jiang, X.; Lu, Z.; Zou, W.; Chen, Y.; Xu, P.; Pan, Y.; Hou, L. A coumarin-based fluorescent
probe for hypochlorite ion detection in environmental water samples and living cells. Talanta 2019, 202,
303–307. [CrossRef] [PubMed]
239. Tang, Y.; Li, Y.; Han, J.; Mao, Y.; Ni, L.; Wang, Y. A coumarin based fluorescent probe for rapidly distinguishing
of hypochlorite and copper (II) ion in organisms. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2019, 208,
299–308. [CrossRef] [PubMed]
240. Starzak, K.; Matwijczuk, A.; Creaven, B.; Matwijczuk, A.; Wybraniec, S.; Karcz, D. Fluorescence
quenching-based mechanism for determination of hypochlorite by coumarin-derived sensors. Int. J.
Mol. Sci. 2019, 20, 281. [CrossRef] [PubMed]
241. Bekhradnia, A.; Domehri, E.; Khosravi, M. Novel coumarin-based fluorescent probe for selective detection of
Cu(II). Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2016, 152, 18–22. [CrossRef]
242. He, G.; Liu, X.; Xu, J.; Ji, L.; Yang, L.; Fan, A.; Wang, S.; Wang, Q. Synthesis and application of a highly
selective copper ions fluorescent probe based on the coumarin group. Spectrochim. Acta Part A Mol. Biomol.
Spectrosc. 2018, 190, 116–120. [CrossRef]
243. Mani, K.S.; Rajamanikandan, R.; Murugesapandian, B.; Shankar, R.; Sivaraman, G.; Ilanchelian, M.;
Rajendran, S.P. Coumarin based hydrazone as an ICT-based fluorescence chemosensor for the detection
of Cu2+ ions and the application in HeLa cells. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2019, 214,
170–176. [CrossRef]
244. Li, H.; Sun, X.; Zheng, T.; Xu, Z.; Song, Y.; Gu, X. Coumarin-based multifunctional chemosensor for
arginine/lysine and Cu2+/Al3+ ions and its Cu2+ complex as colorimetric and fluorescent sensor for biothiols.
Sens. Actuators B Chem. 2019, 279, 400–409. [CrossRef]
245. Chen, X.Z.; Ma, X.D.; Wang, H.M.; Wang, M.; Zhang, Y.Y.; Gao, G.; Liu, J.J.; Hou, S.C. A coumarin-based
colorimetric and fluorescent dual probe for palladium(II) ions that can be used in live cells. New J. Chem.
2017, 41, 8026–8030. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 78 of 81
246. Cheng, X.; Qu, S.; Xiao, L.; Li, W.; He, P. Thioacetalized coumarin-based fluorescent probe for mercury(II):
Ratiometric response, high selectivity and successful bioimaging application. J. Photochem. Photobiol. A Chem.
2018, 364, 503–509. [CrossRef]
247. Warrier, S.; Kharkar, P.S. Highly selective on-off fluorescence recognition of Fe3+ based on a coumarin
derivative and its application in live-cell imaging. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2018, 188,
659–665. [CrossRef] [PubMed]
248. Jiao, S.; Wang, X.; Sun, Y.; Zhang, L.; Sun, W.; Sun, Y.; Wang, X.; Ma, P.; Song, D. A novel
fluorescein-coumarin-based fluorescent probe for fluoride ions and its applications in imaging of living cells
and zebrafish in vivo. Sens. Actuators B Chem. 2018, 262, 188–194. [CrossRef]
249. Yao, K.; Chang, Y.; Li, B.; Yang, H.; Xu, K. A novel coumarin-based fluorescent sensor for Ca2+ and sequential
detection of F− and its live cell imaging. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2019, 216, 385–394.
[CrossRef] [PubMed]
250. Reddy, T.S.; Choi, M.S. Dicyanovinylcoumarin as a turn-on fluorescent sensor for cyanide ion. J. Photochem.
Photobiol. A Chem. 2018, 351, 108–114. [CrossRef]
251. Zhang, Q.; Zhang, Y.; Ding, S.; Zhang, H.; Feng, G. A near-infrared fluorescent probe for rapid, colorimetric
and ratiometric detection of bisulfite in food, serum and living cells. Sens. Actuators B Chem. 2015, 211,
377–384. [CrossRef]
252. Fazio, T.; Warner, C.R. A review of sulphites in foods: Analytical methodologyand reported findings. Food
Addit. Contam. 1990, 7, 433–454. [CrossRef]
253. Taylor, S.L.; Highley, N.A.; Bush, R.K. Bush, Sulfites in foods: Uses, analytical methods, residues, fate,
exposure assessment, metabolism, toxicity and hypersensitivity. Adv. Food Res. 1986, 30, 1–76. [CrossRef]
254. Vally, H.; Misso, N.L.; Madan, V. Clinical effects of sulphite additives. Clin. Exp. Allergy 2009, 39, 1643–1651.
[CrossRef] [PubMed]
255. Hansell, A.; Oppenheimer, C. Health hazards from volcanic gases: A systematicliterature review. Arch.
Environ. Health 2004, 59, 628–639. [CrossRef]
256. Nair, R.R.; Raju, M.; Bhai, S.; Raval, I.H.; Haldar, S.; Ganguly, B.; Chatterjee, P.B. Estimation of bisulfate in
edible plant foods, dog urine and drugs: Picomolar level detection and bio-imaging in living organisms.
Analyst 2019, 144, 5724–5737. [CrossRef] [PubMed]
257. Fujioka, N.; Fritz, V.; Upadhyaya, P.; Kassie, F.; Hetch, S.S. Research on cruciferous vegetables,
indole-3-carbinol and cancer prevention: A tribute to Lee W. Wattenberg. Mol. Nutr. Food Res. 2016,
60, 1228–1238. [CrossRef] [PubMed]
258. Keck, A.-S.; Finley, J.W. Crouciferous Vegetables: Cancer Protective Mechanism of Glcisunolate Hydrolisi
Products and Selenium. Crucif. Veg. Cancer Prot. 2004, 3, 5–12. [CrossRef]
259. Botti, M.G.; Taylor, M.G.; Botting, N.P. Studies on the mechanism of Myrosinase: Investigation of the effect of
glycosil acceptors on enzyme activity. J. Biol. Chem. 1995, 35, 20530–20535. [CrossRef]
260. Marx, J.A.; Hockberger, R.S.; Walls, R.M. Rosen’s Emergency Medicines, 8th ed.; Elsevier: Amsterdam, The
Netherlands, 2014.
261. Yang, L.; Ding, W.; Xu, Y.; Wu, D.; Li, S.; Chen, J.; Guo, B. New insights into the antibacterial activity of
hydroxycoumarins against ralstonia solanacearum. Molecules 2016, 21, 468. [CrossRef]
262. Genin, S. Molecular traits controlling host range and adaptation to plants in Ralstonia solanacearum. New
Phytol. 2010, 187, 920–928. [CrossRef]
263. De Oliveira Monteiro, F. Environmental Cues Controlling the Pathogenicity of “Ralstonia Solanacearum” on
Plants. Master’s Thesis, Universitat de Barcelona, Barcelona, Spain, 2013.
264. Yai, J.; Allen, C. The plant pathogen Ralstonia solanacearum needs aerotaxis for normal biofilm formation and
interactions with its tomato host. J. Bacteriol. 2007, 189, 6415–6524. [CrossRef]
265. Ramírez-Pelayo, C.; Martínez-Quiñones, J.; Gil, J.; Durango, D. Coumarins from the peel of citrus grown in
Colombia: Composition, elicitation and antifungal activity. Heliyon 2019, 5. [CrossRef]
266. Piasecka, A.; Jedrzejczak-Rey, N.; Bednarek, P. Secondary metabolites in plant innate immunity: Conserved
function of divergent chemicals. New Phytol. 2015, 206, 948–964. [CrossRef]
267. VanEtten, H.; Mansfield, J.; Bailey, J.; Farmer, E. Two classes of plant antibiotics: Phytoalexins versus
phytoanticipins. Plant Cell 1994, 6, 1191–1192. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4618 79 of 81
268. Yu, X.; Teng, P.; Zhang, Y.L.; Xu, Z.J.; Zhang, M.Z.; Zhang, W.H. Design, synthesis and antifungal activity
evaluation of coumarin-3-carboxamide derivatives. Fitoterapia 2018, 127, 387–395. [CrossRef] [PubMed]
269. Reddy, N.S.; Mallireddigari, M.R.; Cosenza, S.; Gumireddy, K.; Bell, S.C.; Premkumar Reddy, E.; Ramana
Reddy, M. Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg. Med.
Chem. Lett. 2004, 14, 4093–4097. [CrossRef] [PubMed]
270. Wehrstedt, K.D.; Wandrey, P.A.; Heitkamp, D. Explosive properties of 1-hydroxybenzotriazoles. J. Hazard.
Mater. 2005, 126, 1–7. [CrossRef] [PubMed]
271. Grande, F.; Aiello, F.; Grazie, O.D.; Brizzi, A.; Garofaloa, A.; Neamati, N. Synthesis and antitumor activities
of a series of novel quinoxalinhydrazides. Bioorg. Med. Chem. 2007, 15, 288–294. [CrossRef] [PubMed]
272. Zou, M.; Lu, J.R.; Chen, H.P. Synthesis, characterization and antibacterial activities of N-[1-(substituted
phenyl) ethyl]-2-hydroxybenzohydrazide. Chem. J. Chin. Univ. 2012, 33, 2235–2238. [CrossRef]
273. Yang, G.; Jin, Q.; Xu, C.; Fan, S.; Wang, C.; Xie, P. Synthesis, characterization and antifungal activity of
coumarin-functionalized chitosan derivatives. Int. J. Biol. Macromol. 2018, 106, 179–184. [CrossRef]
274. Lippard, S.J.; Berg, J.M. Principles of Bioinorganic Chemistry; University Science Books: Mill Valley, CA, USA,
1999; ISBN 0-935702-73-3.
275. Karaliota, A.; Kretsi, O.; Tzougraki, C. Synthesis and characterization of a binuclear coumarin-3-carboxylate
copper(II) complex. J. Inorg. Biochem. 2001, 84, 33–37. [CrossRef]
276. MacLean, L.; Karcz, D.; Jenkins, H.; McClean, S.; Devereux, M.; Howe, O.; Pereira, M.D.; May, N.V.;
Enyedy, É.A.; Creaven, B.S. Copper(II) complexes of coumarin-derived Schiff base ligands: Pro- or antioxidant
activity in MCF-7 cells? J. Inorg. Biochem. 2019, 197, 110702. [CrossRef]
277. Dharmaraja, A.T. Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and
Bacteria. J. Med. Chem. 2017, 60, 3221–3240. [CrossRef] [PubMed]
278. Reczek, C.R.; Chandel, N.S. The Two Faces of Reactive Oxygen Species in Cancer. Annu. Rev. Cancer Biol.
2017, 1, 79–98. [CrossRef]
279. Barrera, G.; Peroxidation, L. Oxidative Stress and Lipid Peroxidation Products in cancer progression and
therapy. ISRN Oncol. 2012, 2012, 137289. [CrossRef]
280. Dwyer, F.P.; Mayhew, E.; Roe, E.M.; Shulman, A. Inhibition of Landschutz Ascites Tumour Growth By metal
chelates derived from 3,4,7,8-tetramethyl- 1,1 0-phenanthroline. Br. J. Cancer 1965, 19, 195–199. [CrossRef]
[PubMed]
281. Qin, Q.P.; Wang, Z.F.; Huang, X.L.; Tan, M.X.; Zou, B.Q.; Liang, H. Strong in vitro and vivo cytotoxicity of
novel organoplatinum(II) complexes with quinoline-coumarin derivatives. Eur. J. Med. Chem. 2019, 184,
111751. [CrossRef]
282. Aslkhademi, S.; Noshiranzadeh, N.; Sadjadi, M.S.; Mehrani, K.; Farhadyar, N. Synthesis, crystal structure
and investigation of the catalytic and spectroscopic properties of a Zn(II) complex with coumarin-hydrazone
ligand. Polyhedron 2019, 160, 115–122. [CrossRef]
283. Jaiswal, S.; Bhattacharya, K.; Sullivan, M.; Walsh, M.; Creaven, B.S.; Laffir, F.; Duffy, B.; McHale, P.
Non-cytotoxic antibacterial silver-coumarin complex doped sol-gel coatings. Colloids Surf. B Biointerfaces
2013, 102, 412–419. [CrossRef]
284. Vekariya, R.H.; Patel, H.D. Recent Advances in the Synthesis of Coumarin Derivatives via Knoevenagel
Condensation: A Review. Synth. Commun. 2014, 44, 2756–2788. [CrossRef]
285. Salem, M.A.; Helal, M.H.; Gouda, M.A.; Ammar, Y.A.; El-Gaby, M.S.A.; Abbas, S.Y. An overview on synthetic
strategies to coumarins. Synth. Commun. 2018, 48, 1534–1550. [CrossRef]
286. Hartman, R.L.; McMullen, J.P.; Jensen, K.F. Deciding Wether To Go with the Flow: Evaluating the Merits of
Flow Reactors for Synthesis. Angew. Chem. Int. Ed. 2011, 50, 7502–7519. [CrossRef]
287. Taghavi-Moghadam, S.; Kleemann, A.; Golbig„ K.G. Microreaction Technology as a Novel Approach to Drug
Design, Process Development and Reliability. Org. Process Res. Dev. 2001, 5, 652–658. [CrossRef]
288. Gutmann, B.; Cantillo, D.; Kapper, C.O. Continuous-Flow Technology—A Tool fo the Safe Manifacturing of
Active Pharmaceutical Ingredients. Angew. Chem. Int. Ed. 2015, 54, 6688–6728. [CrossRef]
289. Li, X.; Chen, A.; Zhou, Y.; Huang, L.; Fang, Z.; Gan, H.; Guo, K. Two-stage flow synthesis of coumarin via
O-acetylation of salicylaldehyde. J. Flow Chem. 2015, 5, 82–86. [CrossRef]
290. Mhiri, C.; Ternane, R.; Hamdi, N.; Baklouti, L. Synthesis of coumarin derivative using polymer supported
reagents. Eur. J. Chem. 2018, 9, 89–91. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 80 of 81
291. Metternich, J.B.; Gilmour, R. One Photocatalyst, n Activation Modes Strategy for Cascade Catalysis: Emulating
Coumarin Biosynthesis with (-)-Riboflavin. J. Am. Chem. Soc. 2016, 138, 1040–1045. [CrossRef]
292. Song, D.; Wang, C.M.; Ye, Z.P.; Xia, P.J.; Deng, Z.X.; Xiao, J.A.; Xiang, H.Y.; Yang, H. Visible-light-driven,
photoredox-catalyzed cascade of ortho-hydroxycinnamic esters to access 3-fluoroalkylated coumarins. J.
Org. Chem. 2019, 84, 7480–7487. [CrossRef]
293. Eivgi, O.; Sutar, R.L.; Reany, O.; Lemcoff, N.G. Bichromatic Photosynthesis of Coumarins by UV Filter-Enabled
Olefin Metathesis. Adv. Synth. Catal. 2017, 359, 2352–2357. [CrossRef]
294. Reichardt, C.; Welton, T. Solvents and Solvent Effects in Organic Chemistry, 4th ed.; Wiley-VCH: Weinheim,
Germany, 2011.
295. Horning, E.C. Organic Syntheses, Coll. Vol. III; John Wiley & Sons, Inc.: New York, NY, USA, 1955.
296. Kalita, P.; Kumar, R. Solvent-free coumarin synthesis via Pechmann reaction using solid catalysts. Microporous
Mesoporous Mater. 2012, 149, 1–9. [CrossRef]
297. Loupy, A. Solvent-Free Reactions. In Modern Solvents in Organic Synthesis; Knochel, P., Ed.; Springer: Berlin,
Germany, 1999.
298. Sugino, T.; Tanaka, K. Solvent-free coumarin synthesis. Chem. Lett. 2001, 110–111. [CrossRef]
299. Ebrahimi, S.E.S.; Ghadirian, P.; Emtiazi, H.; Yahya-Meymandi, A.; Saeedi, M.; Mahdavi, M.; Nadri, H.;
Moradi, A.; Sameem, B.; Vosooghi, M.; et al. Hetero-annulated coumarins as new AChE/BuChE inhibitors:
Synthesis and biological evaluation. Med. Chem. Res. 2016, 25, 1831–1841. [CrossRef]
300. Emtiazi, H.; Amrollahi, M.A.; Mirjalili, B.B.F. Nano-silica sulfuric acid as an efficient catalyst for the synthesis
of substituted pyrazoles. Arab. J. Chem. 2015, 8, 793–797. [CrossRef]
301. Kour, M.; Paul, S.; Clark, J.H.; Gupta, V.K.; Kant, R. Preparation and characterization of Lewis acid grafted
sulfonated carbon@titania composites for the multicomponent synthesis of 4H-pyrimido[2,1-b]benzothiazoles
and benzoxanthenones under solvent-free conditions. J. Mol. Catal. A Chem. 2016, 411, 299–310. [CrossRef]
302. Kour, M.; Paul, S. A green and convenient approach for the one-pot solvent-free synthesis of coumarins and
β-amino carbonyl compounds using Lewis acid grafted sulfonated carbon@titania composite. Monatshefte
fur Chem. 2017, 148, 327–337. [CrossRef]
303. Ghomi, J.S.; Akbarzadeh, Z. Ultrasonic accelerated Knoevenagel condensation by magnetically recoverable
MgFe2O4 nanocatalyst: A rapid and green synthesis of coumarins under solvent-free conditions. Ultrason.
Sonochem. 2018, 40, 78–83. [CrossRef]
304. Pakdel, S.; Akhlaghinia, B.; Mohammadinezhad, A. Fe3O4@Boehmite-NH2-CoII NPs: An Environment
Friendly Nanocatalyst for Solvent Free Synthesis of Coumarin Derivatives Through Pechmann Condensation
Reaction. Chem. Afr. 2019, 2, 367–376. [CrossRef]
305. Jenkins, H.D.B. Ionic liquids—An overview. Sci. Prog. 2011, 94, 265–297. [CrossRef]
306. Earle, M.J.; Seddon, K.R. Ionic liquids. Green solvents for the future. Pure Appl. Chem. 2000, 72, 1391–1398.
[CrossRef]
307. Deng, Y.; Beadham, I.; Ghacre, M.; Costa Gomes, M.F.; Gathergood, N.; Husson, P.; Lègeret, B.; Quilty, B.;
Sancelme, M.; Besse-Hoggan, P. When can ionic liquids be considered readily biodegradable? Biodegradation
pathways of pyridinium, pyrrolidinium and ammonium-based ionic liquids. Green Chem. 2015, 17, 1479–1491.
[CrossRef]
308. Coleman, D.; Gathergood, N. Biodegradation studies of ionic liquids. Chem. Soc. Rev. 2010, 39, 600–637.
[CrossRef]
309. Egorova, K.S.; Ananikov, V.P. Toxicity of ionic liquids: Eco(cyto)activity as complicated but unavoidable
parameter for task-specific optimization. ChemSusChem 2014, 7, 336–360. [CrossRef]
310. Mahato, S.; Santra, S.; Chatterjee, R.; Zyryanov, G.V.; Hajra, A.; Majee, A. Brønsted acidic ionic liquid-catalyzed
tandem reaction: An efficient approach towards regioselective synthesis of pyrano[3,2-: C] coumarins under
solvent-free conditions bearing lower E-factors. Green Chem. 2017, 19, 3282–3295. [CrossRef]
311. Cole, A.C.; Jensen, J.L.; Ntai, I.; Tran, K.L.T.; Weaver, K.J.; Forbes, D.C.; Davis, J.H. Novel brønsted acidic
ionic liquids and their use as dual solvent-catalysts. J. Am. Chem. Soc. 2002, 124, 5962–5963. [CrossRef]
312. Moosavi-Zare, A.R.; Zolfigol, M.A.; Khaledian, O.; Khakyzadeh, V. Condensation of 2-naphtol with
arylaldehydes using acetic acid functionalized ionic liquids as highly efficient and reusable catalysts. Chin. J.
Catal. 2014, 35, 573–578. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4618 81 of 81
313. Moosavi-Zare, A.R.; Zolfigol, M.A.; Khaledian, O.; Khakyzadeh, V.; Farahani, M.D.; Kruger, H.G. Tandem
Knoevenagel-Michael-cyclocondensation reactions of malononitrile, various aldehydes and dimedone using
acetic acid functionalized ionic liquid. New J. Chem. 2014, 38, 2342–2347. [CrossRef]
314. Noroozizadeh, E.; Moosavi-Zare, A.R.; Zolfigol, M.A.; Zarei, M.; Karamian, R.; Asadbegy, M.; Yari, S.;
Farida, S.H.M. Synthesis of bis-coumarins over acetic acid functionalized poly(4-vinylpyridinum) bromide
(APVPB) as a green and efficient catalyst under solvent-free conditions and their biological activity. J. Iran.
Chem. Soc. 2018, 15, 471–481. [CrossRef]
315. Lidstrom, P.; Tierney, J.; Wathey, B.; Westman, J. Microwave-assisted organic synthesis—A review. Tetra 2001,
57, 9225–9283. [CrossRef]
316. Gabriel, C.; Gabriel, S.; Grant, E.H.; Halstead, B.S.J.; Michael P Mingos, D. Dielectric parameters relevant to
microwave dielectric heating. Chem. Soc. Rev. 1998, 27, 213–223. [CrossRef]
317. Singh, V.; Singh, J.; Kaur, K.P.; Kad, G.L. Acceleration of the Pechmann Reaction by Microwave Irradiation:
Application to the Preparation of Coumarins. J. Chem. Res. Part S 1997, 58–59. [CrossRef]
318. Saidi, M.R.; Bigdeli, K. Microwave Promoted and Improved Thermal Synthesis of Pyranocoumarins and
Furocoumarins. J. Chem. Res. Part S 1998, 800–801. [CrossRef]
319. Valizadeh, H.; Shockravi, A. Task-specific ionic liquid as reagent and reaction medium for the one-pot
Horner-Wadsworth-Emmons-type reaction under microwave irradiation. Synth. Commun. 2009, 39,
4341–4349. [CrossRef]
320. Valizadeh, H.; Vaghefi, S. One-Pot wittig and knoevenagel reactions in ionic liquid as convenient methods
for the synthesis of coumarin derivatives. Synth. Commun. 2009, 39, 1666–1678. [CrossRef]
321. Fiorito, S.; Epifano, F.; Taddeo, V.A.; Genovese, S. Ytterbium triflate promoted coupling of phenols and
propiolic acids: Synthesis of coumarins. Tetrahedron Lett. 2016, 57, 2939–2942. [CrossRef]
322. Genovese, S.; Fiorito, S.; Specchiulli, M.C.; Taddeo, V.A.; Epifano, F. Microwave-assisted synthesis of
xanthones promoted by ytterbium triflate. Tetrahedron Lett. 2015, 56, 847–850. [CrossRef]
323. Mollica, A.; Genovese, S.; Pinnen, F.; Stefanucci, A.; Curini, M.; Epifano, F. Ytterbium triflate catalysed
Meerwein-Ponndorf-Verley (MPV) reduction. Tetrahedron Lett. 2012, 53, 890–892. [CrossRef]
324. Wang, L.; Xia, J.; Tian, H.; Qian, C.; Ma, Y. Synthesis of coumarin by Yb(OTf)3 catalyzed Pechmann reaction
under the solvent-free conditions. Indian J. Chem. Sect. B Org. Med. Chem. 2003, 42, 2097–2099. [CrossRef]
325. Sabou, R.; Hoelderich, W.F.; Ramprasad, D.; Weinand, R. Synthesis of 7-hydroxy-4-methylcoumarin via the
Pechmann reaction with Amberlyst ion-exchange resins as catalysts. J. Catal. 2005, 232, 34–37. [CrossRef]
326. Bouasla, S.; Amaro-Gahete, J.; Esquivel, D.; López, M.I.; Jiménez-Sanchidrián, C.; Teguiche, M.;
Romero-Salguero, F.J. Coumarin derivatives solvent-free synthesis under microwave irradiation over
heterogeneous solid catalysts. Molecules 2017, 22, 2072. [CrossRef]
327. Konrádová, D.; Kozubíková, H.; Doležal, K.; Pospíšil, J. Microwave-Assisted Synthesis of Phenylpropanoids
and Coumarins: Total Synthesis of Osthol. Eur. J. Org. Chem. 2017, 2017, 5204–5213. [CrossRef]
328. Gu, C.X.; Chen, W.W.; Xu, B.; Xu, M.H. Synthesis of indolo[2,3-c]coumarins and indolo[2,3-c]quinolinones
via microwave-assisted base-free intramolecular cross dehydrogenative coupling. Tetrahedron 2019, 75,
1605–1611. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
